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IRON-CONTAINING NANOPARTICLES FOR THE
TREATMENT OF CHRONIC BIOFILM INFECTIONS
IN CYSTIC FIBROSIS

by
Leisha Marie Armijo
B.S. Biology
M.S. Nanoscience & Microsystems
Doctor of Philosophy, Nanoscience & Microsystems Engineering

ABSTRACT
Cystic fibrosis (CF) is the most common genetic disease resulting in the morbidity and
mortality of Caucasian children and adults worldwide. Due to a genetic mutation resulting
in malfunction of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
protein, CF patients produce highly viscous mucus in their respiratory tract. This leads to
impairment of the mucociliary clearance of inhaled microbes. In addition to reduced
microbial clearance, anoxic environmental conditions in the lungs promote biofilm-mode
growth of the pathogenic bacterial species Pseudomonas aeruginosa. Chronic infections of
P. aeruginosa begin in early childhood and typically persist until respiratory failure and
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death result. The average life-expectancy of CF patients is only about 40 years, with
extensive treatment.
Although the introduction of inhaled antibiotics has increased the life expectancy of
CF patients, the thick mucus and biofilm formation contribute to the failure of inhaled
antibiotic drugs. In order to address these issues, we have synthesized and characterized
nanoparticles and nanoparticle-drug conjugates for magnetic gradient guided drug delivery
alone or in combination with medical magnetic hyperthermia to increase local temperature
and decrease the viscosity of these layers. In the absence of the medical magnetic
hyperthermia application, under static magnetic field, the NP drug conjugates may be
gradient guided through the mucus and biofilm barriers to treat the P. aeruginosa infection
directly. We synthesized and characterized iron oxide (magnetite) and iron nitride
(martensite) nanoparticles as candidate nanomaterials for this application. We synthesized
these materials, using environmentally friendly green chemistry methods, in multiple
nanoscale size ranges. The NPs were synthesized using solvothermal methods, and
characterized by transmission electron microscopy (TEM), energy dispersive x-ray
spectroscopy (EDS), x-ray diffraction (XRD) and direct current (DC) and alternating
current (AC) magnetometry. These nanocomposites demonstrate observable bacterial
growth and biofilm inhibition even at surprisingly low (10 ng/mL) concentrations, making
them ideal candidates for incorporation into a low-cost treatment regime. In vitro
cytotoxicity testing of the iron oxide nanoparticles shows low, dosage dependent
cytotoxicity in human lung adenocarcinoma cells, making the iron oxide nanoparticles an
ideal candidate material for this application.
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Chapter 1

INTRODUCTION TO CYSTIC FIBROSIS:
CURRENT TREATMENT OPTIONS AND PROPOSED
NOVEL TREATMENT METHOD
The most common genetic disease resulting in the morbidity and mortality of Caucasian
children and adults worldwide is cystic fibrosis (CF) [Wood 1976], [Hodson 2007],
[Feuchtbaum 2012]. CF results from a mutation on the gene that codes for a specific ion
channel in the epithelial cells. The faulty ion channel alters normal function in multiple
organ systems, most significantly affecting the respiratory system. Thick viscous mucus
secreted by the goblet epithelial cells coat the cilia in the upper respiratory tract, reducing
mechanical (ciliary) clearance of inhaled microbes (viruses, bacteria, and allergens), thus
resulting in a chronic inflammation condition. The chronic inflammation state in CF is
believed to be caused in part by autophagy frustration due to reactive oxygen species
(ROS)-mediated sequestration of the beclin 1–class III PI(3)K complex in perinuclear
aggregates; which redirect it from the autophagy active site at the endoplasmic reticulum
(ER) [Luciani 2010], [Leivine 2011]. Death occurs when pathogenic bacteria and viruses
set up residence in the respiratory mucus, eventually leading to respiratory failure and
death.
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The first recorded case of CF was in the 1930’s [Davis 2006], at which time
abnormal mucus plugging of the exocrine ducts was believed to be the major cause of the
pathology [Davis 2006]. Autopsies performed on malnourished babies showed abnormal
mucus plugging of the glandular ducts, which is why the disease was initially called,
“cystic fibrosis of the pancreas” [Davis 2006]. During that time, the life expectancy for a
CF patient was only 6 months [Davis 2006]. Despite this being the first recorded case, a
genetic disorder as prevalent and widespread as CF has most likely existed in the human
gene pool for a considerable amount of time before being identified and classified.
Evidence supporting this theory comes from documented European folklore [Busch 1989].
In 1838, it was held that a parent should lick across a child’s forehead; a child who tasted
salty was believed to be, “bewitched” and was feared to soon die [Busch 1989]. Another
paper published elsewhere, theorizes that CF is much older than that [Mateu 2002]. The
age of the most common mutation resulting in CF (ΔF508) is debatable, with estimates
ranging from more than 40,000 years ago (upper Paleolithic era and pre-Neolithic era)
[Morral 1994] to 3,000 years ago (post-Neolithic era) [Serre 1990]. Significant evidence
exists that the disease we would one day be officially named, “cystic fibrosis,” may have
existed for thousands of years prior to recorded history.

1.1 The Epidemiology of Cystic Fibrosis
The description of the distribution and determinants of any disease frequency in the human
population is referred to as the disease epidemiology. The incidence of the disease is
defined as the number of new cases per 100,000 people. The birth prevalence is defined as
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the number of people born with CF per 10,000 live births. Population prevalence is defined
as the number of people with CF per 100,000. It is important to note that an accurate
calculation of incidence and prevalence of CF depends strongly on the existence of a
complete and accurate registry [Hodson 2007]. Population prevalence depends on both
birth prevalence and survival; therefore, birth prevalence will give the best estimate of the
incidence of CF in a population since survival depends on access to adequate medical care.

Table 1.1
Birth Incidence of Cystic Fibrosis Worldwide
Incident case per number of live births, adapted from [Hodson 2007], [Farrell 2008].
According to this table, the lowest incidence in the world, by country, is Japan with only one
incident case per 355,000 live births [Fredericksen 1996]. The highest incidence in the world, by
country, is The Republic of Ireland with once case per 1,353 live births [Farrell 2007]. The
highest birth prevalence is reported for relatively isolated populations such as the Zuni tribe of
New Mexico and the Amish in Ohio [Wood 1976], [Stutman 2002].

Region

CF Incidence

Europe
Austria

1:3,500 [Southern 2007]

Belgium

1:2,850 [Lucotte 1995], [Chung 2002]

Bulgaria

1:2,500 [Chung 2002]

Czech Republic
Denmark
Faroe Islands
Finland
France

Germany

1:2,833 [Romeo 1989], [Lucoette 1995]
1:4,760 [Batten 1965],
1:4,700 [Lucoette 1995], [Klaassen 1998], [Nielsen 2002]
1:1,775 [Kaplan 1968]
1:25,000 [Denning 1968],
1:25,000 [Kere 1994], [Klaassen 1998]
1:2,667 West Brittany [Lev 1965], 1:2,838 Brittany
1:1,972 (including terminated pregnancies) [Danes 1968],
1:4,700 [Southern 2007]
1:3,300 [Romeo 1989], [Lucoette 1995], [Schulz 2006]
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Italy
Italy (Milan)

1:4,238 [Siegel 1960],
1:4,238 [Bossi 2004]

Netherlands

1:3,170 [Chernick 1959]
1:4,750 [Spock 1967],
1:4,750 [Slieker 2005]

Northern Ireland (UK)

1:1,857 [Noblett 1969]

Norway

1:6,574 [Johnson 1984]

Poland

1:5,000 [Southern 2007]

Republic of Ireland

1:1,353 [Farrell 2007]

Romania

1:2,056 [Popa 1997]

Scotland

1:1,984 [Hide 1969]

Slovakia

1:1,800 [Kadasi 1997]

Spain

1:3,750 [Lucotte 1995], [Chung 2002]
1:2,200-4,500 [Rosan 1962],
1:5,600 [Lannefors 2002]
1:2,415 [Gracey 1969],
1:2,381 [Dodge 2007]

Sweden
United Kingdom

North America
United States

1:3,200 Caucasian, 1:10,500 Native American,
1:11,500 Hispanic, 1:14,000-17,000 African American
[Bowman 1969]
1:2,380-2,630 Caucasian, 1:6,800-27,000 Hispanic,
1:13,300-1:14,800 African American, 1:1,790-2,880
Ashkenazi Jewish, 1:13,700-128,000 Asian American
[Palomaki 2004]

Canada

1:2,500 [Mearns 1974], 1:3,608 [Dupuis 2005]

Saguenay-Lac St Jean
(Quebec)

1:895 [Weaver 1994]

Amish, OH, USA

1:569 [Stutman 2002]
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Zuni Tribe, NM, USA

1:333 Native American [Wood 1976]

Middle East
Ashkenazi Jews and Arabs

1:4,000-18,000 [Crozier 1974]

Bahrain

1:5,800 [Corey 1988]

Jordan

1:2,560 [Nielsen 1982]

New Zealand

1:3,179 (non-Maori) [Szaff 1983]

Australia

1:2,021 (British), 1:3,625 (Italian),1:3,726 (Greek)

Oceana

[Jensen 1987]

Other
Japan

1:355,000 [Frederiksen 1996]

South Africa

1:2,000 (Caucasian) [Allan 1973], 1:784-13,924
(African) [Chase 1979]

Although the birth prevalence is higher in Caucasians than other ethnic groups;
estimated to be roughly 1 in every 2,500 people [Hodson 2007], statistics studies done in
2011 identified a considerable number of CF patients with mixed African-Caucasian,
Mexican-Caucasian, and Indian-Caucasian ancestries [Li 2011]. The CFTR mutation has
been found in South Africans of pure African decent and did not arise from mixing with
European populations [Maek 1997]. Another recent study compared CF prevalence in
newborns of various races, and revealed, somewhat surprisingly, the highest prevalence in
Native Americans [Wood 1976], [Feuchtbaum 2012]. In some populations, the birth
prevalence is much higher than expected; such as Ohio (Amish) and Saguernay-Lac St
Jean, Qubec [Hodson 2007]. This is attributed to the founder effect; these populations are
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culturally or geographically isolated. Whereas, in other populations, the birth prevalence is
much lower than expected; such as Norway and Finland [Hodson]. Developing countries
such as Africa or India do not maintain sufficient records on CF incidence, as detection of
CF is a low priority compared to other substantial health problems leading to infant
mortality. Per the cystic fibrosis foundation, there are approximately 30,000 people in the
United States living with CF, and 1,000 new cases are diagnosed annually [Cystic Fibrosis
Foundation 2015].
A more recent publication, “Geographical distribution of cystic fibrosis; the past 70
years of data analysis” [Mirtajani 2017], also cites the same references for incidence, due
to a lack of updated data in peer-reviewed scientific literature. Mirtajani also notes that
African, Asian and the South American continents have limited or no CF registry and
estimates that more than 50 % of countries provide no data on CF incidence, at present
[Mirtajani 2017]. We have provided some relatively older and newer reported values for
CF incidence, and some researchers have noted a slight decrease in CF cases [Massie
2010], these decreases are attributed to screening followed by pregnancy termination, and
do not represent an actual decrease in the incidence of the CF mutation or mutations in the
population. The rate of CF in the population has relatively remained consistent over time
as far as we can tell by considering and comparing the available published data.

1.2 Inheritance of Cystic Fibrosis Disease, Heterozygote Advantage, and Persistence
in the Population

6

The gene that codes for the faulty receptor responsible for the pathology associated with
CF disease is the cystic fibrosis transmembrane receptor (CFTR) gene. The CFTR gene is
recessive; therefore, in order to have clinically diagnosable CF disease, a person must
inherit two defective copies of the CFTR gene; one from the mother and one from the
father. A carrier is a person who has inherited one defective gene and one normal gene, and
would typically present as healthy, although there are some exceptions, depending on the
specific mutation type. Carrier individuals, also called heterozygotes, exist in a much
higher frequency in a population, as they only possess a single defective gene.
Heterozygotes differ in phenotype from homozygotes in that they may be short in stature
[Aitken 2003], and they may exhibit increased upper respiratory inflammation than noncarriers [Kilbourn 1968]. Despite these documented features, heterozygotes exhibit normal
life expectancies. In order to be clinically diagnosed with CF disease, a person must
possess two defective genes, one from each parent (see Figure 1.1).
Figure 1.1 Statistical transmission of the
CFTR gene from parents to offspring. Green
represents normal gene, red represents the
defective gene. Top left shows a carrier
father; top right shows a carrier mother.
Below are the statistically predicted
offspring, each having a 25% chance of
inheriting CF. Genotype is the gene
combination
present,
for
example,
heterozygous, homozygous recessive, or
homozygous dominant and corresponding
phenotype, or expression of the defective
gene of heterozygote parents, and four
statistically predicted offspring. Image by L.
Armijo, 2016.
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The life expectancy of a CF patient with extensive treatment, at the time of this
publication is less than 40 years [Anderson 2016]. Prior to the discovery of antimicrobial
drugs, the life expectancy was much lower. Recall the life expectancy of children
diagnosed with CF in the 1930’s was only six-months [Davis 2006]. Accordingly, it would
stand to reason that if CF sufferers died in childhood, before reaching reproductive age,
that the disease should have been completely eradicated by natural selection. This,
however, has not been the case. Before the late 1960’s, scientists investigated possible
benefits of the defective gene which may have allowed it to persist in the population.
Finally, 1967 studies confirmed that the mean number of live offspring of the grandparents
of CF patients was higher than for the grandparents of the healthy control group [Knudson
1967]. These findings suggest a heterozygote advantage. A so-called, heterozygote
advantage, occurs when a carrier individual demonstrates a selective advantage over the
rest of the population.

Findings confirmed that heterozygote carriers are resistant to

cholera toxin [Gabriel 1994]. Just four years after that, another paper reported that the
single defective CF gene imparts resistance to typhoid fever [Pier 1998]. Considering the
long history and persistence of CF, from the consequences of these long-term selective
advantages, CF is significantly likely to continue to persist in the population long into the
future.

1.3 The CFTR Gene and Different Mutation Types
The CFTR gene encodes the instructions for the cell to manufacture the CFTR protein. The
CFTR protein is a cyclic adenosine monophosphate (cAMP) regulated chloride ion

8

channel, found virtually exclusively in the secretory epithelial cells [Frizzel 2012]. The
CFTR protein is encoded by the DNA and transcribed into messenger RNA (mRNA). The
mRNA is translated and the CFTR protein is manufactured in the rough endoplasmic
reticulum of the cell. The assembled CFTR migrates to the cell membrane where it exerts
its function. A mutation in the DNA coding for the CFTR protein could lead to a premature
stop codon; in which case the message would never be translated, and a CFTR protein
would never be produced.

Figure 1.2 Chromosomal location of the CFTR gene: locus on the q arm of
chromosome 7, in region 3, band 1, and sub band 2; hence the location
designation: 7q31_2. Image after [NIH 2016].
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Alternatively, a different mutation could change the code such that a different
protein is produced resulting in either a faulty or a non-functioning CFTR. Even though the
defect is found on a single gene, there are many different mutations on that gene that can
cause CF disease. All the mutations documented correspond to the same location on
chromosome 7; the difference in the type of mutation is characteristic of the code that was
inserted in this region. Evidence of a tight linkage between the CF locus and a DNA
sequence polymorphism in the center third of the long arm of chromosome 7 between
bands q21 and q31 was found in 1985, drawing more attention to this region [White 1985].
Others identified the CF locus more specifically on human chromosome 7ce-q22 in that
same year [Wainwright 1985].
It was not until much later when it was shown that several different mutations
could result in a faulty or missing CFTR protein (see Table 1.2) [Peebles 2005]. This is
significant because variations in the type of mutation, the presence of some type of
defective CFTR, or the absence of a CFTR protein complicate current standard treatment
regimes. Treatment is most effective when catered to the patient’s specific mutation type.
For practicality, specific mutations are given a class number corresponding to a recognized
treatment regime (see Section 1.4). Since different mutations result in different pathologies
and severities thereof, optimization of treatment requires a personalized approach. A
universal treatment method is needed.
In all cases, the major underlying issue is either a malfunctioning or nonfunctioning chloride ion channel at the epithelial cell membrane resulting in a decreased
volume of periciliary fluid in the lower respiratory tract. This, in turn, leads to impaired
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mucociliary clearance of inhaled microbes, which colonize and ravage the lungs causing
child-onset chronic infections, chronic inflammation, tissue damage, and eventual
respiratory failure and death. Therefore, in order to increase the life-expectancy of CF
patients; we must uncover a reliable method to annihilate the bacterial species that
overwhelms the already compromised respiratory system in these patients.
The CFTR protein is an ATP-binding cassette (ABC) transporter-class ion channel
(Figure 1.3). ABC transporters are classified as proteins based on the sequence and
organization of their domain or domains. For example, the CFTR has Nucleotide Binding
and Regulatory Domains 1 and 2 (NBD1 and NBD2, +R respectively); areas where
nucleotides bind to regulate function. In general, the CFTR is simply a protein that
conducts chloride (Cl-) [Riordan 2008] and thiocyanate (SCN-) [Childers 2007] anions
across epithelial cell membranes. A normally functioning CFTR protein acts as an ion
pump; channeling chloride ions (Cl-) from inside the cell across the cell membrane, and
into the extracellular space, in order to maintain healthy salinity levels within the cell. In
addition, the CFTR protein can inhibit the epithelial sodium channel (ENaC) when
activation is triggered by nucleotide binding to NBF1. The ENaC is a separate channel
through which sodium ions (Na+) are transported. A healthy CFTR protein influences a
low-level sodium intake by regulation of NBF1 [Annereau 2003]. When a defective CFTR
protein or no CFTR protein is produced, the Cl- concentration within the cells is
compromised. ENaC is activated and a subsequent increase in sodium transport into the
cell results.
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Figure 1.3 Normal chloride ion channel function at the cell membrane. CFTR is the
cystic fibrosis transmembrane receptor, shown in active transport of chloride ions
through its channel. NBD1 is the first nucleotide-binding domain, and NBD2 is the
second nucleotide-binding domain, where nucleotides can bind to regulate function.
Image by Armijo, L. 2014.

Mutations of the CFTR gene altering chloride ion channel function cause
dysregulation of epithelial fluid transport in the lung, pancreas, and other organ systems.
Clinical pathologies include thick, condensed mucus in the lungs and recurrent respiratory
infections, causing chronic disability and reduced life expectancy. CF patients also suffer
from pancreatic insufficiency, which results in malnutrition and diabetes. Abnormal ion
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regulation also causes the salty epithelial excretions which promote bacterial colonization
of the lungs.

1.4 Current Therapeutic Regimens, Personalized Medicine, and Investigational
Treatments
The discovery of antibiotics in 1928 was undoubtedly one of the most important
developments in medicine to date, responsible for saving millions of lives by making
formerly deadly infections curable [Tan 2015]. Antibiotic reliability is the foundation for
modern medicine and has facilitated the development of numerous, formerly impossible,
medical procedures. Virtually every aspect of what we call modern medicine: treatment of
autoimmune diseases and allergies, therapeutic use of corticosteroids or other
immunosuppressant drugs, chemo- and radiation therapy, any and all surgical procedures,
burn and wound treatment, to include any procedures or accommodations in which stents,
catheters, orthodontic wires, ventilators, staples, sutures, bandages, clamps, belts, implants,
or virtually any procedure in which an inert object-biological interface exists; they all put
the patient at risk for infection. The development of antibiotic drugs made all this possible.
On the other hand, researchers and medical professionals alike continue to struggle with
the intensifying issue of antibiotic resistance, especially prominent in healthcare
environments, which threatens to collapse the crucial foundation on which modern
medicine was built.
Since death from respiratory failure is preceded by bacterial colonization of the lungs
of CF patients, most treatment regimens include the use of aminoglycoside antibiotics
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[Peebles 2005], [De Boeck and Amaral 2016]. The most common pathogenic bacterial
species, having the ability to form biofilm colonies, and causing respiratory failure in CF,
is Pseudomonas aeruginosa [Govan 1996]. The next most important adversary in the war
on morbidity and mortality in CF is Burkholderia cepacia. Burkholderia cepacia is
believed by some to be the most significant and provocative new opportunistic pathogen to
torment the CF community [Govan 1996] Other microbiological organisms contributing to
pulmonary disease in CF lungs by predisposing the patient to Pseudomonas aeruginosa
colonization are often referred to as nonpseudomonal CF pathogens. The following
nonpseudomonal pathogens are known: Staphylococcus aureus and Haemophilus influenza
(common); Streptococcus pneumoniae, Legionella species, viruses (in particular:
respiratory syncytial virus (RSV), various glucose nonfermenters, mycobacteria, fungal
agents (less-common) [Gilligan 1991, Govan 1996]. Because of the infectious disease
aspect, antibiotic therapy is a common component of the current CF treatment regime.
1.4.1 CFTR Mutation Types and Personalized Medicine
CF is a genetic disease that can manifest differently, depending on the type of
mutation of CFTR gene. Therefore, treatments are optimized when they are catered to a
specific CFTR gene mutation. In the interest of treatment optimization, the CFTR
mutations resulting in CF disease have been traditionally been separated into V classes
[Peebles 2005]. A new class, class VI was later described, and is distinguished by rapid
CFTR turnover at the channel surface [Zielenski 2000]. Even more recently, a new
classification, based on therapeutic strategies, and accounting for the potential of

14

personalized medicine and targeted drugs was proposed [De Boeck and Amaral 2016]. In
this model, De Boeck and Amaral separated the class I mutations into class I (stop-codon)
and a new class; class IV (no mRNA transcription) due to the differing successful
treatment options for the two [De Boeck and Amaral 2016].
One example of mutation type is caused by a single nucleotide polymorphism
(SNP). A SNP occurs when a single base (nucleotide) along the DNA ladder is replaced by
a different one. Another mutation type, called a nonsense mutation, converts a codon (a
triplet of bases that codes for an amino acid) into a stop codon (a triplet of bases encoding
the termination of translation). A nonsense mutation is responsible for the pathology
described in a CF class I mutation. For example, an adenosine molecule replaces a cysteine
molecule, resulting in synthesis of a faulty protein, or no protein synthesis at all. A
missense mutation, as in CF mutation classes II, III, IV, or V, occurs when a SNP results in
the substitution of a different amino acid in the amino acid chain. It should be noted that
overlaps between different classes of mutations can also exist. For example, the delta-F508
(ΔF508) mutation can cause reduced chloride channel opening time in addition to
abnormal CFTR processing. Occasionally, the CFTR mutation can be modified by another
mutation or polymorphism on the same allele (a modifier gene).
The most common therapeutic regime for class I mutations includes
aminoglycoside antibiotics. Aminoglycosides are antibiotics traditionally used for the
treatment of gram-negative bacterial infections (such as P. aeruginosa infection). They are
named as such because they contain as a portion of the molecule an aminomodified glycoside; an aminoglycoside. This family of antibiotics consists of tobramycin,
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streptomycin, gentamycin, and the neomycins. The drug tobramycin, which we have
chosen for our investigations, annihilates bacterial cells in a synergistic manner. Initially, it
electrostatically binds the negatively charged lipopolysaccharide bacterial membrane,
compromising membrane integrity and thus, resulting in its degradation [Shakil 2008].
Once internalized, acting from the inside of the bacterial cell, tobramycin inhibits
ribosomal translocation thus interfering with protein synthesis [Saiman 2004]. This
treatment is used for the chronic bacterial infections of respiratory tract characteristic of
CF.
For a class II mutation, a faulty CFTR is produced in the endoplasmic reticulum,
where it remains. Butyrates are a popular treatment for class II mutations. Butyrate is the
generic name for the conjugate base of hydrocarbons containing butanoic acid (C4H7O2−)
somewhere in their structure. These agents cause a reduction in CFTR current amplitude,
suggesting a kinetically fast blocking mechanism [Linsdel 2001] thus, artificially
regulating that component of the CFTR.
In a class III mutation, a faulty CFTR causes inappropriate activation and
regulation of ion transport. Despite expression of the full-length protein at the apical
plasma membrane, class III mutations change CFTR gating which results in decreased Cl −
transport [Kreindler 2010]. Genistein supplementation has been recommended for class III
mutations. Genistein has been demonstrated to alter the maturation, cell surface expression
and single-channel function of CFTR protein [Schmidt 2008]. Genistein is a phytoestrogen
(plant-derived xenoestrogen) belonging to the category of isoflavones. Although it has
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many uses in hormone modulation, in this case it is exploited for its ability to modulate the
CFTR channel, potentiating its opening at low concentration and inhibiting at higher doses.

Table 1.2
Classes of CFTR Mutations
This table summarizes the recognized classes of mutations that cause cystic fibrosis disease. There
are IV mutation classes, each resulting in a specific alteration to, or absence of, the CFTR protein.
Due to the unique resulting manifestations, each mutation class has a specific treatment regime.
*Proposed class [De Boeck and Amaral 2016]. **Approved therapy. Adapted from [Peebles 2005]
and [De Boeck and Amaral 2016].

Class

Effect on CFTR

Types of Mutation

Therapy/ Potential
Therapy

I

Defective
synthesis
of Premature stop codon
message (messenger RNA) (nonsense or frame
causing absence of CFTR
shift)

Aminoglycosides**/
Gene transfer, readthrough compounds

II

Abnormal CFTR produced Amino acid deletion
which
fails
to
leave (∆ F508 or missense
endoplasmic reticulum
mutation)

Correctors**/
Butyrates
Gene transfer

III

Abnormal CFTR causing
disruption of activation and
regulation at cell membrane;
impaired gating
Abnormal CFTR reducing
chloride conductance

Missense mutation
(i.e. G551D)

Potentiators**/
Genistein,
Gene transfer

VI *

Absence of CFTR

No mRNA
transcription

VII*

Absence of CFTR

No mRNA

Missense mutation
(i.e. R117H or
R347P)
Reduced or absent synthesis Missense mutation or
of CFTR due to decreased splice site mutation
splicing of normal CFTR
(i.e. A445E or 5T)

IV

V

Milrinone**/
Potentiators,
Gene transfer
Aminoglycosides**/
Antisense
oligonucleotides,
Correctors,
Gene
transfer
Aminoglycosides**/
Stabilizers,
Gene transfer
Aminoglycosides**/
Bypass therapies

In class IV mutations, a faulty CFTR reduces chloride conductance and transport is
altered. Milrinone is used for the treatment of class IV mutations. Milrinone, marketed
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under the brand name Primacor® Milrinone is an inhibitor of phosphodiesterase 3, a
vasodilator. Although class V mutations can lead to the production of normal CFTR, the
same mutation can also result in a reduced or absent CFTR. A limitation of transcriptional
regulation results in a reduced quantity of the protein being produced. As with the other
mutations resulting in an absent CFTR (I, VI, and VII) the only approved treatment is
aminoglycoside antibiotic and supportive therapy.
Many of the identified CFTR gene mutations can be placed into one of the six
classes, thus accounting for approximately 80% of all CF patients [Rogan 2011]. However,
of the >1,900 CFTR mutations that have been identified, there are only roughly 20
mutations have a frequency greater than 0.1% [Rogan 2011]. CF disease can result from
any one of those numerous mutations on a single gene. Despite the considerable number of
mutations, the encoded gene product is one and the same; the CFTR protein. The most
common mutation, accounting for 70% of the disease alleles leads to a single amino acid
deletion (∆F508), [Zielenski 1995]. As presented in Table 1.2, the class II mutation, which
includes the ∆F508 deletion, is responsible for 85% of cases in Europe [Peebles 2005]. It is
important to note that the percentage of CF patients expressing the most common mutation
type varies among ethnic groups. For example, only 30% of Israelis with CF have the most
common mutation (∆F508) [Shoshani 1992].
1.4.2 Complications in Gene Therapy
Because CF is a genetic disease, it was initially believed that gene therapy would
be the most effective treatment for all classes of CFTR mutations. In gene therapy, correct
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copies of the CFTR gene are transferred to the respiratory epithelial cells, where the gene
can be translated, and a functional CFTR can be synthesized [Burney 2012]. Previous
studies have focused on increased chloride secretion out of the cell, demonstrating positive
results of some normal CFTR function, however, clinical efficacy has not yet been
achieved [Burney 2012]. Despite the vast knowledge obtained by research focused on
understanding the genetic defect underlying CF, this understanding has been referred to as
only “half the battle” in finding the cure for this disease [Hearst 1995]. Anxiously awaited
cures focused on the gene therapy approach have failed to materialize, in spite of the
significant amount of research performed in this field. Complementation of CF using gene
transfer or gene therapy methods, specifically focusing on the delivery of a CFTR cDNA
to the airway epithelium seemed appealing initially since the proposed target cells are
accessible by aerosol delivery approaches (or other direct instillation), however, since the
first human gene therapy trial in 1993, realization of this goal has proved challenging [Sinn
2011]. The use of the previous gold standard in CF gene therapy; adenoviral vectors, has
decreased recently due to low transduction efficiency, weak promoter activity, and
incapability for re-administration due to the development of an anti-viral vector immune
response [Griesenbach 2006]. The adenovirus package is also very small and packaging
the large CFTR gene has proven difficult. One group attempted to package the gene by
cutting it in half and using two separate viral vectors (each carrying half the gene) [Song
2009]. Another study pointed out immune responses to the viral vector may be enhanced if
the patient already has an established P. aeruginosa infection [Tosi 2004]. A similar
problem has been reported when the alternative, Sendai virus (SeV) vector is used for gene
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transfer. Although the SeV is an efficient gene transfer agent, the gene expression is
transient, and requires repeat administration, as with the adenovirus vectors, readministration of SeV vectors also results in an immune response [Griesenbach 2006]. A
more serious problem with SeV vectors is that they have demonstrated the induction of
oncogenesis in certain trials [Hacein-Bey-Abina 2008]. The developments of novel nonviral methods for gene transfer have been slow. One report on NP-mediated gene transfer
did show increased chloride transport, however, vector-specific mRNA was could not be
detected [Konstan 2004]. Another problem with non-viral gene transfer is caused by the
heightened inflammatory state further frustrated by the introduction of plasmid DNA
[Burney 2012]. The unmethylated nucleotide sequence in the plasmid DNA is identified as
an antigen by the immune system, thus, causing further inflammation in the lower
respiratory tract [Zabner 1996], [Schwartz 1997]. CRISPR/Cas9 has demonstrated the
ability to repair a single-gene hereditary defect causing CF in murine and human stem cells
[Schwank 2013] and this treatment may become available soon. However, a recent paper
published in Nature Communications shows that CRISPR/Cas9 causes numerous,
unwanted insertions and deletions (up to 600 bp) in the mouse genome [Shin 2017] and
may need significantly more investigation before it is used to treat human patients. It is
also unlikely that gene transfer would be a viable option for patients with more than a
single mutation or patients with a class VII mutation, alone or in combination with other
mutations. A class VII mutation results in the total absence of a CFTR as well as an
absence of mRNA.
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1.4.3 Summary of Treatment Failure
Yet another hurdle was realized after treatment data for a larger population was
available; patients with the same CFTR mutation genotype often respond differently to
drug treatments [Amaral 2015], [Marson 2015]. This data suggests an even deeper level of
personalization may be necessary to achieve sufficient efficacy of current therapeutics.
Personalized medicine, despite presenting significant benefits is also costly, and may not
become available in developing countries for quite some time.

1.5 The Role of Pseudomonas aeruginosa in the Morbidity and Mortality of Cystic
Fibrosis Patients
The most frequently reported pathogenic microbial species, colonizing the lungs of
CF patients is Pseudomonas aeruginosa. P. aeruginosa has been cultured from the
respiratory tract of 61% of all patients (ranging from 21 % of patients under 1 year of age
to ˃80 % of patients 26 years or older) [FitzSimmons 1993]. P. aeruginosa is also the top
etiology of all gram-negative nosocomial (acquired in hospitals) infectious bacteria, with a
striking mortality rate of 50% or more [Baltch 1994], [Hauser 2003].
Pseudomonas aeruginosa is one of the notorious ESKAPE pathogens (a group
consisting of Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), which
have developed resistance to the bulk of our current antimicrobial regimes, and instead
“escape” the lethal action of antibiotics [Rice 2008]. More specifically, many highly
resistant Gram-negative bacteria from the ESKAPE group, including P. aeruginosa, are
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emerging as exceptionally noteworthy pathogens in threatening public health in United
States as well as other parts of the world [Boucher 2009]. The ESKAPE bacteria are of
tremendous concern because they are responsible for causing the overwhelming majority
of nosocomial infections. Several reports identify significant limitations in current
treatment options for these pathogens that force medical professionals to settle on the use
of previously discontinued drugs having documented toxicity and unclear dosage and
administration guidelines [Bradford 2004, Cardo 2004, Falgas 2007, Urban 2008]. They
also provide complex models of pathogenesis, transmission, and drug resistance [Rice
2008, Boucher 2009]. Treatment regimens found to exhibit success against the ESKAPE
bacteria can be applied to virtually any other species. Successful treatment of these species
alone will result in significantly safer healthcare environments, more suitable for treating
disease and illness.
This member of the Gammaproteobacteria class and the Pseudomonadaceae
family is a deadly pathogen, responsible for the morbidity and mortality of CF and
oncology patients, as well as burn unit patients, and infects up to two-thirds of ICU
patients with nosocomial pneumonia [Torres 1990]. It is responsible for more than 90% of
respiratory failure cases in CF patients [Gilligan 1981]. P. aeruginosa has inherent as well
as acquired resistance to many drug classes. In addition, it possesses the ability to quickly
alter its genetics to impart resistance to the presence of new, unrecognized treatments [Lee
2007]. Despite its classification as an “opportunistic pathogen” [Fick 1992], [Campon
1993], it remains a major worldwide public health problem due to its ubiquity in the
environment, its ability to colonize virtually all regions of the body, and its overall vitality,
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which has allowed it to adapt to a wide range of environmental conditions. The pathogen
possesses the ability to grow with limited nutrients and can metabolize some unusual
organic molecules as carbon sources; some examples are acetate and citrate. It can grow
without oxygen if NO3 is available as an electron acceptor for cellular respiration. This
species is so robust that it is one of the few extremophiles that can colonize deionized
water.
Many issues arise when attempting to treat P. aeruginosa infections in the
respiratory tract of CF patients using conventional methods. First, CF sputum is highly
viscous, interfering with normal oxygen diffusion, thus, hypoxic conditions exist. The
hypoxic environment promotes biofilm formation by P. aeruginosa [Worlitzsch 2002] as
low-oxygen conditions trigger the phenotypic switch to biofilm mode. Once in the biofilm
mode of growth, the bacterial colony produces a protective alginate layer around itself. At
this point, two barriers to drug diffusion exist, physically blocking the aerosol antibiotics
from reaching the target; the viscous mucus layer and the biofilm layer (Figure 1.4). No
antimicrobial agent can penetrate the biofilm; unless the microorganisms form aggregates
that affect its diffusion [Stewart 2001].
While numerous microbial species can successfully colonize the respiratory tract of
CF patients, P. aeruginosa ultimately dominates the microbial flora, becoming the chief
contributor to disease severity and respiratory failure. The phenotypic switch of P.
aeruginosa microcolonies from a planktonic (non-mucoid) to a biofilm (mucoid) state, is
characterized by both antibiotic resistance and accelerated pulmonary decline [Govan
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1996]. Therefore, an artificial active transport method is needed to deliver antibacterial
drugs to the bacterial cells.

Figure 1.4 Biofilm and mucus barriers in a CF lung infection. Illustration of
biofilm layer fixed to infected tissue protecting bacterial cells and CF mucus layer
inhibiting penetration of antibiotics and antibodies.

1.6 Antibiotic Drug Resistance and Biofilms
Many bacterial species, in response to the presence of antibiotics or bacteriophages, or in
low oxygen or low nutrient conditions, switch to the biofilm mode of growth. These initial
bacteria release chemical signals inducing the switch in neighboring populations as well.
Biofilm mode consists of a phenotypic switch from planktonic (free) cells by means of
gene regulation [An 2007]. To form a biofilm, planktonic cells first adhere to a surface via
van der Waals forces, then by using flagella or cilia as an anchor. Quorum sensing (QS) is
used to recruit other bacterial cells and promote expression of the genes necessary for cell
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aggregation and subsequently biofilm production. An inducer binds the bacterial QS
receptor, triggering transcription and translation of necessary genes.
Once a colony is established, the anchor cells produce exopolysaccharides, which
form the protective biofilm layer around the bacterial colonies. N-acyl homoserine lactones
are signaling molecules, called auto-inducers (AIs) used in QS [Smith 2002]. It is
interesting to note that compounds with similar structures may be of interest for blocking
QS (receptor antagonists) [Sio 2006]. Antibiotic resistance typically results from a transfer
of antibiotic resistance genes through bacterial conjugation, gene regulation, or other
modes of gene transfer. However, a major factor contributing to antibiotic drug resistance
in P. aeruginosa is the production of biofilms. The production of a biofilm results in a
slower growth combined with bacterial production of extracellular polysaccharides (EPS),
which form a physical barrier that limits the ability of antibiotic drugs to interact with the
bacteria. The EPS biofilm is mainly composed of alginate, a slimy anionic co-block
polymer which forms a viscous gum when in the presence of water, hence the designation,
“mucoidal.” Alginate or alginic acid is a linear copolymer consisting of homopolymeric
blocks of (1-4)-linked β-D-mannuronate (M) and its C-5 epimer α-L-guluronate (G)
residues [Gacesa 1990] (see Figure 1.5,). The M and G residues are covalently linked
together in different sequences or blocks. The monomers may be homopolymeric; in
blocks of consecutive G-residues or consecutive M-residues, co-block; alternating M and
G-residues. The known and proposed roles of alginate in biofilm infections include;
generation of an alginate covering, forming a direct barrier to phagocytosis and
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opsonization, immunomodulatory effects, and other biofilm-related phenomena such as
bacterial adhesion and antibiotic resistance [Govan 1996].

Figure 1.5 Alginate molecule. Carbon skeleton showing the homopolymeric
blocks of (1-4)-linked β-D-mannuronate (M) (upper ring) and its C-5 epimer αL-guluronate (G) (lower ring). Image created with MarvinSketch™

Bacterial biofilm infections in general, are a significant public health problem.
Specifically, P. aeruginosa biofilms cause infections in indwelling catheters, burns, open
wounds, orthodontic wires, CF lungs, and stents and can infect virtually any part of the
body. As discussed earlier, bacterial biofilms reduce the efficacy of therapeutics due to
their physical interference with drug diffusion; by blocking diffusion of the drug to the
target bacterial colonies [Govan 1996]. In addition, with regards to the more than 20 genes
that are differentially expressed in tobramycin-treated biofilms, sheer existence in a biofilm
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indicates moderate resistance to all antibiotic drugs [Whiteley 2001]. Regarding the P.
aeruginosa species; interference of the alginate barrier with antibiotic penetration to the
strain, and thus, antibacterial action, has also been thoroughly investigated [Kumon 1994].
Interestingly, when bacterial cells are released from a biofilm, they typically experience an
abrupt increased susceptibility to antibiotics. This suggests that the antibiotic resistance of
biofilm bacteria was not acquired through mutations or incorporation of mobile genetic
elements into the bacterial genome [Anwar 1989]. Since the most common cause death for
CF patients is respiratory failure from chronic bacterial infections, and P. aeruginosa is the
top etiology responsible for such infections; annihilation of P. aeruginosa is a fundamental
step in increasing the life expectancy of CF patients.

1.7 Proposed Universal Treatment Method Using Superparamagnetic Nanoparticles
Significant improvements have been made in the treatment of CF over the past 30 years.
Direct drug delivery via inhalation aerosols have increased the average life expectancy of
CF positive children born in developed countries to approximately 40 years [Elborn 1991],
[Staab 1998]. Despite this, the life expectancy of CF patients could still stand to improve.
The efficacy of inhaled therapies still remains marginal due to the presence of the viscous
mucus barrier within the airways, extensive degradation and metabolism of inhaled drug
prior to exerting its pharmacological action, and the development of mucoid P. aeruginosa
biofilm colonies. Therefore, an adequate active transport method is necessary to deliver
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antibiotic drug to the bacterial colonies below the mucus layer, within the protective
biofilm.
The possibility of using magnetic gradient guided active transport of antibiotic
drug, using superparamagnetic nanoparticles, was investigated further since the barriers to
diffusion of therapeutic drug or gene through mucus and biofilm are the principal bases for
treatment failure. Nanoparticle carrier mediated of drug or gene delivery based on passive
transport have demonstrated inadequate penetration efficiencies [Sanders 2000]. Similar
passive transport-based nanocarrier methods perform insufficiently and are unlikely to
enhance the penetration efficiencies to clinically relevant levels. Frequently, drugs or gene
vectors are unable to reach the intended target prior to their activity being diminished or
eliminated. Poor transport efficiencies in drug delivery have resulted in the inadequacy of
therapies since the mucus and biofilm barriers to drug diffusion result in sub-therapeutic
levels of drug at the infected area. These low-levels of antibiotic drug near the bacterial
colonies further leads to drug resistant bacterial strains as the colonies become sensitized to
the drug. Because the use of nanomagnetic materials bound to antibiotic drug would allow
us to guide the magnetic nanoparticles (MNPs) to the area of interest by using an external
magnetic field, the particles could be guided deeper into the respiratory tract than
inhalation alone would allow. Particularly of interest is the capability of MNP systems to
put forth robust influences on their local environment by means of heat under an
oscillating magnetic field. In other words, MNPs, once guided via directed motion under
an inhomogeneous static magnetic field to an area of interest, can be placed in an
oscillating magnetic field and raise the local temperature by means of inductive heating. A
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local temperature increase is anticipated to reduce the viscosity of the mucus and biofilm
layers facilitating delivery of the antibiotic drug. We have demonstrated the ability of the
iron oxide NPs to increase local water temperature in vitro under AC magnetic field. These
are attractive functional attributes for fostering transport and drug distribution in CFrelated lung infections. Therefore, utilizing the unique transport and inherent
superparamagnetic properties of selected nanoscale systems provides a promising strategy
for overcoming the biological mucus and biofilm barriers in CF lung disease.

1.7.1 Particle Transport and Drug Delivery

Our group has previously demonstrated marked increases in particle transport of
nanoparticles can be attained using a static non-uniform magnetic field [Smyth 2008],
[McGill 2009a], in Chapter 3 we show that both ferromagnetic iron oxide NPs as well as
superparamagnetic iron oxide nanoparticles (SPIONs) can be heated using an external AC
magnetic field, under which, the SPION could cut through biopolymers, such as alginate
and DNA, which are responsible for the diffusion-limiting properties of the biofilm. In
addition, in Chapters 2 and 4 we demonstrate our ability to synthesize several different
types of magnetic nanoparticles (MNPs) to optimize the physical properties and chemical
stability. We synthesized and characterized iron oxide NPs having various morphologies
iron nitride NPs, and zero-valent iron NPs. These particles are surface-biofunctionalized
for drug conjugation. We then attach a model drug to the surface using a biocleavable
conjugation scheme (see Chapter 5). Drug release could potentially be triggered by
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external magnetic fields in a non-invasive manner, if necessary. Many researchers have
reported the use of external magnetic fields to achieve controlled drug delivery using
hyperthermia via two general methods: Hyperthermia-based controlled Drug delivery
through Bond Breaking (DBB) and Hyperthermia-based controlled Drug delivery through
Enhanced Permeability (DEP) [Kumar 2011]. The first successful demonstration of DBB
was reported using radiofrequency EMF activation of release of fluorescein-labeled 18 bp
in a model tumor near the posterior mammary fat pad of mice [Derfus 2007]. Our
laboratory later confirmed this concept by triggering the release of fluorophore bimane
amine from the surface of SPIONs under external oscillating magnetic fields [McGill
2009b]. The first report was by Kost and others, who demonstrated insulin release from a
magnetic composite of ethylene vinyl acetate under a low frequency magnetic field [Kost
1987]. A commonly proposed approach is to use a composite carrier consisting of a
magnetic iron oxide core inside any thermally sensitive polymer having a temperaturedependent drug release profile, then when the core is self-heated drug release is triggered
[Liu 2008]. [Liu 2008] reported the successful triggered delivery of Vitamin B12 within
minutes

between

40-45

°C,

using

poly(ethylene-oxide)-poly(propylene-oxide)-

poly(ethylene-oxide) block copolymers, 4-nitrophenyl chloroformate, gelatin, and 1-ethyl3-(3- dimethylaminopropyl) carbodiimide self-assembled nanocapsules and magnetic iron
oxide NP cores which were responsible for the heating [Liu 2008]. Triggered drug delivery
would be necessary if the required therapeutic dose is found to be higher than the dose
found to be cytotoxic to healthy cells. In this case, the overall environment could be kept
at a safe drug concentration while the highest concentration would be released specifically
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at the infection site, reducing collateral damage. Finally, when loaded with drug, the MNPs
will be incorporated into inhalable microparticles, suitable for lung targeting. This will
initiate simultaneous highly efficient transport and highly specific lung deposition.
Additionally, these systems will transport inhibitory drug concentrations directly to the site
of action and will therefore facilitate improvements in drug and gene therapies in CF,
prolonging survival and enhancing quality of life.
The physics of particle delivery to the lower respiratory tract has been well
characterized. Further engineering of the particle or particles into a stable micron-range
polymer matrix in a stable dry-powder form is necessary for successful pulmonary
delivery. Many factors impact the performance of a particle system, such as mass median
aerodynamic diameter (MMAD), particle size distribution, dispersibility, particle
morphology, and thermodynamic stability [Chow 2007], [Hickey 2007b]. The combination
of two specific parameters; size and surface roughness greatly influence performance. It is
known that the particles must be further engineered to increase the diameter from the
nanoscale to the microscale range to avoid deposition in the throat [Hickey 2003]. Previous
research has also demonstrated that particles with MMADs 1-2 μm deposit in the smaller
(lower) airways and 5-10 μm deposit in the larger (upper) airways [Vehring 2007].
Particles having a high degree of surface roughness exhibit increased dispersibility due to
decreased interparticulate interactions, consequently resulting in significantly decreased
particle aggregation resulting in a larger aerodynamic size (for the agglomerate) [Gilani
2005]. Typically, lactose [Kaialy 2012] or mannitol [Hamishehkar 2012] is used as a
carrier, because it has a sweet taste. Some other polymers which have been previously
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investigated for this application are: the FDA approved polymer poly(lactic-coglycolic)
(PLGA) [Tomoda 2009], poly(ethylene glycol)-co-poly(sebacic acid) (PEG-PSA) [Tang
2010], and dipalmitoylphosphatidylcholine (DPPC) with dipalmitoyl phosphatidylethanol
aminemethoxy-polyethylene glycol (DPPE-PEG) [Meenach 2013].
1.7.2 Biocompatibility
Previous work on biocompatible magnetic materials has focused on the iron oxides [Gupta
2005], [Xie 2009], [Xie 2010], iron core-iron oxide shell particles [Qiang 2006], cobalt
[Bao 2005], [Xu 2007], [Lukanov 2011], iron core gold shell particles [Chen 2003], or the
rare-earth elements [Meiser 2004], [Setua 2010], [Dobson 2006]. However, the iron oxides
have shown the greatest potential as biofilm inhibitors having low cytotoxicity [Johannsen
2007]. Significant research on silver NPs as antimicrobial agents has been reported in the
literature [Sondi 2004, Morones 2005, Cho 2005, Kim 2007, Pal 2007, Shrivastava 2007,
Durán 2007, Martínez-Castañón 2008, Rai 2009, Chudasama 2010, Lara 2011, El-Kheshen
2012, Dong 2012, Prabhu 2012, Le 2012, Sadeghi 2012, Rai 2012, Emeka 2014, Losasso
2014, Agnihotri 2014, Franci 2015, Cavaliere 2015, Lara 2015, Giessen 2016, Russol
2017, Patra 2017, Shaker 2017] and much research has also been done on the efficacy of
silver NPs against P. aeruginosa [Afreen 2011, Eid 2013, Palanisamy 2014, Singh 2014a,
Anasari 2014, Mushin 2014, Singh 2014b, Mapara 2015, Raza 2016, Haghighi 2016,
Nasiri 2016, Kasitherar 2017]. Due to their undisputable antibacterial properties, silver
NPs are among the most commonly exploited nanomaterials in commercialized products
[Beer 2012]. Although silver NPs have demonstrated antimicrobial properties against
many bacterial species, silver is costly, and is also known to exhibit toxicity in multiple
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species [Asharani 2008], including in vitro cytotoxicity in various human cell lines
[Kawata 2009, Beer 2012, Foldbjerg 2011]. Most researchers attribute the observed
toxicity either to silver ions [Asharani 2008] or the combination of silver NPs and silver
ions [Bilberg 2011, Foldbjerg 2011]. An ideal bactericidal agent should be lethal to
bacteria, but safe to human cells. One such candidate is iron and its compounds. Iron-oxide
NPs have been shown to be non-toxic [Sumanta 2008, Sun 2010, Prodan 2013, Grottone
2014]. For example, feraheme/ferumoxytol containing superparamagnetic iron-oxide NPs
was approved by the U.S. Food and Drug Administration as an iron supplement for
treatment of iron deficiency in patients with renal failure [Provenzano 2009, Coyne 2009,
Lu 2010]. According to a previous report, iron-oxide in NP form is not only non-toxic, but
its byproduct, degraded iron from the cores, apparently accumulates in natural iron stores
in the body [Weissleder 1989]. Properly biofunctionalized iron-oxide NPs have been
shown to inhibit growth of Staphylococcus aureus [Tran 2010, Darwish 2015, Shi 2016]
and Escherichia coli [Darwish 2015, Chatterjee 2011], prevent biofilm formation by P.
aeruginosa [Niemirowicz 2015] and Streptococcus mutans [Javanbakht 2016], and exhibit
bactericidal activity against a range of Gram-negative and Gram-positive bacterial species
[Behera 2012, Prodan 2013, Thukkaram 2014, Prabhu 2015, Arakha 2015, Nehra 2018].
While these are very encouraging results, more work is necessary in the investigation of
iron-oxide NPs as a feasible alternative to silver NPs in the treatment of bacterial infections
and for biofilm disruption.
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1.7.3 Biofilm Considerations
According to a previous report, there are no clinically effective inhibitors of biofilm
formation presently available [Musk 2005]. However, iron salts appeared to inhibit biofilm
formation in a concentration-dependent manner. Investigations into the P. aeruginosa
genetics show that elevated iron concentrations repress the expression of certain genes
essential for biofilm production in P. aeruginosa [Musk 2005]. To address the biofilm
problem, we have synthesized and characterized iron oxide (magnetite) NPs capped with
biodegradable short-chain carboxylic acid derivatives conjugated to the most common
antibiotic arsenal for the treatment of gram-negative bacteria. The functionalized
nanoparticles may carry the drug past the mucus and biofilm layers to target the bacterial
colonies via magnetic gradient-guided transport. Additionally, the magnetic ferrofluid may
be used under application of an oscillating magnetic field to raise the local temperature,
causing biofilm disruption, slowed growth, and mechanical disruption. P. aeruginosa can
sustain normal growth at temperatures up to 42 ˚C; therefore, an increase in the local
temperature may increase the bacterial susceptibility to the antibiotic drugs, if not
destroying them. This temperature increase would not harm local healthy cells as a
temperature reached by natural fever does not harm healthy tissue. It is well-known that
hyperthermia increases the penetration of cytostatic drugs into tissue/cells [Witkamp 2001]
and may also increase penetration of drug into biofilms and bacterial colonies. In this case
because the drug we are using is beta lactam antibiotic drug which works by interfering
with production of peptidoglycan cell walls, increased influx of beta lactam antibiotics into
of healthy mammalian cells would have no effect, as they do not have peptidoglycan cell
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walls. Caution must be used, however, if this technology was used in the delivery of a
chemotherapy agent. The healthy tissue (along with the cancerous tissue) would become
more susceptible to the toxic effects of the chemotherapeutic agent [Witkamp 2001],
[Koning 2010]. These abilities of the ferrofluid would also treat multi-drug resistant
strains, which appear to be increasing in many nosocomial as well as acquired
opportunistic infections.
1.7.4 Critical Parameters
Particle size, prior to polymer engineering is a crucial parameter; as polymer
coating and drug conjugation will increase particle diameter. Previous studies have shown
that although conventional particles are often entrapped in mucus, small sized particles
(120 nm) exceeded the rate of diffusion through mucus when compared to larger particles
(560 nm) [Sanders 2000]. These findings are significant since it is now known that the
maximum pore size in CF sputum is 400 nm. Therefore, an ideal drug carrier would have
to be significantly smaller than 400 nm to enhance the rate of free diffusion of the particles
through mucus pores. Our group has previously shown that superparamagnetic iron oxide
nanoparticles (SPIONS) exhibit enhanced diffusion through alginate biofilms using
magnetic field gradient guiding in vitro [McGill 2009a]. In addition to magnetic field
guided transport capability, MNPs are capable of releasing heat upon placement in an
external oscillating magnetic field [McGill 2009b]. Three potential mechanisms are
implicated in heating in the frequency range suitable for human patient treatment: Néel
relaxation, Brownian motion relaxation, and hysteresis losses in the ferro (ferri) magnetic
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size range. This phenomenon is exploited in the application of hyperthermic tumor
destruction, or thermotherapy an experimental cancer treatment in which heat released
from MNP placed in an AC magnetic field may be used to kill tumor cells. We expect heat
released from MNP hyperthermia would further enhance the magnetic-field-guided particle
movement through the mucus and EPS matrix in the lower respiratory tract by reducing
their viscosity. These methods would provide a viable universal treatment method which
would likely increase life expectancy for all CF sufferers without regard to the mutation
type or severity of the disease.

1.8 Overview of Dissertation
In Chapter 2, we describe the synthesis and characterization of iron oxide nanoparticles
(NPs) of which we investigated several sizes and morphologies, iron martensite NPs
(Fe16N2), and zero-valent iron NPs (Fe0). These samples were either uncapped or capped
with polyethylene glycol (PEG) for structural and magnetic characterization, and either
uncapped or capped with alginate or PEG for in vitro bacterial sensitivity studies. Capping
is done by attaching a water-soluble molecule or polymer to the positively-charged NP via
a negatively-charged terminal carboxyl group. This is done to enhance solubility of NPs in
water. When the iron oxide NPs come out of synthesis, they are coated in the metal carrier
molecule, oleic acid. Oleic acid is a long chain hydrocarbon with a terminal carboxyl group
that attaches to the positively charged metal (Fe+). The long chain hydrocarbon which
remains surrounding the metal NP after its formation contains no other carboxyl, carbonyl,
or hydroxyl groups, and is therefore hydrophobic. In order to prevent NP oxidation in air
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or aqueous solution, prevent particle aggregation, and allow for drug conjugation, the NPs
should be coated with a passivation layer. If the NPs are to be used in vivo, it is necessary
to coat them with a water-soluble substance; otherwise entropic forces would cause them
to aggregate in the aqueous environment of the body. For these studies, we chose alginate,
citrate, or polyethylene glycol coatings because they are FDA approved for human
consumption in food and pharmaceuticals. The samples were characterized by transmission
electron microscopy (TEM), X-ray diffraction (XRD), and energy dispersive X-ray
spectroscopy (EDS) (Chapters 3 and 4) and tested for magnetic hyperthermia using the
NanoTherics, Ltd. MagneTherm™ as described in Chapter 4. Spherical magnetite (Fe3O4)
NPs having high iron content and a mean radius between 15 and 25 nm were found to
exhibit the best magnetic properties (Chapter 4). The NPs having a radius <19 were
superparamagnetic. The NPs were further functionalized and conjugated to tobramycin
using EDC/sulfo-NHS cross-linking discussed in detail in Chapter 5. The drug-loaded NPs,
as well as NP samples with different capping agents were investigated alone. Antibiotic
drug was used to test the sensitivities of mucoidal colonies of P. aeruginosa at time
intervals from 3-60 days, to determine if growth time alters the dosage response; the results
of these experiments are described in Chapter 6. Cytotoxicity, viability and apoptosis
assays in a human adenocarcinoma cell line were performed on two concentrations of iron
oxide NPs and the results are described in chapter 7. Overall, the iron oxide NPs did not
exhibit statistically significant cytotoxicity in this cell line.
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Chapter 2

SYNTHESIS AND CHARACTERIZATION OF IRON
OXIDE NANOPARTICLES
The iron oxides exist naturally, the most common phases being hematite (α-Fe2O3),
maghemite (γ-Fe2O3), and magnetite (Fe3O4) [Cornell 2006]. Magnetite exhibits the
strongest magnetic properties of all phases of iron oxide [Cornell 2006], [Majewski 2007],
[Teja 2009] which is why it was selected for this application. The concept of magneticfield-guided drug delivery has existed for over 30 years [Indara 2010]. Aside from our
antibacterial application, colloidal suspensions of (SPIONs), called ferrofluids, have been
proposed for a range of biomedical applications, such as magnetic gradient-guided drug
carriers for targeted drug delivery [Sahoo 2003], [Veiseh 2010], cancer thermotherapy
[Hirsch 2003], [Thiesen 2008], and magnetic resonance imaging (MRI) contrast agents
[Kim 2005], [Alexiou 2006].
We have synthesized and characterized magnetic nanoparticles (MNPs) to
overcome the existing barriers and achieve critical improvements in CF therapy which will
increase the life expectancy of CF patients. Antibiotic conjugated nanomaterial systems
will facilitate significant enhancement of the efficacy of model therapeutic agents due to
increased diffusion and penetration through mucus and biofilm barriers in cystic fibrosis
when administered directly to the lung as an inhalation aerosol. Along with the numerous
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applications, numerous methods for synthesis of SPIONs have been previously published
[Laurent 2008]. Various methods include thermal or sonochemical decomposition of iron
pentacarbonyl (Fe(CO)5) [Shafi 2001], [Hyeon 2003], [Wu 2008], microemulsions [López
Pérez1997], [Santra 2001], [Chin 2007], sol-gel synthesis [Gash 2001], [Lu 2002]
hydrothermal reactions [Hu 2007], [Takami 2007], [Ge 2009], hydrolysis and thermolysis
of precursors [Iida 2007], flow injection syntheses [Salazar-Alvarez 2006], and
electrospray syntheses [Kruis 1998], [Basak 2007].
We have selected a green chemistry solvothermal method for our syntheses due to
the flawless crystallinity, morphology control, and monodispersity. Green chemistry
applied to the practice of synthetic materials engineering focuses not only on minimizing
waste, reducing energy use, and recycling, but also using natural, water-soluble, non-toxic
or reduced toxicity precursors and reagents. When possible, petroleum products are
replaced with natural lipids and toxic nitrates are replaced with chloride salts.
Iron oxide NPs were synthesized in a high boiling point solvent consisting of inert
hydrocarbons. The NP growth was facilitated and somewhat controlled by the organic
carrier molecule, oleate. At the end of synthesis, the NPs remained capped with oleate.
Later, cap exchange may be performed using either alginate, citrate, PEG-OH (hydroxylterminated polyethylene glycol), or PEG-COOH (carboxyl-terminated polyethylene
glycol) for water solubility, as discussed further in Chapter 5. The synthesis is a
modification of a procedure published elsewhere [Park 2004]. Our modifications to this
popular method yielded NPs of various sizes and morphologies, achieved by changing the
boiling point of the solvent or reflux time. These methods were not previously reported in

39

the literature. Additional modifications were made to reduce cost while developing green
chemistry methods. Spherical, cube-shaped, and polymorphous NPs, as well as nanowires
were obtained by varying the reaction time and reflux temperature. This was achieved by
using higher boiling point organic solvents for higher reaction temperatures. In addition,
green chemistry and lower-cost alternative chemicals were also investigated.

2.1 Synthesis of Colloidal Magnetite Nanoparticles
The procedure consisted of two steps, as described by [Park 2004]: synthesis of the iron
oleate precursor complex and synthesis of the iron oxide NPs. The precursor was iron
oleate, (iron(II, III) [(9Z)-9-octadecenoate] n) where n is the coordination number of iron,
and could form a monomer, dimer, or trimer [Bronstein 2007], [Palchoudhury 2011],
produced in our laboratory using a modified procedure of Bronstein et al. [Bronstein
2007]. The iron oleate complex was formed from the combination of sodium oleate salt
(sodium (9Z)-9 octadecenoate) and iron(III) chloride hexahydrate (FeCl3·6H2O). The
precursor preparation was modified by washing with water, ethanol, and acetone, to
remove additional contaminants before aging in the oven overnight.
2.1.1 Materials
FeCl3·6H2O (97%) was purchased from Sigma-Aldrich, n-docosane (99%) and n-eicosane
(99%) were purchased from Alfa Aesar, n-dodecane (>99%) was purchased from Fischer
Scientific, sodium oleate (>97%) was purchased from Tokyo Chemical Industry Co.,
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hexanes (95%), ethanol (99%), and acetone (99%) were purchased from EMD Chemicals
Inc. All chemicals and their physical properties may be referenced in Appendix I.
2.1.2 Synthesis of Iron Oleate Precursor Complex
In a standard reaction, 6.75 g of FeCl3·6H2O was combined with 25 mL of deionized
water and vacuum-filtered through 0.22 μm filter paper. The mixture was then combined
with 24.35 g of sodium oleate in a three-neck round-bottom flask. 150 mL of a stock
solution, consisting of a 2:4:6 mixture of deionized water, ethanol, and hexane, was added
to the flask. Under argon flow, the mixture was vented and filled

Figure 2.1 Ion exchange reaction between iron(III) chloride and sodium oleate, producing
iron oleate and the byproduct sodium chloride. Image by L. Armijo 2012.
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for three one-minute intervals, to remove all oxygen from the reaction flask. The solution
was then slowly (5 °C/min) heated to 50 °C under vigorous stirring.
Once the solid sodium oleate had completely melted and the reflux had begun
(around 50–60 °C), the temperature was further increased (3 °C/min) to 70 °C and the flask
was kept at this temperature for four hours, ensuring that the total reflux time was 4 hours.
The mixture was then cooled to 60 °C and washed three times with deionized water in a
separatory flask, if necessary, additional hexane was added to dissolve the organic layer.
The product was then washed twice with 12 mL aliquots of acetone and ethanol. The
organic layer was placed in a rotary evaporator (Rotovap) with the water bath set at 30 °C
until the hexane and ethanol were evaporated away. The resulting waxy complex was then
dried in a vacuum oven for 24 hours at 70 °C. The final product was a waxy dark-brown
solid. The overall reaction is illustrated in Figure 2.1.
2.1.3 Synthesis of Cubic, Polymorphous, and Spherical Nanoparticles
Using a 500 mL three-neck-flask attached to the Schlenk line (Figure 2.3), the reaction was
carried out. In a standard reaction, 5 g of iron oleate (washed with water for cubes, and
water, acetone, and ethanol for spheres), was combined with 5.6 mL of oleic acid and
13.15 g of n-eicosane (boiling point 342.7 °C). The mixture was slowly heated (3 °C/min)
to 50 °C under argon flow and vigorous stirring. Once the reactants had dissolved, the
temperature was further increased to 342 °C at a heating rate of 3.0 °C/min. For 19 nm
cubes, the mixture was refluxed for 30 minutes. For larger particles, the reflux time was
extended, with an average growth rate of 2.2 nm per minute. The maximum size
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achievable without adding additional reagents was 250 nm after 99 min. If the solution was
allowed to cool below the nucleation temperature (~ 200 °C), [Bronstein 2007] for any
amount of time before being refluxed at the same maximum temperature again, the NP
growth favored spherical morphology in which polymorphous NPs represented an
intermediate morphology (see Figure 2.2). It appears from these results, that the spherical
morphology is thermodynamically favored; exhibiting stability at high temperatures. After
30 minutes, the spheres were highly monodisperse.

Figure 2.2 Morphology alterations of iron oxide nanoparticles via
additional nucleation event(s).

2.1.4 Synthesis of Iron Oxide Nanowires
In a standard reaction, 5 g of iron oleate was combined with 1.6 mL of oleic acid and
13.15 g of n-dodecane (boiling point 216.2 °C). The mixture was slowly (3 °C/min)
heated to 50 °C under argon flow and vigorous stirring. For ~55×2 nm wires, once the
reactants had dissolved, the temperature was further increased to 216 °C at a heating rate
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of 3 °C per minute and the mixture was refluxed for 60minutes. For smaller wires, ~25×2
nm, the reflux was carried out at 150 °C for the same time. These findings confirm those
reported by [Palchoudhury 2011].

Figure 2.3 Active iron oxide nanoparticle synthesis in the Schlenk line.

2.1.5 Synthesis of Spherical Nanoparticles
In a standard reaction, 5 g of iron oleate was combined with 1.6 mL of oleic acid and
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13.15 g of n-docosane (boiling point 370 °C). The mixture was slowly heated to 50 °C at a
heating rate of 3°C per minute under argon flow and vigorous stirring. Once the reactants
had dissolved, the temperature was further increased to 370 °C at a heating rate of
3°C/min. For ~20 nm particles, the mixture was allowed to reflux for 32 minutes. For
larger particles, the reflux time was extended, with an average growth rate of 1.6 nm per
minute. The maximum size without adding additional reagents was 158 nm after 99 min.

Figure 2.4 Summary of morphology control, time, and temperature
parameters established by this study for the synthesis of Fe3O4 NPs.
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2.1.6 Summary of Green Chemistry Modifications
The sustainability of novel materials is crucial to human progress. Ensuring environmental
friendliness, the engineering process and integrating natural compounds into the materials
was a priority in these studies. Naturally existing molecules may have lower cytotoxicity
compared with synthetic products and are less likely to detrimentally affect the delicate
ecosystem upon disposal. In addition, the procedure for manufacturing many synthetic or
purified compounds is typically not environmentally friendly. The Environmental
Protection Agency (EPA) standards for green chemistry [EPA 2015] are very clear; reduce
waste, maximize yield, use less hazardous materials, minimize accident risk. By simply
replacing the popular metal nitrate precursors with water soluble chloride salts, many
environmental benefits are suggested. Our environmentally-friendly carrier molecule and
stabilizing agent, oleic acid, is a derivative of vegetable oil.
2.1.7 Cost Reduction
A lower cost and environmentally sound modification may be made to the aforementioned
procedures, by simply replacing the high molecular weight hydrocarbon solvent with
paraffin wax (bp >370 ˚C) or the natural solvent, beeswax. Paraffin wax or beeswax may
be thermally separated for reuse as well, rather than disposing of solvents after each
synthesis. This simple, green chemistry modification resulted in the same monodisperse
NPs above. Docosane costs $78.60 for 100 g, or ~$0.79 per gram (Sigma-Aldrich),
paraffin wax costs $5 for 453 g (1 lb.). This roughly corresponds to ~$0.01 per gram,
compared to the cost of docosane, thereby reducing the cost by 98.7%. Beeswax costs ~$9
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for 453 g (1 lb.), or approximately $0.02 per gram resulting in a cost reduction of 97.4%!
In addition, we have used re-distilled solvents, and saved them for use in future NP
syntheses. These solvents were processed and purified in-house to further reduce cost and
eliminate toxic waste.

2.2 Structural Characterization
The transmission electron microscope (TEM) images in Figures 2.5 through 2.7 show the
various morphologies and sizes of Fe3O4 NPs we were able to obtain using this method.
Cubic NPs having a maximum size of 250 nm were obtained after a 99-minute reflux.

Figure 2.5 Transmission electron microscope image of 250 nm magnetite nanocube
(left image) formed after 99-minute reflux, scale bar is 100 nm, and ~15 nm spherical
NPs (right image), scale bar is 10 nm.

Cubic and spherical NPs were easily produced with high monodispersity in sizes ranging
from 16 to 250 nm. Polymorphous NPs shown in Figure 2.6a were obtained by allowing the
cubic NPs to cool below their nucleation temperature of 200 ˚C prior to refluxing above the
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nucleation temperature. Interestingly, while attempting to measure particle size during
synthesis, by taking aliquots of the NPs as time went on, the temperature controller failed,
triggering the power supply to shut-off, and the particles cooled to room temperature. In hopes
of salvaging the experiment, we returned the temperature to 340 ºC. We found that the aliquot
taken after a 3-minute reflux performed after allowing the sample to cool below the nucleation
temperature was polymorphous.

Figure 2.6. Transmission electron microscopy (TEM) images of magnetite
nanoparticles capped with oleic acid. a) Polymorphous NPs, scale bar is 100 nm;
b) monodisperse spheres formed from refluxing of polymorphous NPs, scale bar
is 100 nm; c) monodisperse spherical NPs ~22 nm in diameter, scale bar is 100
nm; d) nanowires, scale bar is 50 nm [Armijo 2012a].
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A second aliquot, taken after 30 minutes of refluxing, consisted of monodisperse
spherical NPs. These findings suggest that the spherical morphology may be favored at
higher temperatures due to growth on all faces. Monodisperse spheres with a diameter
of ~30 nm in Figure2.6b formed from polymorphous NPs shown in Figure 2.6a,
when the reaction mixture was allowed below the nucleation temperature of 200 ˚C
for approximately 30 minutes before being refluxed again. Spheres of ~22 nm in
diameter (Figure 2.6c) and 55×2 nm nanowires (Figure 2.6d) were made in ndocosane (boiling point 370 °C) and n-dodecane (boiling point 216.2 °C),
respectively [Armijo 2012a]. We performed high-resolution (HR) TEM to
characterize morphology and to confirm high crystallinity of the NPs.

Figure 2.7 Transmission electron microscope (TEM) image of Fe3O4 spherical
superparamagnetic nanoparticles capped with oleic acid. This sample was chosen for
bacterial sensitivity studies discussed in Chapter 6 due to its excellent monodispersity
and superparamagnetic properties, scale bar is 50 nm.
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Figure 2.8. High-resolution transmission electron microscope
(TEM) image and its fast Fourier transform (FFT) of the iron
oxide monodisperse spheres (shown in Figure 2.6b above) scale
bar is 5 nm.
The image in Figure 2.8 represents fringes observed for the monodisperse spheres from
Figure 2.6b. The TEM images demonstrate the wide range of NP sizes and morphologies
attainable with minor time and temperature modifications to the procedure.
Elemental composition of the Fe3O4 NPs was verified with energy dispersive x-ray
spectroscopy (EDS), and example is shown in Figure 2.9. Magnetite samples of all
morphologies gave the same spectrum in EDS, therefore presented the same elemental
composition. Iron and oxygen are present in the monodisperse spheres from Figure 2.6b.
The carbon and copper peaks are due to the carbon-coated copper grid.
The x-ray diffraction (XRD) data for iron oxide polymorphous nanoparticles
(Figure 2.10) and the XRD data for the ~17 nm spherical particles are similar and suggests
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that the composition of the nanoparticles synthesized by this method to be ~70% (±5%)
magnetite Fe3O4 with space group Fd3m{F41/d32/m}, due to a perfect card match to the
major peaks in the crystallography database.

Figure 2.9 Energy dispersive x-ray spectroscopy (EDS) spectrum of magnetite
nanoparticles. This particular spectrum was taken from the monodisperse spherical
NP sample imaged in Figure 2.6b.

However, it is important to note that the several of the peaks assigned [220], [311], [400],
[440], [422] and [511], which match magnetite in the database, correspond to the spinel
phase. Spinel phase peaks are present in XRD spectra of both γ-Fe2O3 and Fe3O4, as well
as multiphase crystals containing these phases [Casula 2006]. [Bronstien 2007], who also
characterized SPIONS synthesized by this method, attributed these peaks to (likely) being
Fe3O4 as do we. The remaining 30% of the crystal appears to be composed of ferrous oxide
wüstite (Fe1-xO), where x can be between 0.05 and 0.17 and α-Fe2O3. The Wüstite is a
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phase of iron(II) composing meteorites. The presence of this highly dense, highly
magnetic phase is typical of iron oxides produced under low oxygen conditions [Casula
2006]. There are small peaks at ~56° and 84° which match to the [116] and [128] of αFe2O3, possibly the result of surface oxidation. Since the wüstite phase is metastable, it is
known to convert to α-iron and magnetite or a mixture of wustite, α-iron and magnetite
[Redl 2004]. The α-iron is reported to accumulate on the shell, where, on exposure to
atmosphere, it oxidizes [Bronstein 2007], which would explain why it is not detected on
the XRD, however α-Fe2O3 is. Wüstite and magnetite are structurally similar and likely
compatible in a multiphase crystal, therefore it is not uncommon to observe both phases
together [Bronstein 2007]. Magnetite and magemite are indistinguishable from one another
by XRD analysis [Bronstein 2007]. It is important to note that due to the similarity in space
groups and lattice constant, the oxidation state of iron oxide phases is difficult to determine
with absolute certainty using XRD.

Figure 2.10 XRD spectrum of polymorphous nanoparticles (NPs) (pictured in
Fig. 2.6a). The majority of the prominent peaks in this spectrum correspond to
magnetite or spinel phase iron oxide.
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Figure 2.11 X-ray diffraction (XRD) spectrum of 17 nm spherical NPs, taken
with monochromator attached for noise reduction. This spectrum also shows
spinel phase, hematite and magnetite peaks.

2.3 Summary of Findings
We synthesized and characterized magnetite NPs having various sizes and morphologies
using green chemistry methods. Our synthesis method significantly reduces cost, while
producing superior nanomaterials while exercising environmental consciousness. We were
able to synthesize iron oxide nanowires at a temperature that was not previously believed
to facilitate NP formation [Palchoudhury 2011]. We have also shown that spherical
particles are the most thermodynamically stable.
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Although we thoroughly investigated the physical properties of all three NP
morphologies, it was decided that the magnetic properties of spherical NPs in the
superparamagnetic size range (<20 nm) were best for our specific application. For
magnetic characterization, refer to Chapter 3. In addition, because this material will be
administered to the lung, lower aspect ratios NPs (spheres rather than nanowires) are
anticipated to have lower cytotoxicity than high aspect ratio NPs. Furthermore, the
procedure for synthesizing spherical NPs is much simpler than the procedures for the
synthesis of other morphologies because the temperature range required for successful
synthesis is not as narrow. Spherical NPs, having an easily reproducible synthesis
procedure can be used to provide for further studies thus, ensuring minimal variation
between batches. For these reasons, the 16-18 nm spherical NPs (Figure 2.7) were used in
the bacterial sensitivity studies discussed in Chapter 6.
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Chapter 3

MAGNETIC CHARACTERIZATION OF IRON OXIDE
NANOPARTICLES AND
MAGNETIC HYPERTHERMIA INVESTIGATIONS
The history of magnetism in medicine is extensive. The first report of the use of magnetite
powder for in vivo medical treatment of iron poisoning was in the 11th century A.D. by the
Persian polymath Avicenna [Häfeli 1998]. Since the dawn of the era of nanotechnology,
thousands of papers have been published proposing uses of nanoscale grain sized magnetic
powders for many biomedical applications. One important application, which has arisen
only after the modern medicine acknowledged the fact that magnetic fields are not
especially contraindicated for humans, is medical hyperthermia [Mornet 2004], also called
thermotherapy.The therapeutic potential of heat has been known for a very long time,
beginning with the recognition that fever enhancement promotes faster recovery from
illness by homeopaths; it is now known that heat can be used to cure a variety of different
diseases [Andrä 2007]. Heat use for cancer therapy and tumor cauterization has been
proposed since as early as 3000 B.C. [Strohbehn 1984]. A more contemporary historical
account actually suggested the use of lower temperatures, which would not cause damage
to healthy tissues (hyperthermia vs cauterization) [Busch 1866]. In the past 150 years,
much work has been done attempting to maximize heat effects in a local area of interest,
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with varying degrees of success [Streffer 1987], [Baronzio 2010], [Minev 2011], [Moros
2013].
In magnetic thermotherapy, the response of MNPs to oscillating magnetic field
causes thermal energy to be dissipated into the surroundings, killing the adjacent cells.
Additionally, hyperthermia can be used to enhance radiation and chemotherapy treatment
of cancer [Praetorius 2007], [Krishnan 2010], [Maier-Hauff 2011]. As mentioned in
Chapter 1, one of our original aims was to use the hyperthermic heat evolved to thin the
alginate biofilm characteristic of chronic Pseudomonas aeruginosa lung infections, and the
thick CF mucus barrier, in conjunction with magnetic gradient guided drug delivery to
deliver antibiotic drug to the infected area. Magnetic hyperthermia results from domain
switching upon AC electromagnetic (EM) radiation application. Our group previously
investigated iron oxide nanoparticles for heating applications [Armijo 2012a], [Armijo
2012b], however, the major mechanism involved in the temperature increases in these
specific nanomaterials have, only now, been uncovered. Biomedical applications require a
material with a large magnetic moment as well as the control of the magnetic properties
imparted by superparamagnetism. The attractive property of superparamagnetic materials
relates to the ability of the physician to induce their magnetic properties only after the
magnetic nanoparticles have arrived at the area of interest; by application of an external
magnetic field. This allows for venous delivery without agglomeration within the blood
vessels. Iron-containing nanomaterials having high saturation magnetic moments in the
SPM size-range are attractive for in vivo use. The iron oxides, specifically, have
demonstrated high biocompatibility and low systemic toxicity [Maier-Hauff 2011],
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[Soenen 2010], [Soenen 2011] as well as having received FDA approval for use as contrast
agents in magnetic resonance imaging (MRI) [Shieh 2005], [Veiseh 2005]. We have
investigated magnetic properties of iron oxide nanomaterials in the 15-30 nm size range for
this potential application. This size range was chosen, because it is close to the singledomain multi-domain size limit for iron oxides; 20-30 nm. This size range has shown the
greatest temperature increase under oscillating magnetic field application at many of the
frequencies being investigated for medical hyperthermia, in our case, 111.1 kHz with a
magnetic field of 25 mT [Hergt 2006].

3.1 Theory
Considering nanoscale colloidal suspensions of superparamagnetic NPs; also called
ferrofluids, the dominant relaxation mechanism resulting in heat generation could be due to
Brownian motion [Maier-Hauff 2011] or Néel relaxation [Shieh 2005]. Figure 3.1A
illustrates Néel losses: magnetic losses owing to domain wall displacements. Figure 3.1B
(lower image) shows Brownian losses: energy loss from mechanical rotation of the
particles in a colloidal suspension acting against viscous forces of medium. Heat energy
generated results from the contribution of both energy loss effects. Figure 3.1 is the
analysis of the AC data allows us to determine which of these mechanisms dominates:
Brownian or Néel relaxation of the particles.
Single domain particles have a magnetic moment, mp, given by

mp = Msυ

(3.1)
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Where Ms denotes the saturation magnetization and υ is the magnetic volume of the
particle. The Brownian relaxation time τB is given by:

τB = 4πr3η=kBT

(3.2)

Where r is the hydrodynamic radius, η is the dynamic viscosity of the solvent, kB is
Boltzman’s constant and T is absolute temperature (K).
For uniaxial anisotropy, the Neel relaxation energy barrier is given by Kυ, where K
is the anisotropy value of the particle. The associated magnetic moment direction reversal
or domain switching time is given by [Fannin 1989], [Fannin 1994], [Neel 1949], [Prévot
2001]:

τN = τ0exp(σ)

(3.3)

Where τ0 is a damping time having an average value of 10-9 s and σ=Kυ/kT.

Figure 3.1 Mechanisms of energy loss leading to heat production in magnetic
hyperthermia. A) Models Néel relaxation; the magnetic field flipping within the
NP, B) Models Brownian motion; the entire particle moves within the solvent.
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For polydisperse samples, combinations of the mechanisms respond to the heating in AC
fields. This is why it is crucial to use a monodisperse sample for magnetic characterization.
These samples were characterized using an effective relaxation time as follows.

τeff=τNτB/(τNτB)

(3.4)

In which the dominant mechanism is the one with the shortest relaxation time. [Fannin
1989], [Shliomis 1974], [Shliomis 1993]. This is analogous to the dominant rate of a
chemical reaction being the slowest step.

3.2 Experimental
A typical feature of magnetic nanocrystals is their irreversible ferromagnetic behavior
below the blocking temperature TB and reversible magnetization above it, caused by
superparamagnetic behavior of

the

nanocrystals.

We investigated the magnetic

properties, blocking temperature, magnetic saturation, and coercivity (hysteresis) using
a superconducting quantum interference device (SQUID) magnetometer. We investigated
the heat evolved at two different frequencies and magnetic field strengths using the
nanoTherics, Ltd. MagneTherm ™. Later, we looked at the dominant loss mechanism
under AC field at room temperature using the DynoMag® AC Susceptometer (IMEGO
AB, Sweden).
3.2.1 SQUID Magnetic Characterization of Iron Oxide Nanoparticles
The

blocking

temperature

can

be

found

experimentally

by

measuring

magnetization under field-cooling (FC) and zero-field cooling (ZFC) conditions. Below

59

TB, the Néel relaxation time τN is larger than the measurement time, τm (typically 100 s),
and magnetization depends strongly on the field history. Above TB, magnetization is
strongly affected by thermal fluctuations (τm>τN), making FC and ZFC curves coincide. In
other words, for a given measurement time τm, hysteretic behavior observed below TB
would not be observed above TB.

0.0016

Field-Cooled
Zero Field-Cooled

Magnetization (emu)

0.0014

0.0012

0.0010

0.0008

0.0006

0.0004
0

50

100

150

200

250

300

350

Temperature (K)

Figure 3.2 Magnetization vs. temperature for polymorphous Fe3O4 nanoparticles
(NPs) zero-field cooled (circle symbols) and field cooled (square symbols). We
measured temperature dependence of magnetization for the Fe3O4 NP samples under
ZFC and FC conditions. The DC (τm = 100 s) magnetization of the ferrofluid
samples was measured with a dc field of 100 Oe in the temperature range between 9
K and 350 K. Data shown in Figure 3.2 for 22 nm spherical particles [Armijo
2012a].

In the entire temperature range up to 350 K, the Fe3O4 NP samples demonstrated strong
ferri/ferromagnetic behavior as evidenced by the gap between the ZFC and FC curves
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persisting even at 350 K (Figure 3.2). From the ZFC curve, we can loosely estimate TB to
be ~175 K, but even above that temperature equilibrium magnetization of the nanocrystal
sample was not reached, and superparamagnetic behavior of the nanocrystals was not
observed.

Figure 3.3 Ferromagnetic hysteresis loops for (a) Fe3O4 polymorphous nanocrystals
and (b) ~22 nm spherical Fe3O4 nanospheres. τm= 100 s. Left: full sweep of magnetic
field measured at 293 K showing saturation. Right: enlarged loop measured at 293K
at low field [Armijo 2012a].

Strong ferromagnetic behavior of the Fe3O4 nanocrystal samples was confirmed in
magnetic hysteresis measurements. Consistent with the results of dc magnetization
measurements, magnetic hysteresis measurements at 293 K performed on Fe3O4
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polymorphous NPs (Figure 3.3a) find large coercivity ~37 mT (~29 kA/m) at 100 s
measurement time. Even larger coercivity of ~119 mT (~94.7 kA/m) was measured for ~22
nm Fe3O4 nanospheres.
An additional sample, which consisted of 17 nm spherical particles, displayed no
hysteresis under full magnetization vs field strength (M/H) sweep (Figure 3.4). This
demonstrates the significance of a 5 nm size difference on the magnetic properties. Zero
coercivity is a typical feature of superparamagnetic materials [Cai 2007]. Magnetite NPs in
this size range (10-20 nm) were the only samples shown to be truly superparamagnetic,
and therefore, are of the greatest interest for in vivo use.

Figure 3.4 Superparamagnetic hysteresis loop for 17 nm spherical particles
showing no coercivity (hysteresis), thus, superparamagnetic properties.
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Figure 3.5 MagneTherm™ inductive heater setup in its entirety. Shows
MagneTherm™, function generator, DC power supply oscilloscope, and infrared
thermometer.

Figure 3.6 Inside of MagneTherm™ inductive heater, with front cover removed,
shows inductor (coil) and capacitor (black box on right), clear hoses above and right carry
cooling water.
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3.2.2 Magnetic Hyperthermia Experiments
Magnetic hyperthermia for the Fe3O4 NP samples was tested using the nanoTherics, Ltd.
MagneTherm™ which operates at frequencies between 100 and 1000 kHz. The
MagneTherm is frequency tunable changing capacitor and or inductors out. The ranges of
frequencies and magnetic field strengths that may be achieved using this equipment were
calculated and may be referenced in Appendix III.
In Figure 3.6, you can see the number of coils on the inductor, by changing out coils
and capacitors, you can tune to a range of frequencies (and magnetic field strengths). The
temperature of the sample was measured using the Omega HHTFO-A portable fiber optic
data logger thermometer, version 1.0.25, with 0.1 °C resolution. Samples were prepared as
described in Chapters 2 and 4, coated with water soluble polymer as described in Chapter
5, and dispersed in deionized water. All concentrations were 30 mg/mL and sample
volumes were 5 mL. The NPs compared in the following graphs were 22 nm spheres,
polymorphous nanocrystals, and 55 × 2 nm wires. Later we investigated the heating of ~17
nm superparamagnetic spherical particles in water and in viscous (glycerol) media. The
heating efficiency of the NP samples was tested at frequencies of 111.1 kHz and 629.2
kHz. Data acquisition for hyperthermia was started at ambient temperature. Figure 3.7a
shows the heating of NPs of various morphologies; 22 nm spheres, 25 nm polymorphous
NPs and 55x2 nm wires at a frequency of 111.1 kHz (magnetic field of 25 mT). Figure
3.7b shows the heating of the same NPs at a frequency of 629.2 kHz (magnetic field of 9
mT). The spherical and polymorphous particles follow a similar trend consistent with their
similar morphology and particle volume. Although they do heat at the frequency of 111.1
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Adapted from [Armijo, 2012a].

kHz, the observed heating was relatively low. Interestingly, the total increase in
temperature after 40 minutes was 6 °C for spheres, whereas, it was only 1 °C for
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polymorphous NPs. However, as shown in Figure 3.8, the 17 nm spherical particles
performed significantly better at low frequency, with a total temperature increase of 25 ˚C.
When the frequency of the oscillating magnetic field was increased to 629.2 kHz, the
spheres and polymorphous NPs showed increased heating.
This temperature increase can likely be attributed to a size effect. However, unlike
the data obtained at 111.1 kHz, the total temperature increase was similar for the
polymorphous NPs and NPs of spherical shape: 16° C for spheres and 15 °C for
polymorphous NPs. As for the nanowires, the observed trend was just the opposite. The
total temperature increase at 111.1 kHz after 40 minutes was a remarkable 30° C and,
notably, saturation of the temperature was not reached in this timeframe. At 629.2 kHz,
however, the increase in temperature generated by the wires was much less than the one
obtained by spheres and polymorphous NPs, representing the total temperature increase of
4 °C.
It has been shown that the transition from ferromagnetic to superparamagnetic
behavior is associated with the change of the loss mechanism and, accordingly, of the
heating effect of magnetic NPs in hyperthermia experiments. Hysteresis losses dominate in
ferromagnetic nanocrystals, whereas heat production in superparamagnetic ones is due to
relaxation losses. Since the blocking temperature TB explicitly depends on the
measurement time τm (inversely proportional to the frequency of the oscillating magnetic
field), superparamagnetic NPs, as measured in DC magnetization experiments, become
ferromagnetic at sufficiently high frequencies > 1/τN (or > 1/τ, where τ = τΝτΒ/ (τΝ + τΒ), if
both Néel and Brownian relaxation mechanisms are present) and generate heat due to
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hysteresis losses. With the Fe3O4 NP samples demonstrating strong ferromagnetic behavior
in DC magnetization and hysteresis measurements, hysteresis losses are expected to be the
main mechanism of heating in the operating frequency range of our hyperthermia
experiments.
We estimated the Néel relaxation time τN at room temperature for the Fe3O4
polymorphous NPs (Figure 3.1) as follows:

τN = τ0exp(Eb/kT)

(3.4)

Where Eb is the magnetic anisotropy energy barrier, k is the Boltzmann constant and
τ0=10−10 s is the attempt time. Eb is related to the blocking temperature TB as Eb =
kTBln(τm/τ0) = 27.6 kTB, and we arrive at τN = τ0exp(27.6 TB/T) for the Néel relaxation
time. At T = 300 K, τN ≈ 0.001 s. At the frequencies of interest ω >> 1/τN, which is far
from the relaxation resonance, the Néel relaxation losses saturate at a level that is
negligible for large enough τN [Hergt 1998]. Therefore, we will interpret our results based
on the mechanism of hysteresis losses prevailing for NPs in this size range. When
hysteresis losses are the main heating factor, heating power is proportional to the area of
the hysteresis loop and to the frequency of the applied magnetic field. An approximately 6fold increase in the heating power is expected when the frequency is changed from 111.1
kHz to 629.2 kHz. The observed increase in heating power from the Fe3O4 polymorphous
NPs and nanospheres is not that large. We note, however, that both the frequency and
amplitude of the magnetic field were changed in our experiments, and the magnetic field
strength was reduced from 25 mT at 111.1 kHz to 9 mT at 629.2 kHz, which can explain
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the heating power increase not being proportional to the frequency for the Fe3O4
polymorphous NPs and nanospheres. The higher temperature increase of 6 °C for the
spheres compared to 1 °C for the polymorphous NPs at 111.1 kHz can be explained by a
significantly larger area of their hysteresis. However, the difference in the specific heat
production between the spherical and polymorphous NPs at 629.2 kHz is not significantly
pronounced.
We consider hyperthermia experiments with nanowires separately, as their
morphology differs dramatically from that of polymorphous NPs and nanospheres and may
be the decisive factor. Fine magnetite particles of needle shape with high aspect ratio have
been investigated previously by [Hergt 1998]. High potential for hyperthermia was noted
there for the particles that possess very high shape anisotropy, and hence high-energy
barrier for remagnetization, resulting in a wide hysteresis and high hysteresis losses. It was
concluded, however, that strong magnetic fields, very often unacceptable for human
patients, are required to fully utilize their potential. Very strong nonlinear dependence of
the hysteresis loss on the strength of the applied magnetic field was reported. Comparison
was made among particles of different shapes, and it was found that needles were by far
superior when applied magnetic field exceeded ~35 kA/m (43.89 mT), while below that
value the magnetic field was not strong enough to open the hysteresis loop in needles, and
their hysteresis losses were by several orders of magnitude lower compared to particles of
other shapes with low aspect ratio. We expect similar effects to be observed in nanowires
that are characterized with even higher aspect ratios of their shape. We believe that our
results for hyperthermia in nanowires can be explained by similar superlinear dependence
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of their hysteresis loss on the magnetic field strength, with that superlinear dependence
being much stronger than mere proportionality of the heating power to the frequency of the
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Figure 3.8 Hyperthermia results for superparamagnetic NPs having
an average diameter of 17 nm in water and water/glycerol mixture
having high viscosity. Data was taken at a frequency of 111.1 kHz
with a magnetic field of 25 mT in the inductor.

We note that the remarkable 30 °C temperature increase was observed in nanowire
sample at 111 kHz and magnetic field of 25 mT (19.6 kA/m), which is very close to the
typical values used in medical treatments; 100 kHz and 20 mT [Wust 2006], [Mehdaoui
2011]. Smaller spherical particles having an average diameter of 17 nm were shown to
perform comparably (see Figure 3.8) at low frequency. In order to verify our findings in
viscous media, an additional sample consisting of 16-20 nm spherical magnetite particles
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was characterized. Figure 3.8 shows the summary of hyperthermia experiments with the
SPIONs dispersed in water and in aqueous glycerol (50 % w/w) mixture six times more
viscous than water alone.
Additionally, no temperature increase was observed for the control experiments
using DI water under the same AC field and under identical experimental conditions with
no NPs (not shown). With this sample we were able to achieve a total temperature increase
in excess of 25 °C, and the initial fast heating rate of ~4 °C/min decreased to ~0.2 °C/min
after 12 minutes. This confirms the heat-generation is a result of the magnetic AC energy
absorption by the magnetic component of the ferrofluid samples. Due to the similar heating
trends in water and high viscosity aqueous glycerol, we attributed most of the heating
losses to a Néel process. This further verifies our susceptometry findings (recall that NP
samples below 20 nm in size displayed no coercivity (hysteresis losses) in M/H curves).
3.2.3 AC Susceptometry
Measurements of the frequency-dependent volume susceptibility in the frequency range
1 Hz to 100 kHz were performed using the DynoMag® (IMEGOAB, Sweden), with a
frequency range from 1 Hz to 200 kHz, a resolution magnetic moment of 3×10 -11 Am2, and
excitation amplitude of 0.5 mT. The ferrofluid magnetite (Fe3O4) sample 1 and 2 in water
solvent at a concentration of 130 M was measured using a 200-µL sample. Measurements
were performed on a sample which consisted of the base ferrofluid; colloidal suspension of
magnetite (Fe3O4) particles having spherical morphology of mean particle diameter 15 nm
in deionized water solvent, with succinylated PEG as a capping agent.
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Susceptometry data verify the magnetic hysteresis measurements in which we
found that the sample was superparamagnetic at room temperature. The susceptometry
measurements demonstrate a single peak, which we attribute to a Néel process, in which
τN=1.29x10-6 ms. Assuming the superparamagnetism, the Néel relaxation time of moment
rotations activated by thermal fluctuation is given by Eq. (4.3) and (4.4), with, where V =
1.767x10-24 m3 for the 15 nm diameter spherical SPIONs. When kBT > KuV, the magnetic
moment flips during the measurement time, demonstrating zero coercivity. Presently, the
effective anisotropy energy (Ku) of the iron oxide sample may be estimated to be 4.2 × 105
ergs/cc by the relation KuV = 25kBTB (assuming TB = 215 K) [Zhang 2010] higher than the
Ku of bulk Fe3O4 (Ku = 6.4 × 104) due to additional anisotropies which agrees with the
findings of [Zhang 2010], for particles of similar size. The effective anisotropy energy of
the iron nitride sample was calculated to be 5.6 x105 ergs/cc. A reference value for bulk
Fe16N2 is not presently available in the literature. The real part of the susceptibility (χ’)
values for both samples was greater than zero; a typical feature of ferri/ferromagnetic
materials. Despite this, the χ’ value for iron nitride is two times higher than the value for
iron oxide. As expected, the real part of the susceptibility (χ’) curve remains above zero for
both materials; a typical feature of ferri/ferromagnetic materials.

3.3 Summary of Findings
We characterized the magnetic properties of iron oxide NPs of various morphologies in the
paramagnetic to ferromagnetic size range, thus allowing for further functionalization and
drug conjugation. DC magnetization and AC heating power (hyperthermia characteristics)
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of the Fe3O4 NPs in water have been studied. The Fe3O4 NPs samples having a mean
diameter >20 nm demonstrated strong ferromagnetic behavior and hysteresis losses were
identified as the main mechanism of heating in hyperthermia experiments. Whereas, the
NP samples having a mean diameter of 15-17 nm demonstrated superparamagnetism and
Néel relaxation appears to be the dominant heating mechanism. Our hyperthermia data
shows that all three NP morphologies, spheres, polymorphous NPs, and wires are good
candidates for thermotherapy. Significant heating was observed well within the limits for
oscillating magnetic field parameters established for biological applications. The observed
temperature increase for 22 nm Fe3O4 nanospheres at 111.1 kHz and 25 mT after 40 min
was 6 °C. If the corresponding temperature increase took place from normal human body
temperature (36.6 °C) as a starting point, it would bring the local temperature up to 42.6
°C, which is right within the desirable temperature limits for the applications of medical
hyperthermia (41–45 °C) [Hergt 2006]. In the water/glycerol study we showed that the
initial fast heating rate of ~4 °C/min decreased to ~0.2 °C/min after 12 minutes (when the
temperature reached 45 °C). Although the heating rate is not linear and appears to slow
down as a function of temperature (when the slope between one point and the next is
considered), the data points considered to be within the initial fast heating rate are the data
points of interest for medical hyperthermia (36-42 °C). Of special interest for hyperthermia
applications, the nanowires demonstrated a remarkable 30 °C temperature increase, and the
superparamagnetic (~17 nm) spherical particles demonstrated a 25 °C temperature increase
under magnetic field conditions that were very close to (or lower than) the typical values
used in medical treatments.
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Chapter 4

SYNTHESIS AND CHARACTERIZATION OF HIGHLY
SUPERPARAMAGNETIC IRON NITRIDE
NANOPARTICLES (Fe16N2)
The Fe16N2 (martensite) phase is of interest for our application, and many others, not just
because it is, in-fact, the most magnetic material in the world [Kim 1972], [Ji 2010], but
also because it is free from toxic cobalt and the costly rare-earth elements. Using a stronger
magnet has many benefits for gradient-guided drug delivery, one obvious one being an
anticipated increased in the active transport rate due to a stronger interaction with the
external applied field. Zero-valent iron is another highly magnetic phase which serves as
an intermediate in the synthesis of iron nitride described in Section 4.3. Samples of zerovalent iron were taken from this procedure for use in bacterial sensitivity studies described
in Chapter 6.
Over 20 years ago, the iron nitride phase having the empirical formula Fe16N2 and
the specific phase of α”, was claimed to possess a giant saturation magnetization (Msat)
[Metzger 1994], [Ji 2010]. At that time, it was well established that iron cobalt, having the
formula Fe65Co35 composed the strongest magnet in the world [O’Handley 2000].
However, it was suggested that Fe16N2 might possess a saturation magnetization far
exceeding the iron-cobalt alloy [Metzger, 1994]. The α”-Fe16N2 phase was first discovered
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prior to 1950, the procedure having been published in 1951 when researchers initially
characterize the temperature dependence on the formation of different phases of iron
nitrides [Jack 1951]. In this paper, phase diagrams for iron-nitrogen systems were
proposed and the α”-Fe16N2 phase was described as a metastable crystal formed from rapid
quenching of γ-FeN (austenite) [Jack 1951]. Unfortunately, the magnetic properties were
not measured, and it was not until 1972, after the giant saturation magnetization was
finally measured, that interest in this material finally peaked [Kim 1972]. Since then, there
have been many attempts to synthesize this material as the sole phase in a crystal system,
however, typically these findings report the presence of a phase of α”-Fe16N2 mixed in with
other phases of iron nitride, iron oxide, or alpha iron [Comstock 2002]. Even now, more
than 40 years later, a need still existed to engineer single-phase crystals on the large-scale.
This method was developed in the interest of solving that problem while promoting the use
of green chemistry methods.

4.1 Introduction to Fe16N2
Iron nitride magnets offer a low cost, however, superior alternative to rare earth
magnets. In addition, the questionable stability of rare earth magnets on the nanoscale is
avoided in the binary iron phases. It has been shown that the low nitrogen content phases
such as γ-Fe4N, ε-Fe2–3N, α’-Fe8N and α’’-Fe16N2 are ferromagnetic compounds having
exceptionally well characterized stoichiometry [Wang 2003] and electronic properties [Eck
1999], are attractive compounds for magnetic functional nanomaterials [Grachev 2001].
The synthetic routes for commercial production are also well-documented. In order to
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create a timeless protocol for large-scale manufacturing of these nanomaterials, we must
anticipate the future regulations requiring green-chemistry procedures for the production of
all synthetic materials. By making minor, though profound modifications to known
methods using known physical and chemical properties, we can be environmentally
conscious while continuing to engineer superior materials. Fe16N2 being a phase of iron
nitride, being a superior material, reported to possess a very high magnetic moment, even
greater than pure iron [Cadogan 1997] and iron cobalt [Hattori 2001]. The saturation
magnetization of Fe16N2 powder with the largest specific surface area at room temperature
was previously reported to be a striking 200 emu/g with a maximum, coercive force 2250
Oe [Hattori 2001].

4.2 Theory
The Fe16N2 phase is considered ferromagnetic [Wang 2003], meaning it consists of an
array of atomic moments exhibiting very strong interactions. These interactions stem from
electronic exchange forces; quantum mechanical phenomenon resulting from the relative
orientation of the electron spins. These spin orientations result in either parallel or
antiparallel atomic moment alignment. Exchange forces are exceptionally large in
magnitude; on the order of 100 T, or 1x108 times the strength of the Earth’s magnetic field
[Wang 2003]. It is important to note that this field is detectable with simple low-cost
equipment. Ferromagnetic materials exhibit parallel alignment of moments resulting in
large net magnetization even in the absence of a magnetic field. The α”-Fe16N2 phase, in
particular being the most important new material of interest for high-density magnetic
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recording due to its exceptionally high magnetic moment which, as previously mentioned,
is larger than α-iron [Sugita 1991], [Bao 1994]. The coercivity and saturation
magnetization (Msat) of these phases incorporated into thin films have been investigated by
many researchers.
The saturation magnetization, Msat, of the other ferromagnetic phases is generally
lower than that of the α-Fe, except for the phases of α”-Fe8N and α”-Fe16N2, which have
been demonstrated by the above-mentioned researchers. Although others appear to have
achieved a phase of α”-Fe16N2 mixed with other phases, we believe that their ultra-high
temperature synthesis to be unfavorable to the stability of the α”-Fe16N2phase, and the sole
parameter (aside from accidental oxidation) being responsible for the existence of mixed
phase crystals. Producing these crystals at a temperature higher than 400° C facilitates
formation of the more thermodynamically stable phases of iron nitride: γ-Fe4N and ε-Fe3N.
These other phases have signature saturation magnetizations lower than that of α-Fe which
makes the Msat measurement an essential tool for differentiating between phases [Wang
2003].

4.3 Synthesis of Iron Nitride (Fe16N2) and Zero-valent (Fe0) Iron Nanoparticles
This green-chemistry procedure consisted of five-steps: 1) synthesis of the iron oleate
precursor complex, 2) synthesis of the iron oxide NPs, 3) oleic acid cap removal and
purification of iron oxide NPs, 4) reduction to α-iron, and 5) nitrogenation under ammonia
gas.
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4.3.1 Materials
FeCl3·6H2O (97%) was purchased from Sigma-Aldrich, n-docosane (99%) and n-eicosane
(99%) were purchased from Alfa Aesar, n-dodecane (>99%) and hydrochloric acid (1N
certified) were purchased from Fischer Scientific, sodium oleate (>97%) was purchased
from Tokyo Chemical Industry Co., UHP hydrogen gas (99.9999 %) and UHP ammonia
gas (99.9999 %) were purchased from Matheson Tri-Gas. All chemicals were used as
received, without purification. Chemicals and their physical properties may be referenced
in Appendix I.
4.3.2 Synthesis of Iron Oleate Precursor Complex
The precursor was iron oleate, (iron(II, III) [(9Z)-9-octadecenoate]n) where n is the
coordination number of iron, and could form a monomer, dimer, or trimer [Bronstein
2007], [Palchoudhury 2011], as described in detail in Chapter 2. Iron oleate is produced in
our laboratory using a modified procedure published elsewhere [Bronstein 2005]. The
formation of the complex was verified with UV-Vis-NIR spectroscopy. The iron oleate
complex was formed from the combination of sodium oleate salt (sodium (9Z)-9octadecenoate) and iron(III) chloride hexahydrate (FeCl3·6H2O). In a standard reaction,
6.75 g of FeCl3·6H2O was combined with 25 mL of deionized water and vacuum-filtered
through 0.22 μm filter paper. The mixture was then combined with 24.35 g of sodium
oleate in a three-neck round-bottom flask. 150 mL of a stock solution, consisting of a 2:4:6
mixture of deionized water, ethanol, and hexane, was added to the flask. Under argon flow,
the mixture was vented and filled for three one-minute intervals, in order to remove all
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oxygen from the reaction flask. The solution was the slowly (5° C/min) heated to 50° C
under vigorous stirring. Once the solid sodium oleate salt had completely melted and the
reflux had begun (around 50–60° C), the temperature was further increased (3 °C/min) to
70° C and the flask was kept at this temperature for four hours, ensuring that the total
reflux time was 4 hours. The mixture was then cooled to 60° C and washed three times
with a 1:1 mixture of hexane and deionized water in a separatory flask. The organic layer
was placed in a rotary evaporator (Rotovap) with the water bath set at 30° C until the
hexane and ethanol were evaporated away. Wet iron oleate complex (the hydrate form) as
obtained from the procedure described above was a reddish-brown, highly viscous liquid.
The precursor was further purified with ethanol, acetone, hexane, and water washes and
dried in the oven at 70° C for 24 hours. After drying, the product was a dark-brown waxy
solid.
4.3.3 Synthesis of Iron Oxide Precursor
Subsequently, iron oxide nanoparticles were prepared using a modification of a procedure
published previously [Park 2004]. 14.8 mmol (5 g) of iron oleate were combined with 1.6
mL (5.0 mmol) of oleic acid and 13.15 g (46.5 mmol) of n-docosane (for spherical
particles) or a molar equivalent of eicosane (for cubic morphology). The mixture was
slowly (3 °C/min) heated to 50 °C under argon flow and vigorous stirring. Once the
reactants had dissolved, the temperature was further increased to 370° C, with a heating
rate of 3.0° C/min. For 20 nm particles (±1.4 nm), the mixture was allowed to reflux for 30
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minutes. For larger particles, the reflux time may be extended, with an average growth rate
of 1.6 nm per minute. The particles were washed three times with hexane and acetone.
4.3.4 Removal of Oleic Acid Cap
As discussed in Chapter 2, the iron oxide NPs come out of synthesis capped with oleic
acid. The presence of the cap may introduce unwanted contaminants into the new iron
nitride crystal and must be removed. Either of two methods may be used to remove this
cap. Chemically, the coating is removed by adding 1M solution of hydrochloric acid, dropwise until the carboxyl group of the oleic acid is protonated (pH<5), and detaches from the
NPs. The uncapped particles are then isolated using the standard methanol and hexanes
extraction. An alternative method, which does not require hazardous reagents, is to simply
anneal the oleate coated NPs above the melting point of oleic acid, allowing the capping
agent to evaporate off (T> 250º C). Annealing is typically done for 20-30 minutes.
4.3.5 Production of Zero-valent Iron Nanoparticles
The iron oxide NP powder sample is reduced under UHP hydrogen gas overnight at 300350 °C. Then, the sample is exposed to ammonia gas for 2-24 hours at a temperature
between 250-400 °C. This temperature is below the ammonia decomposition temperature,
however, recall that iron catalyses the decomposition of ammonia making the lower
temperature sufficient. A sample of zero-valent iron NPs was preserved for bacterial
sensitivity studies reported in Chapter 6. For this study we produced zero-valent iron using
a hydrogen gas reduction (above), however, other options exist for the synthesis of zerovalent iron NPs. Zero-valent iron nanoparticles may be produced from iron pentacarbonyl
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in sonicated in a medium molecular weight alcohol under air-free conditions. In addition,
zero-valent iron NPs may be produced by mixing iron oxide NPs with a molar equivalent
of sodium borohydride then annealed in a high boiling point inert hydrocarbon under inert
gas for 30 minutes.
4.3.6 Production of Iron Nitride Nanoparticles
Iron nitride NPs were produced using zero-valent iron nanoparticles as a precursor. Any
capping agents are removed as described in Section 4.3.4. Then, the sample is exposed to
ammonia gas overnight at a temperature between 250-400 °C for 2 to 24 hours.

4.4 Structural Characterization of Iron Nitride Nanoparticles
Iron nitride NPs were characterized by XRD and TEM magnetic characterization was done
by SQUID magnetometry. For structural characterization, TEM/EDS samples were
prepared by placing a drop of the colloidal solution onto a 200-mesh carbon-coated copper
grid. The solvent was allowed to evaporate away, thus fixing the sample on the grid. The
JEOL-2010F transmission electron microscope was equipped with an OXFORD Link ISIS
energy dispersive

spectroscopy (EDS)

apparatus,

which

determined

elemental

composition. The electron beam was focused on a single nanocrystal and the characteristic
X-ray peaks specific to each element were identified using the OXFORD Link ISIS
software. EDS showed the presence of iron and a small peak corresponding to nitrogen.
The iron binary phase and crystal structure were determined using a Rigaku Smartlab® XRay Diffractometer (XRD) with a Cu Kα source (0.154 nm) and attached monochromator.
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It is important to note also, that the TEM analysis was difficult due to the strong magnetic
interaction between the material and the electron beam. The strong magnetic properties of
the sample caused the beam to oscillate, interfering with the analysis. Both the XRD and
TEM show a body centered tetragonal (BCT) crystal system. This system would be
expected for Fe16N2, thus, differentiating it from iron or iron oxide. Excellent crystallinity
is demonstrated in the TEM image shown in Figure 4.1.

Figure 4.1 High-resolution TEM image of Fe16N2 NP showing crystallinity.

Figure 4.2 shows the XRD spectrum for the uncapped iron nitride NP sample. The Jade
softward automatched the spectrum to the iron nitride (martinsite) phases Fe8N,
ICDD/ICSD card number 01-070-6150 and Fe16N2, ICDD/ICSD card number 01-0781865, both tetragonal crystals with lattice constants a=5.71 Å, b=5.71 Å, c=6.016 Å and
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a=5.72 Å, b=5.72 Å, c=6.29 Å, respectively. The scan also reveals some magnetite
(Fe+2Fe2+3O4) ICDD/ICSD card number 00-019-0629, which is a cubic crystal with lattice
constants a=8.38 Å, b=8.38 Å, c=8.38Å. This iron oxide likely resulted from surface
oxidation of the uncapped NP sample which was set onto the slide using ethyl alcohol,
chloroform and heat.

Figure 4.2 XRD spectrum for iron nitride NPs taken with CuKα, having a 0.154 nm
wavelength and using attached monochromator.

4.5 Magnetic Characterization of Iron Nitride NPs
We measured temperature dependence of magnetization for the Fe16N2 NP samples under
zero-field cooled (ZFC) and field cooled (FC) conditions. The DC (τm = 100 s)
magnetization of the samples was measured with a DC field of 100 Oe in the temperature
range between 10 K and 350 K. In the entire temperature range up to 350 K, the Fe16N2 NP
samples demonstrated strong ferromagnetic behavior as evidenced by the gap between the
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ZFC and FC curves persisting even at 350 K. From the ZFC curve, we can loosely estimate
TB to be ~350 K, but even above that temperature equilibrium magnetization of the NP
sample was not reached. Superparamagnetic behavior of the nanocrystals was observed in
this sample, but not observed in larger samples (>20 nm).

Figure 4.3 Magnetization vs temperature for Fe16N2 NPs (blue) compared to magnetite
(red). Zero-field cooled (lower curves) and field cooled (upper curves). Magnetization measured
with a DC field of 100 s. We measured temperature dependence of magnetization for the Fe 16N2
NP samples under ZFC and FC conditions. The DC (τ m= 100 s) magnetization of the ferrofluid
samples was measured with a dc field of 100 Oe in the temperature range between 9 K and 350 K.
Iron nitride appears to block around 350 K, whereas, iron oxide blocks around 210 K. The
elevated blocking temperature of iron nitride makes it attractive for many applications that
presently require supercooling.

Superparamagnetic behavior of the Fe16N2 NP samples was observed in magnetic
hysteresis measurements. Consistent with the results of DC magnetization measurements,
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magnetic hysteresis measurements at 293 K performed on Fe16N2 NPs find no coercivity
verifying that the magnetic hyperthermia results from a Néel process. We were unable to
find saturation Msat with the field strengths presently attainable by the equipment (Figure
4.5). Extrapolating the line gives a loose estimate of Msat ~ 100 emu/g. The DC (τm = 100
s) magnetization of the ferrofluid samples was measured with a dc field of 100 Oe in the
temperature range between 9 K and 350 K using a Quantum Design™ magnetic property
measurement system (MPMS) superconducting quantum interference device (SQUID)
magnetometer.
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Figure 4.5 Close up of hysteresis curve (positive axis), showing
that Msat was not reached in the 50 T applied field at room
temperature.

4.6 Summary of Findings
Iron nitride NPs were synthesized via solvothermal and solid-gas phase reaction in which
iron oxide powder as an intermediate. The composition, structure was characterized using
x-ray diffraction (XRD). Saturation magnetization (Msat) and coercivity of NPs was
determined using superconducting quantum interference device (SQUID). We found that
the successful formation of the Fe16N2 phase is strongly dependent on temperature and
reducing agent selection. Fe16N2 exhibits saturation magnetizations larger than that of α-Fe.

85

The highly magnetic Fe16N2 phase of iron nitride may be produced in high yields having
good resistance to oxidation, exceptionally high blocking temperatures, and depending on
the precursor, some control of particle morphology [Armijo 2012a]. This material has a
high magnetic moment though it contains no costly rare earth elements or toxic cobalt.
Additionally, the green chemistry procedure produces minimal toxic waste. It still remains
unclear whether this material is safe for use in vivo.
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Chapter 5

HYDROPHILIZATION AND BIOCONJUGATION

All charged (metal) nanoparticles (NPs) require an organic or non-organic polymer shell
to prevent aggregation, potential oxidation, and allow for further conjugation. In the case
of ferri/ferromagnetic NPs, the coating of magnetic nanoparticles (MNPs) must also be
sufficient to prevent magnetic interactions between particles. In general, to keep the
particles from interacting magnetically in such a manner that they agglomerate the polymer
shell should have a thickness equal to at least half the radius of the magnetic NP. In the
case of superparamagnetic NPs, no magnetic interaction in the absence of an external
magnetic field occurs. When the application is biomedical, the organic coating or polymer
shell must be water-soluble in order to be used in the aqueous biological environment.
Many FDA-approved polymers are available for use, such as poly(lactic-co-glycolic acid)
(PLGA) and polyethylene glycol (PEG), are often chosen simply because of their
confirmed safety rather than their physical or chemical properties. Some other attractive
options are natural polymers, which are anticipated to be biocompatible simply due to their
existence in other biological systems. Many are produced by plants, algae, or fungal
species, and must simply be purified for use [Lehr 1992], [Dang 2006]. These are typically
water-soluble and happen to possess many useful functional groups which allow for further
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conjugation to a gene or drug. Any organic molecule or polymer having a negatively
charged terminal functional group (OH- or COOH- are ideal) may be used to
electrostatically bind a positively charged NP. The stronger charge on the carboxyl group
will hold stronger, especially in high salinity. The colloidal stability of the NPs depends on
the ability of the polymer to maintain a strong ionic interaction with the NP as charged salt
ions can easily electrostatically bind to the charged functional groups on an organic
molecule or polymer. Shelf life as well as the systemic half-life of nanomaterials are
strongly dependent on and are highly controllable by this one parameter [Braatz 1993],
[Prencipe 2009].

NOTE: The terms, “organic molecules” or “organic polymers” were not used to describe potential
NP passivation coatings because silicon-based polymers may also be used. We use standard
chemistry terminology in which “organic” refers to “carbon-based.”

5.1 Experimental
Prior to engineering polymer or other organic coatings, the stabilizing agent, oleic acid,
must be removed from the surface of the NPs. Afterwards, water soluble polymers
presenting additional functional groups for bioconjugation may be attached. We
investigated the FDA approved polymer PEG as well as the naturally occurring
biodegradable capping agents, citrate and alginate, for this application. These capping
agents present carboxyl terminal groups for conjugation to the amine group of the
tobramycin molecule.
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5.1.1 Materials
m-PEG 5000 (methyl-terminated PEG) powder and sodium alginate from green algae
(medium molecular weight), succinic anhydride (>99%), phosphate buffered saline (PBS)
powder, and TRIS hydrochloride (PharmaGrade) were purchased from Sigma Aldrich,
anhydrous citric acid (99.5 %), chloroform (99.9 %) hexane (99%), acetone (99%), and
hexanes (99%), pyridine (99%), methanol (99%),were purchased from EMD Chemicals,
Inc., 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (cat# 22981)
and

N-hydroxysulfosuccinimide Sulfo-NHS (cat # 24510) were purchased from

ThermoFisher Scientific. Chemicals and their physical and chemical properties can be
referenced in Appendix I.
5.1.2 Removal of Oleic Acid Cap
The NPs come out of synthesis, described in Chapter 2, capped with oleate (oleic acid). As
discussed earlier in Chapter 2, the major reagent is iron oleate, an oleate molecule acting as
the organic carrier facilitating high temperature (solvothermal) crystal growth. Since iron
oleate served as the organometallic (metal carbonyl) complex by which the iron was
delivered to the iron-oxide crystal [Bronstein 2007, Palchoudhry 2011, Armijo 2012a]. The
oleic acid on the NP surface consists of a hydrocarbon chain and a single carboxyl group
that is electrostatically bound to the metal oxide NP (Figure 5.1); it has no functional
groups for drug conjugation and is not water soluble. Due to these significant limitations,
many researchers simply coat the NP with an additional water-soluble polymer (over the
existing oleate coating) [Liu 2012] in the case of Yb NPs. Other groups have reported the
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encapsulation of oleate-capped magnetite with a polystyrene layer [Ramirez 2003] or
chitosan [Shete 2014].
In order to ensure direct bacterial contact with the NP as well as sufficient charge
shielding for our application, the oleic acid cap was removed using a hydrochloride
solution wash at a pH of 1. The carboxyl group of the oleic acid becomes protonated at a
pH around 5; because pKa is ~5.4. Fatty acids like oleic acid contain long carbon chains
and typically have Ka values near 1 × 10-5 (pKa ~ 5). The oleate cap was removed with a
hydrochloric acid wash. The process of removing the cap is governed by the HendersonHasselbalch equation [Henderson 1908a, Henderson 1908b], which derives the pH as a
measure of acidity from pKa (the negative log of the dissociation constant) and the ratio of
the concentrations of an undissociated acid and its conjugate base [Brown 2012]:
𝑝𝐻 = 𝑝𝐾𝑎 + 𝑙𝑜𝑔10 (

[𝐴 −]
[𝐻𝐴]

(1)

where [A-] is the conjugate base (oleate anion) concentration, and [HA] is the organic acid
(oleic acid in our case) concentration.
The pKa is given by [Kanicky 2002]:
𝑝𝐾𝑎 = −𝑙𝑜𝑔10 (

[𝐻3 𝑂+ ][𝐴− ]
[𝐻𝐴]

(2)

where [H3O+] is the hydronium ion concentration.
When the pH is equal to the pKa, there will exist, in solution, an equal amount of
protonated (acid) and deprotonated (conjugate base) molecules ([A-]/[HA] = 1. A typical
carboxylic acid has a pKa between 4 and 5 [154], however, titration experiments have
shown that oleic acid has a much higher pKa of 9.85 [Kanicky 2002]. An organic acid will
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be significantly deprotonated in a solution if its pKa is two or more units lower than the pH
of the solution. Although the reaction would have proceeded at a higher pH, we used an
HCl solution having a pH of 1 to ensure a more rapid protonation and thus, detachment of
oleate from the iron-oxide NP at 25 °C. Inserting our pH value of 1 and the oleate pKa of
9.85 into equation 1 returns a value of 6974.3 for the ratio [HA]/[A-].

NOTE: THIS PROCEDURE WAS DESIGNED USING BASIC
ORGANIC CHEMISTRY METHODS, SPECIFICALLY, THE
PKA OF THE OLEIC ACID MOLECULE, WHICH IS KNOWN
AND CAN BE DETERMINED EXPERIMENTALLY. WE CAN
DEDUCE FROM THE PKA OF THE TERMINAL CARBOXYL
GROUP THE PH AT WHICH IT IS PROTONATED AND WILL
DETACH FROM THE NANOPARTICLE. THE METAL (M+)
BEING REPLACED BY THE HYDROGEN ION (H+) AND
BALANCING OUT THE NEGATIVE CHARGE ON THE
TERMINAL CARBOXYL GROUP.

The oleate ion is the ionized form of oleic acid [Raymond 2010]:

CH3 (CH2)7CH=CH(CH2)7CO2H + H2O ⇌ CH3(CH2)7CH=CH(CH2)7CO2- + H3O+
oleic acid

𝐾𝑎 =

+

water

oleate ion

⇌

[𝑜𝑙𝑒𝑎𝑡𝑒 𝑖𝑜𝑛][𝐻3 𝑂+ ]
[𝑜𝑙𝑒𝑖𝑐 𝑎𝑐𝑖𝑑 ]

+

hydronium ion

= 1 × 10-5; pKa = 5

Upon reaching the pH which favors formation of the carboxylic acid group, the
yellow-tinged transparent oleic acid could be visually observed to fall out of solution.
Oleic acid is soluble in methanol, so a standard methanol/hexanes extraction removes the
oleic acid from the bare iron oxide NPs. The NPs were separated in a 95%
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hexanes/methanol mixture, in which the methanol solvated the oleic acid. Acidic solution
slows oxidation dramatically, so there is no need to use inert gas flow for this procedure.
Once the two phases are separated the oleic acid is removed using a separatory funnel and
the NPs are isolated via centrifugation. The NPs are then redispersed in chloroform.
Capping should be done immediately to maintain passivation.

Figure 5.1 Removal of oleate cap; acid-wash facilitated removal of oleate cap
leading to uncapped NP and free oleic acid (the protonated form of the oleate
ion). Image by L. Armijo 2014.

Figure 5.2 Citric acid molecule; the
protonated form of the citrate ion,
3D image (upper image) and carbon
skeleton (lower image) drawn with
MarvinSketch.
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5.1.3 Citrate Capping
Citrate was the first biodegradable capping agent investigated. The citrate molecule has 3
carboxyl groups and one hydroxyl group, (Figure 5.2) available for attachment to the NP
and further conjugation to drug. Attachment to a specific group cannot be controlled at
present. Citrate was added to the NP solution in chloroform ensuring a (pH > 6) by adding
drop-wise amounts of 1M sodium hydroxide solution to ensure that a free carboxyl group
is available for attachment to the colloidal NPs. The sample was then sonicated and
washed. The sample remained stable in water for more than one year when an excess of
citrate was used to ensure complete coverage. The citrate cap may also be removed using
an acid wash, which converts citrate to citric acid, as in Figure 5.1.
5.1.4 Alginate Capping
Because a major component of the P. aeruginosa biofilm is alginate, we anticipated that
alginate capping should facilitate transport through biofilms based on the principle that
“like dissolves like.” The alginate monomer, shown in Figure 5.3, has 2 carboxyl groups
and 4 hydroxyl groups contributing to electronegativity and facilitating attachment to the
positively-charged NP. As with application of the other polymers, alginate was added to
the NP solution in a basic aqueous chloroform solution (pH > 6) to ensure a free carboxyl
group for attachment to the colloidal NPs. The sample was then sonicated for 30 minutes
to an hour in order to keep the particles from agglomerating, and then the NPs were
washed in water and removed via centrifugation. This sample also remained stable in water
for more than one year when an excess of alginate was used to ensure complete coverage.
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Figure 5.3 Monomer of alginic acid; the protonated form of the alginate ion,
showing 3D image (left) and carbon skeleton (right), drawn with MarvinSketch.
5.1.5 Polyethylene Glycol Succinylation
In order to enhance the binding affinity of PEG-OH to the NPs, we further engineered
mPEG using a simple succinylation procedure. mPEG-5000 was chosen as its use is
thoroughly documented for biomedical applications. Succinylated PEG was produced inhouse from the PEG-OH terminal of mPEG (methyl terminated polyethylene glycol), in a
process during which the terminal hydroxyl group was converted, by a small chain
extension, to a more electronegative carboxyl group which enhances binding affinity, and
thus, promotes long-term colloidal stability even under increasing salinities. In order to
keep a sealed pyridine bottle under close to atmospheric pressure, 25 mL of nitrogen gas
were drawn up into a syringe through the septum of a nitrogen-filled three-neck flask
connected to the Schlenk line and injected into the pyridine bottle. After injection, 25 mL
of anhydrous pyridine (the solvent) were drawn up from the bottle and injected into the
nitrogen-filled flask. The temperature controller was set to 50 °C, the temperature at which
the solid mPEG dissolves. Subsequently, 2.5 g of succinic anhydride were added to the
three-neck flask. This reaction process lasted for one hour at 50 °C. The addition of
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pyridine was repeated four more times using the same methodology as described above
and the reaction was allowed to continue for another 2 hours at 50 °C. Pyridine was then
removed using three DI water washes using the rotary evaporator. The material was then
re-dissolved in water and placed in 1 kDa cutoff dialysis tubing in a 1 L beaker of DI
water. The DI water in the 1 L beaker was replaced after 2, 4, and 8 hours. The final
material is a light brown substance that originally was thought to be a contaminant of the
original synthesis.

Figure 5.4 Dialysis of succinylated polyethylene 5000 glycol, using
dialysis tubing (under stirring in deionized water at room temperature)
for removal of precursors and unreacted reagents.

Figure 5.5 PEG Succinylation overall reaction. Shows the initial PEG molecule
having the characteristic terminal hydroxyl group and the product of PEG
succinylation procedure, now having a more electronegative terminal carboxyl
group.
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Figure 5.6 Dried and purified succinylated polyethylene glycol
(PEG) 5000 powder.

In the first synthesis, most of the succinylated PEG was lost through repeated
efforts to purify the material through crystallization and the use of activated charcoal.
Once this was realized, a second synthesis was performed by the original protocol that had
better results. Shown in Figure 5.4 is the purification through dialysis with 1000 Dalton
(Da) dialysis bags. The succinylated 5000 Da PEG is trapped inside of the dialysis tubing
while the lighter precursor materials are able to diffuse out of the bag into the surrounding
fluid called the dialyte. After dialysis purification, the mixture was dried with the rotary
evaporator with the water bath set to 50 °C, the same temperature of synthesis. The dried
succinylated polyethylene glycol was still liquid at this temperature and becomes a brown
waxy solid when cooled to room temperature as shown in Figure 5.7. Absorbance
measurements were performed on the succinylated polyethylene glycol using a Cary 5000
UV-VIS spectrophotometer. It is known that iron oxide is a semiconductor having a band
gap of 2.2 eV. The measurement of 1% by weight solution was performed from 200 to 700
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nanometers, which showed increasing absorption below 600 nm, with a shoulder peak at
250 nm. This data is especially important if this material is used in the future as a coating
for optically active materials such as quantum dots. The graph of the absorbance curve is
shown below; Figure 5.7.

1.4

1% Syccinylated mPEG 5000 in D.I. H20

1.2

Absorbance [O.D/cm]

1.0
0.8
0.6
0.4
0.2
0.0
200

300

400

500

600

700

Wavelength [nm]

Figure 5.7 Absorbance spectra for succinylated polyethylene
glycol (PEG) 5000.
5.1.6 Polyethylene Glycol (PEG) Capping of Iron Oxide Nanoparticles
After succinylation, PEG capping was performed using a modified procedure from
[Shtykova 2007]; for our work, we only used PEG, as opposed to a combination of costly
polymers. The iron oxide NPs were solvated in chloroform and combined with PEG using
a NP to PEG mass ratio of 1:2. The NP polymer solution was sonicated at 40 Hz for an
hour at room temperature. The NPs were then washed three times with DI water via
centrifugation before being resuspended in DI water.

97

5.1.7 Conjugation to Tobramycin
Drug conjugation to tobramycin was done using EDC with Sulfo-NHS. Sulfo-NHS is a
chemical modification reagent used in the conversion of carboxyl groups to amine-reactive
esters in bioconjugation or crosslinking. Sulfo-NHS is a charged analog of NHS (Nhydroxysuccinimide) and, like NHS, facilitates control and alteration of carbodiimide
crosslinking reactions in which carboxylates (–COOH), such as those present in the
polymer molecule, are activated for conjugation with primary amines (–NH2) found on the
tobramycin molecule. Such derivatives are synthesized by mixing the sulfo-NHS with a
carboxyl-containing molecule, such as alginate, citrate, or carboxy-PEG with a dehydrating
agent such as the carbodiimide EDC (also abbreviated EDAC). EDC is a “zero-length
cross-linker” meaning that it acts by bringing the two molecules of interest together but
does not change the hydrodynamic size by increasing the polymer chain length. In the first
step of the reaction, the carboxylated particles are activated by addition of the EDC
followed by the formation of a reactive ester intermediate, O-acylisourea. After that, the
ester will react with an amine group forming an amide, however, this amide is highly
unstable and will hydrolyze, regenerating the carboxyl group, if it does not encounter
another amine functional group. Our procedure was adapted from a previous publication
[Hermanson 2013]. In order to conjugate the SPIONs capped with any of the abovementioned organic molecules or polymers, 100 mg of Fe3O4 NPs have been washed three
times with 10 mL of coupling buffer (50 mM phosphate buffered saline, pH 7.2) and
removed by magnetic separation. The purified NPs were then suspended in 5 mL of
coupling buffer. To ensure an excess of the ligand, 50 mg of tobramycin (50 mg
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tobramycin per 100 mg NPs) was dissolved in coupling buffer, thus making a 10 mg/mL
tobramycin solution. The detailed protocol for drug conjugation can be referenced in
Appendix II.

Figure 5.8 Tobramycin molecule; an aminoglycoside antibiotic having the formula
C18H37N5O9, shows 3D image (left) and carbon skeleton (right), drawn with
MarvinSketch.

Under gentle stirring, the NP solution was added drop-wise into a beaker containing
the tobramycin solution and allowed to sit for 2 min at 450 rpm. 100 mg of EDC for each
100 mg of NPs were added to the reaction mixture, under stirring until solvated. The
conjugation reaction was allowed to proceed for 4 hours at room temperature under gentle
stirring. Afterwards, the NPs were washed twice with 5 mL of coupling buffer before
being resuspended in coupling buffer containing 35 mM Tris to block excess reactive sites.
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Afterwards, the particles were washed twice again, suspended in deionized water (DI
H2O), and stored in the refrigerator.

Figure 5.9 EDC/Sulfo-NHS crosslinking reaction scheme in which the alginate coating
on the NP is conjugated to tobramycin, thus, binding drug to the NP via a new amide
linkage. Image after [Conde 2014].
NOTE: The sulfite in tobramycin sulfate completely ionizes in an aqueous environment; it
is not covalently bound to the molecule and does not participate in the reaction.
5.2 Characterization of Functionalized Nanoparticles
5.2.1 Size Determination
Hydrodynamic size distributions of the nanocrystals have been measured using a DynaPro
Titan Dynamic Light Scattering (DLS) module from Wyatt Technology Corporation. In
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order to reduce aggregation and maximize the accuracy of the measurement, samples were
prepared for analysis by diluting the NP@oleate stock solution to 50 µg/mL in pure
chloroform. The NP@alginate stock solution was diluted in DI H2O. The 1-mL samples
were vortexed, then sonicated at 40 kHz for 5 minutes prior to analysis to separate
agglomerates and ensure that a more homogeneous solution was analyzed. DLS results on
OA capped NPs right after synthesis returned an average diameter of ~16 nm (not shown),
in agreement with the TEM observations. values. PEG-5000 has a theoretical average
length of ~30 nm, however it is important to note that the polymer length is just an average
value, in addition the polymer chain can bend and twist resulting in a range of measured.

Fig. 5.10 DLS size distribution showing average hydrodynamic size of iron-oxide NPs
after alginate capping.
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In our experiments, the succinylated PEG-5000 capping increased the hydrodynamic size
of the NPs from 16 to 40.65 nm (not shown). Alginate capping, using the natural alginate,
also having a range of polymer lengths, increased the hydrodynamic size of the NPs to
229.71 nm (Fig. 5.10) Tobramycin conjugation did not alter hydrodynamic size, as
expected, due to the small sizes of both the tobramycin molecule and the crosslinker.
Tobramycin conjugation was confirmed by FTIR spectroscopy.
5.2.2 Zeta potential measurements
Zeta potential measurements have been used to characterize the electrostatic potential at
the electrical double layer that forms at the interface of a colloidal NP and the dispersing
solvent. Although the zeta potential measurement is often regarded as NP surface charge, it
is not actually a measure of surface charge. Zeta potential measures the potential difference
between the dispersion medium and the adsorbed layer of solvent ions surrounding the
particle. This is not equal to the surface charge or the Stern potential [Kirby 2010], which
are defined at a different location. Colloids with a zeta potential between -10 to +10 mV
are considered neutral, while colloids with a zeta potential greater than 30 mV or smaller
than -30 mV are considered strongly cationic, or anionic, respectively [McNeil 2011].
Particles with a large measured value of zeta potential, whether negative or positive, are
electrostatically stabilized, whereas particles with low absolute values of zeta potential
aggregate or flocculate [Greenwood 1999, McNeil 2011, Hanoar 2012]. According to Liao
et al. [Liao 2015], iron oxide NPs in water had a zeta potential of +16.1 mV (incipient
stability), which shifted to -60.1 mV (good-excellent stability) after capping with alginate.
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Because most cell membranes are negatively charged, zeta potential is a key parameter in
membrane permeability, and cationic particles tend to exhibit toxicity associated with
membrane disruption (lysis) [McNeil 2011]. In our case, the alginate coating will impart
the nanocomposites similar negatively charged electrostatic properties to the target
membrane and biofilm environment, which should promote diffusion through the alginate
biofilms, while also imparting the colloid significant stability at physiological pH.
Additionally, the average diameter of the functionalized NPs is still small enough to
diffuse through the pores in the mucus, as long as they do not, agglomerate.
5.2.3 Forrier transform infrared (FTIR) spectroscopy.
Was performed on tobramycin-conjugated NPs to confirm the successful conjugation of
the drug. Since neither the tobramycin molecule, nor the capping polymer have an amide
linkage preexisting in their structure, the presence of an amide bond (1630-1681 cm-1) can
be used to verify a successful EDC conjugation. The samples were dispersed in KBr pellets
for FTIR analysis. The presence of an amide stretch, visible on FTIR at 1630–1680 cm−1
was used to verify the success of the crosslinking procedure. Loading efficiency of
tobramycin calculated as mass of NP conjugates/ mass of alginate capped NPs was found
to be ~2%.
5.3 Summary of Findings
We report on a method for removal of the organic coating resulting from the carrier
molecule used in the solvothermal synthesis method. We report a successful synthesis of
the more colloidally stable succinylated PEG from mPEG, as well as a method for coating

103

uncapped NPs. We have synthesized and water-solubilized magnetite NPs using various
organic shells. We have conjugated drug (tobramycin) and verified conjugation to NP
samples capped with two biodegradable polymers; alginate and citrate. Using EDC
crosslinking in synergy with sulfo-NHS, the NP samples were easily conjugated to the
amine groups on the tobramycin molecule. The amide bond between the two groups is not
present on either organic molecule prior to conjugation and is visible on FTIR
spectroscopy. We report an increase in colloidal stability and hydrodynamic size of
uncapped NPs (~60 nm) to ~230 nm for NPs capped in alginate.
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Chapter 6

DETERMINATION OF MINIMUM INHIBITORY
TREATMENT CONCENTRATIONS AND BACTERIAL
SENSITIVITY TESTING

Several different batches of NPs were used to thoroughly investigate against P. aeruginosa
biofilms and liquid cultures; uncapped magnetite NPs, magnetite NPs capped with
alginate, magnetite NPs capped with polyethylene glycol (PEG), zero-valent iron NPs
capped with alginate, and magnetite NPs capped with alginate and conjugated to
tobramycin. Citrate capped magnetite NPs were also produced; however, their use was
limited as they became oxidized and fell out of solution (lost colloidal stability) much
faster than the other compounds. In addition, initial investigations into the antimicrobial
properties of citrate-capped iron oxide NPs showed that they enhanced bacterial growth
[Brandt 2013]. Iron oxide NPs were investigated in the uncapped form as well as with a
biodegradable (alginate) and a non-biodegradable (PEG) polymer coating, because our
previous research showed that the PEG capped iron oxide did not inhibit bacterial growth
[Armijo 2014], and it was necessary to determine any inhibition without the contribution
of the cap. The lack of inhibition observed in the PEG-capped sample is possibly due to the
non-biodegradable plastic PEG cap which kept the iron from ever interacting directly with
bacterial cells. Despite the numerous investigations into the antibacterial effects of noble
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metal and other nanomaterials described in the literature [Pal 2007], [Panáček 2006],
[Shrestha 2009], and [Moritz 2013], not much focus has been placed on the role the
capping agent plays in the antibacterial properties. Our findings demonstrate a major
dependence on the type of capping agent (if any) that is used. We have investigated this
role by examining the same nanomaterial uncapped and capped with several different
polymers. An ideal control would include a non-drug conjugated sample having the same
polymer cap used for drug conjugation. Because it is well known that zero-valent iron
inactivates viruses [You 2005], gram negative E. coli [Auffan 2008], [Lee 2008], and was
investigated in inactivating gram positive and gram-negative microbes as well as fungal
cells [Diao 2009] we investigated the antimicrobial properties of zero-valent iron NPs as a
positive control.
Prior to the characterization of drug conjugates, we investigated the bacterial
sensitivities to two FDA approved antibiotic drugs; tobramycin (an aminoglycoside
antibiotic) and ciprofloxacin (a fluoroquinolone antibiotic). Proof of bacterial sensitivity to
tobramycin and determination of the minimum inhibitory concentration of tobramycin was
a necessary baseline establishment for the nanocomposite characterization studies since
tobramycin is the aminoglycoside antibiotic proposed for delivery by the nanosystem. We
also investigated bacterial sensitivity to ciprofloxacin, as an additional control, in the event
that

the

bacterial

colonies

demonstrated

resistance

to

tobramycin.

Although

fluoroquinolone antibiotics are not typically used in treatment due to their considerable
side-effects, ciprofloxacin specifically, is known to have a low MIC for the P. aeruginosa
species. Both the antibiotic drugs are known to be effective against P. aeruginosa that has
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not acquired resistance, causing bacterial cell death via two different mechanisms of
action. Therefore, acquired genetic resistance to one mechanism should not impart
resistance to the other.

Aminoglycoside antibiotics possess several amino functional

groups becoming protonated in biological media, thus, resulting in a polycationic species
[Kotra 2000]. The polycationic nature of the molecule imparts a high binding affinity to
negatively charged nucleic acids, especially prokaryotic rRNA [Fourmy 1996], [Fourmy
1998]. The simplest manifestation of resistance is posttranslational modification of the
rRNA target or to production of resistance enzymes [Kotra 2000].
It is important to note that P. aeruginosa is a human pathogen, therefore,
appropriate biosafety practices need to be followed, personal protective equipment used,
and engineering controls must be in place and functional when working with this species.
All experiments involving the use of live P. aeruginosa must be performed in a biosafety
level 2 (BSL-2) laboratory. Laboratory biosafety criteria detailing essential elements for
the BSL-2 and describing in detail required standard microbiological practices, special
practices, safety equipment, and laboratory facilities can be obtained from the Centers for
Disease Control (CDC).
Although biomedical researchers typically limit their biofilm growth to 6 days;
[Sauer 2012], [Benamara 2014] a previous report published [Moritz 2010], showed that
30-60-day-old biofilms have greater resistance to some stresses. However, another group
reports that after 7 days of biofilm formation the accumulation of biomass had not yet
reached a plateau [Klausen 2003], while a classic publication reports that 5 weeks of
growth was the optimal amount of time to achieve the maximum amount of biomass [Hays
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1945], and yet another report in which the mucoid (biofilm) phenotype observed in P.
aeruginosa typical of CF infections was investigated, biofilm cultures were maintained for
90 days [Speert 1990]. Because a typical P. aeruginosa infection in CF patients is typically
thoroughly established, we have chosen the extended growth period of 60-days. We
anticipate that this model will more closely represent a classic CF infection. Therefore,
although much of the research on P. aeruginosa is reported on biofilms which have
undergone shorter term growth, it appears that short term cultures are only merited in in
vitro diagnostics, as they were originally intended. In diagnostic studies, colonies are
allowed to differentiate just long enough to obtain diagnostic and sensitivity information.

Figure 6.1 Pyocyanin.
Image showing the
presence of pyocyanin
(blue-green) pigment
produced
by
P.
aeruginosa cultures
grown on agar for
disk diffusion testing.
Image by L. Armijo,
2014.

Longer term studies, although costlier, are no doubt merited in research settings
due to the documented difference and robustness of established colonies. Since
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we are interested in modeling a typical P. aeruginosa infection in CF patients
which is an established infection known to have more inherent resistance to
antibacterial agents, we maintained our biofilms for a period of 60-days prior to
testing susceptibility to NPs and NP-tobramycin conjugates. Established colonies
produced a thick alginate polymer matrix and secrete several pigments
characteristic of P. aeruginosa; pyocyanin (blue-green), pyoverdine (fluorescent
yellow-green), and pyorubin (red-brown). The optical color changes were noted in
the biofilm communities. The blue-green pyocyanin can clearly be seen in figure
6.1.
6.1 Microbiological Methods
6.1.1 Materials
Luria Bertani (LB) broth (cat #11006-004) and LB agar (cat #11006-001) were purchased
from IPM Scientific, Inc. Eldersburg, Maryland, USA, Pseudomonas aeruginosa cultures
were purchased from ATCC (ATCC 27853).
6.1.2 Minimum Inhibitory Concentration of Tobramycin Determination
Because our proposed treatment method is based on the delivery of Tobramycin to P.
aeruginosa colonies, it was critical to first establish susceptibility to, as well as the
inhibitory concentration of Tobramycin in this strain. According to a previous report 1,000
µg of tobramycin per mL was not sufficient to kill biofilm cells [Nickel 1985], however,
others have reported minimum inhibitory concentrations (MICs) ranging from 0.5 µg/mL
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to 2 µg/mL [Nichols 1981]. Loosely considering these findings, an initial range of 25-250
µg/mL was selected for determination of the MIC of this strain. To measure the MIC,
tobramycin sulfate was first diluted with sterile DI H2O to 1 mg/mL (stock solution).
Afterward, tobramycin was serially diluted and added to the 1 mL aliquots of culture to
final concentrations between 25 and 250 µg/mL with 25 µg/mL increments. 1 mL of sterile
DI H2O was added to the aliquot of the culture as a negative control. The cultures were
then grown overnight on a rotary shaker at 37 ºC and 150 rpm. The next day, 50 µL
aliquots of the cultures were diluted 1:2 with nutrient broth, plated on the nutrient agar
plates, and grown for 24 hours at 37 ºC. The next-day, plates were examined for the
presence of bacterial colonies. The MIC was accurately determined by using the dilution
series with 5 µg/mL increments of tobramycin concentration, ranging between its highest
concentration that still allowed the growth of P. aeruginosa colonies on the plate and the
next lowest concentration that completely inhibited their growth [Brandt 2013]. MIC of
tobramycin was measured over time beginning on day 1 after one overnight incubation (in
liquid culture without boiling stones), days 3, 10, 60 of biofilm growth.
6.1.3 Establishment of Biofilm Communities
Cultures of Pseudomonas aeruginosa were maintained as a frozen stock (in 75 % glycerol)
in a liquid nitrogen tank. Two days before the experiment, the broth medium was
inoculated and grown overnight on a rotary shaker at 37 ºC and 150 rpm until the optical
density at 600 nm (OD600) reached 0.5-0.6. OD600 is a well-established method for
determination of bacterial cell concentration (mg/mL) from the linear determination of
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colony forming units (CFU) in the media. The number of CFUs corresponding to the
optical density for P. aeruginosa at an OD600=1.0 is 2.04x108 CFU/mL which is equal to a
bacterial concentration of 2.085 mg/mL [Kim 2012]. OD600 was determined using Cary
5000 UV-VIS-IR spectrophotometer against a blank cuvette containing the same volume
of the liquid medium. This concentration was used to inoculate cultures in liquid media.
P. aeruginosa PAO1 biofilm communities were grown on sterile boiling stones in
liquid media for 60 days until firmly established. P. aeruginosa PAO1 biofilm
communities were grown on sterile boiling stones in liquid growth media for 60 days until
firmly established. Other researchers have published protocols in which P. aeruginosa was
grown for 3 days [Mandelbaum 1995], [Grassmé 2000], 6 days [Davey 2003], 8 days
[Suzuki 1973], or 7-10 days [Moreau-Marqiuis 2010]. As mentioned above, we not only
investigated these typical growth periods, but investigated an extended growth period in
hopes of modeling an established (chronic) infection. This significant amount of time for
biofilm establishment has not been previously reported. Liquid cultures were grown in LB
broth at 37 ˚C for increments of 3, 10, or 60 days. Other researchers have reported
protocols for growth of P. aeruginosa on sterile granite pebbles [Whiteley 2001], sterile
glass beads, [Leboffe 2012], or glass wool [Benamara 2014]. For our protocol, biofilm
cultures were grown in LB broth on sterile boiling stones which have significant surface
area for nucleation events, and conveniently, biofilm attachment. The liquid media was
decanted, thus, leaving only attached cells in the culture, followed by replenishing cells
with fresh broth. This method is a sufficient, low-cost alternative to a flow chamber. At the
end of the 60-day period, the cultures were sonicated at 40 Hz for 15 minutes to remove
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attached cells without damaging them, similar protocols have been previously published
[Schmitt 1986], [Vandevivere 1993]. The cells were then diluted to an optical density at a
600 nm wavelength (O.D.600) between 0.5 and 0.6, corresponding to about 1.02x107
CFU/mL and a bacterial cell concentration of 1.0425 mg/mL. OD600 was determined using
the Cary 5000 UV-VIS-IR spectrophotometer against a blank cuvette; which contained
only un-inoculated broth. Once diluted, the cultures were tested in liquid media or applied
to agar plates for susceptibility testing.
6.1.4 Motility Testing
Motility testing was done on cultures after 1, 3 and 60-days of growth. Motility testing was
done by preparing agar in test tubes and inoculating the agar using the stab technique with
a sterile inoculation loop having a pointed end. In this method the sharp end of the
inoculation loop is dipped into the cultures and stabbed into the agar inside of the test tube
one time. The tubes are then incubated overnight and observed the next day. Motile strains
can be seen to have disrupted the agar surrounding the place where the stab inoculation
was inserted into the agar. This disruption of the agar is not detectable in non-motile
strains.
6.1.5 Disk Diffusion Method
The disk diffusion method is one of the most popular approaches to bacterial sensitivity
testing due to its low cost and efficiency [Tendencia 2004]. The disk, impregnated with a
candidate antibiotic drug or compound of interest, is placed on the inoculated agar, which
contains a uniform layer of bacteria taken from liquid culture. The disks are commercially
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available, containing the proper concentrations of antibiotic drugs based in moles per gram.
As low-cost alternative, disks may be prepared using filter paper soaked in the appropriate
aqueous concentrations of the antibiotic drugs of interest [Loo 1945], [Van Bijsterveld
1969]. The underside of the plate is numbered for each sample to be tested. The cultures
are distributed evenly onto a sterile agar plate using a sterile cotton swab to form a uniform
layer on the agar. The disks, containint the prescribed amount of antibiotic drug
recommended for susceptibility testing by the Clinical and Laboratory Standards Institute
(CLSI), the institution responsible for maintaining uniform standards for such research.
Disks can also be made out of filter paper saturated in the standard dose of drug using a
known concentration and pipetting the corresponding volume onto the disk. The underside
of the plate is numbered for each sample to be tested. The method used was the agar disk
diffusion, as described in CLSI, where impregnated disks were applied to the cultured agar
plates overnight for 16-18 hours [CLSI 2014].
Approximately 108 CFU/mL of bacterial cultures, corresponding to an approximate 1
mg/mL concentration, determined by OD measurements, was distributed evenly onto a
sterile agar plate using a sterile cotton swab to form a uniform layer on the agar. The disks,
impregnated with NPs, drug, or NP-drug conjugates were then placed on top of the agar,
shown in Figure 6.2. A previous method of impregnation, the dip method, in which dry
disks were dipped into known concentrations by forceps and then placed onto the agar
cultures was found to produce inconsistent results because it was shown that the disks can
absorb different amounts of liquid, introducing variability in the absorbed concentrations
[Simon 1970]. Instead, the more accurate drop method described by Sabath, [Sabath 1976]
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was used. In this method, the dry disks are placed on the agar plates, then a known volume.
The dry disks were placed atop the cultures and a 0.1 μL drop of the solution of interest at
the desired concentration was applied to the disk using a micropipette calibrated
micropipette.

Figure 6.2 Agar plates inoculated with Pseudomonas aeruginosa colonies taken from
biofilm cultures, showing disks impregnated with DI water, NPs, or NPs bound to
drug. Image was taken prior to incubation [Armijo 2014].

This method eliminates variability in the total absorbed amount since a known volume is
applied. Disk concentrations of tobramycin were initiated at the CLSI recommended disk
content for tobramycin, corresponding to 10 μg absorbed into the disk, when this mass
returned a negative susceptibility, the concentrations were increased incrementally, until a
susceptible mass was determined. For the initial disk diffusion study investigating
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tobramycin, NPs and NP-conjugates, the mass on the disk was determined from
concentration and applied volume. For example, a 0.1 μL aliquot of a solution having a
concentration of 100 mg/mL corresponds to 10 μg in the disk (0.1 μL*100 mg/1 mL = 10
μg), a 50 mg/mL concentration corresponds to 5 μg in the disk (0.1 μL*100 mg/1 mL = 5
μg), and a 25 mg/mL concentration corresponds to 2.5 μg in the disk (0.1 μL*25 mg/1 mL
= 2.5 μg), and so on. The cultures were grown under the previous conditions overnight (1618 hours) at 37 °C. The diameter of zone of inhibition around the disc was observed and
recorded.
6.1.6 Biofilm and Mucus Model and Static Magnetic Field Application
A CF biofilm, mucus model was also investigated on the 60-day-old biofilms, in order to
determine whether magnetic field application susceptibility. For this model, the cultures
were prepared on solid agar in a petri dish, as described above, however, 1 mL of either
prepared pig mucin, aqueous alginate, or both were applied on top of the plated colonies.
The drug or NP-drug impregnated disks were applied over the barriers. Half of the agar
plates were placed on top of a ring magnet composed of sintered neodymium, iron, and
boron magnetic alloy blendgrade N45, having a Gauss rating of 13,500 Gauss, a pulling
force of 282 lbs., an axial pole orientation, a NiCuNi coating, and a tolerance of  0.002
inches. The magnets were left below the agar plate in the incubator for the entire overnight
growth period.
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Figure 6.3 Pole orientation options for ring magnets. Left: Axial, Right: Radial.
Ring magnets having axial pole orientation were used for this study.

6.1.7 Determination of Minimum Inhibitory Concentration of Test Articles
The diluted bacterial cultures were treated with various treatment concentrations. The
concentrations were attained by performing a standard serial dilution. A 17.35 mg/mL
stock solution was serially diluted by removing 0.5 mL from the stock tube and moving it
to the next tube containing the same total volume, and so on as shown below. Twelve

116

dilutions were done in total. Serial dilutions of tobramycin, tobramycin bound NPs, or NP
suspensions were prepared.

Figure 6.4 Illustration of serial dilution procedure. Starting
concentration in the first vial (red) was 17.35 mg/mL and 0.5 mL was
transferred from the previous vial to the subsequent vial in line, all of
which contained the same final volume.

For the MIC measurements, the compound of interest (NPs, tobramycin, or NPconjugates) were serially diluted in liquid growth media, as shown in figure 6.2, inoculated
from cultures grown for a specific period and incubated in sterile 2 mL vials overnight.
The cultures were then grown overnight on a rotary shaker at 37 °C and 150 rpm. Optical
density (OD) of liquid cultures was compared to a control cuvette containing only growth
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media, and ODs comparable to the growth media alone were considered inhibited growth.
OD typically increased with decreasing treatment concentrations, as the bacterial cells
were increasingly able to differentiate at the decreasing treatment concentrations. The MIC
was narrowed down by using the dilution series with even smaller increments of
tobramycin concentration, ranging between its highest concentration that still allowed the
growth of P. aeruginosa colonies and the next lowest concentration that completely
inhibited their growth. The MIC experiments are schematically illustrated in Figure 6.5.

Figure 6.5 Schematic diagram of minimum inhibitory concentration (MIC) determination
of tobramycin, iron-oxide NPs, tobramycin-NP conjugates, and zero-valent iron NPs in P.
aeruginosa liquid cultures

To verify inhibition, an inoculation loop was used to plate samples from liquid
cultures, having been incubated overnight with a known treatment concentration, and
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having an OD comparable to growth media alone. The bacteria were allowed to grow on
the agar plates overnight at 37 °C. MIC was determined by complete inhibition, defined by
negative growth on agar as well as no apparent growth in liquid cultures determined by
OD. For the control, sterile DI water was added to the aliquot of the culture, as opposed to
an investigational compound. Due to the potential for interference of NPs with OD
measurements, NPs were removed from solution, by magnetic separation, after inoculates
were plated on agar, but prior to OD measurement.
6.1.8 Graphical and Statistical Analyses
Graphical and statistical analyses analysis of variance (ANOVA) were performed on
Microsoft Excel and GraphPad Prizm™. Average values and standard deviations being
calculated on Microsoft Excel® and ANOVA performed on GraphPad Prizm™.
6.2 Results
6.2.1 Minimum Inhibitory Concentration of Tobramycin Results
Using the procedure described in Section 6.1 and a tobramycin concentration curve, we
determined the MIC of this particular strain of P. aeruginosa in the initial pilot study to be
between 10-15 µg/mL for planktonic cultures and averaged 50 µg/mL for established, oneweek-old old biofilms in liquid media (±5 µg/mL). These findings are similar to the
previously reported MIC of 35-50 µg/mL (±5 µg/mL) found in planktonic cultures [Brandt
2013]. Despite the documented need for a significantly increased drug concentration for
the treatment of bacterial biofilm infections (if drug susceptible at all). A previous report
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found that 1,000 µg of tobramycin per mL was applied to an established biofilm, and a
significant proportion of the bacterial cells within the biofilm were found to remain viable
after 12 h of exposure to this very high concentration [Nickel 1985]. The same group
reported the MIC in another study was found to be several orders of magnitude lower; only
0.4 µg/mL, so MIC may differ tremendously from strain to strain and among different
growth modes. Others have reported MICs ranging from 0.5-2 µg/mL [Nichols 1981].
Another previous investigation found that oxygen limitation and low metabolic activity in
the interior of the biofilm, not poor antibiotic penetration, to be factors contributing to the
antibiotic tolerance of the P. aeruginosa biofilm system [Walters 2003].

Figure 6.6 Minimum inhibitory concentration (MIC) of tobramycin to P. aeruginosa
colonies as a function of growth time. Please note that the cutoff concentration for
susceptibility of P. aeruginosa to tobramycin in liquid cultures is ≤4 μg/mL, therefore,
none of the cultures are tobramycin susceptible by CLSI standards.
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The MIC of tobramycin in this strain of P. aeruginosa, determined at several time
points during biofilm growth increased over time and was found to be 32 μg/mL for 3-day
old biofilm cells, 50 µg/mL for 10-day old biofilms and 93.7 mg/mL for 60-day old
biofilms. The MIC of tobramycin differs significantly from strain to strain, when
comparing planktonic vs biofilm cells, and biofilm growth time. These trends were not
observed for shorter periods of growth. These findings add merit to our longer-term growth
period for the establishment of biofilm colonies. According to the breakpoints
recommended by the CLSI for determination of MIC, inhibition at a concentration ≤ 4
µg/mL of tobramycin means the strain is susceptible; inhibition at a concentration of 8
µg/mL is intermediate; and inhibition at concentrations ≥ 16 µg/mL means the strain is
tobramycin resistant [CLSI 2019]. Therefore, according to the CLSI breakpoints for
interpretation of MIC, the cultures taken from biofilm communities were never found to be
susceptible to concentration of tobramycin defining susceptibility. This strain exhibited
intermediate susceptibility in some cases, in planktonic colonies (liquid cultures grown
overnight), with a MIC of 10-15 µg/mL. The biofilm cultures were found to be
tobramycin-resistant in all cases, beginning on day 3 and becoming more resistant over
time.
6.2.2 Interpretation of Disk Diffusion Results
The impregnated disks diffuse antibiotic drug, with the highest drug concentration
assumed to be at the center of the disk and decreasing with the distance from that center
point. According to the Clinical and Laboratory Standards Institute (CLSI), the investigator
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must use the standards provided for the organism and the corresponding infected tissue or
organ. CLSI tables provide the drugs and corresponding concentration dose for
susceptibility testing using the disk diffusion method for many bacterial species, including
Pseudomonas. The doses recommended by the CLSI were used for the initial studies
(Table 6.1), the recommended dose used for the susceptibility determination of P.
aeruginosa is 2 µg/mL for tobramycin, and the 0.2 µg/mL for ciprofloxacin. Since the
plates were streaked using a sterile inoculation loop dipped in the liquid culture (having an
O.D. between 0.5 and 0.6).

Figure 6.7 Agar cultures used for susceptibility testing. A) Agar plate with impregnated
disks prior to overnight incubation. B) Image shows zone of inhibition (ZOI) halo around
disk impregnated with antimicrobial agent of interest; a positive susceptibility result. C)
Motility testing results in agar stab cultures after incubation; upper tube is a negative
motility result and lower tube is a positive motility result.
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The effective doses for the susceptibility testing are much lower than the MIC reported for
cultures in liquid media because the number of bacterial cells is much lower when a plate
is inoculated. For example, in a 1 mL liquid culture tube having a concentration of 1.04
mg/mL corresponds to a total biomass of about 1 mg, whereas, an inoculation loop is
dipped into the tube, and used for streaking the plate only contains about 50 µL,
corresponding to a total biomass of 0.05 mg. If we examine as mg per mass of bacterial
cells, it is apparent that the CLSI dose of 2 µg/mL on the disk for a biomass of about 0.05
mg is close to our initial, experimentally determined average MIC of 35 µg/mL applied to
a 1 mg biomass.
After overnight incubation, the agar plates were examined. The presence of a “halo,”
around the disk suggests some degree of bacterial susceptibility to the compound applied.
The halo surrounding the disk is a positive result for sensitivity, called the zone of
inhibition (ZOI). The diameter of the ZOI is used for interpretation of these results based
on CLSI breakpoints. This represents a concentration gradient with the maximum drug
concentration at the center of the disk. The diameter of the halo was measured, and
susceptibility was based on this measurement as follows:

Table 6.1
Guidelines for interpretation of disk diffusion results
Method
Susceptible
Intermediate
Resistant
Disk diffusion
≥ 15
13-14
≤ 12
[mm]
Where R is resistant, S is susceptible, and I is intermediate.
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6.2.3 Disk Diffusion Results
The results of disk diffusion susceptibility studies are reported. The first table , 6.2, shows
the results of Fe3O4 NPs capped with PEG-OH, Fe2O3 capped with PEG-OH, Fe3O4 NPs
capped with alginate and bound to tobramycin, Fe3O4 NPs capped with citrate and bound
to tobramycin, tobramycin, ciprofloxacin, citrate and a DI water negative control.
Table 6.2
Comparison of 3-day old biofilm sensitivities to MNPs capped with
PEG, tobramycin, ciprofloxacin, and NP-drug conjugates
Disk
number

chemical or drug

Radius
of Sensitivity
inhibition

1

NPs alone (Fe3O4) capped
with PEG-OH

17 mm

S

2

NPs alone (Fe2O3) capped
with PEG-OH

0

R

3

NP (Fe3O4)-alginatetobramycin

17 mm

S

4

NP (Fe3O4)-citrate-tobramycin

29.5

S

5

Tobramycin alone

10 mm

R

6

Ciprofloxacin alone

40 mm

S

7

Deionized water

0

R

8

Aqueous citrate

1 mm

R

The bacterial colonies were susceptible to the CLSI concentrations for the treatment of P.
aeruginosa; 0.2 µg/mL for ciprofloxacin. The colonies did not demonstrate antibiotic

124

resistance to ciprofloxacin. It is important to note that despite the effectiveness of the drug
ciprofloxacin, this drug is not typically included in the normal treatment regime for P.
aeruginosa infections. Ciprofloxacin has been given a black box warning by the FDA [US
Food and Drug Administration 2008] due to its potential to cause permanent damage to
muscles, tendons, joints, nerves, and the central nervous system. Its use is recommended
only when there are no other treatment options.
The results of overnight sensitivity studies comparing different capping agents are
summarized in Table 6.2. Due to our previous findings in which citrate capped NPs
slightly promoted bacterial growth [Brandt 2013] we also tested citrate alone. Although no
explanation for this was described by [Brandt 2013] it is possible that the citrate on the NP
surfaces was used as a source for pyruvate synthesis by the bacterial cells. We were not
able to characterize increased bacterial growth on this solid agar as was observed
previously in liquid cultures, however, we did not observe inhibition by citrate or citratecapped NPs.
These results were obtained on 3-day-old biofilms plated on LB agar using the
standard dose described in the introduction. In this result, we can see that the P.
aeruginosa biofilm colonies did have an intermediate sensitivity to PEG-OH capped
magnetite in this initial study, suggesting incomplete coverage of the NP by the nonbiodegradable polymer. There was no inhibition by maghemite NPs capped with PEG-OH,
either due to the lower iron content of the material, or due to complete coverage by the
capping agent. It is important to note that we have observed PEG-OH capped NPs to be
less colloidally stable than a capping agent that is attached to the NP via a COO- group.
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Table 6.3
Susceptibility of P. aeruginosa biofilms to various treatments after 3 and 60 days of
growth, by disk diffusion
Sensitivity is described with S for sensitive, I for intermediate, and R for resistant. DI
water was used as a negative control and no ZOI was observed for DI water

Material

Dose on disk ZOI (mm) ZOI (mm)
day 3

day 60

10 μg

22/S

21/S

5 μg

17.5/S

16/S

2.5 μg

11/R

10/R

10 μg

0/R

0/R

5 μg

0/R

0/R

2.5 μg

0/R

0/R

10 μg

22/S

22/S

5 μg

16/S

15/S

2.5 μg

10/R

8/R

Fe3O4@ALG:TOBRA NPs 10 μg

23/S

22/S

5 μg

11/R

15/I

2.5 μg

7/R

5/R

10 μg

25/S

24/S

5 μg

21/S

22/S

2.5 μg

20/S

20/S

10 μg*

10/R

0/R

100 μg**

25/R**

15/R**

1,000 μg**

35/R**

32/R**

Fe3O4 NPs†

Fe3O4@PEG NPs

Fe3O4@ALG NPs

ZVFe@ALG NPs

Tobramycin

Interpretation: R – resistant, I – intermediate; S –susceptible. †Uncapped NPs. *CLSI breakpoint for
susceptibility of tobramycin by disk diffusion is 10 μg, therefore, all colonies are found to be
tobramycin resistant by CLSI standards. **Higher tobramycin doses in the disk were investigated
to determine whether any susceptibility existed at higher doses. At present, there are no CLSI
values/breakpoints for NPs as antimicrobial agents. ZOI: zone of inhibition; PEG: polyethylene
glycol; ALG: alginate, TOBRA: tobramycin, ZVFe: zero-valent iron.
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It is probable that a percentage of the polymer is protonated and detached from the NP in a
colloidal suspension, at an undetermined equilibrium concentration. As is well known,
water at equilibrium contains H+ and OH- at pH dependent concentrations, so it is possible
that some of the PEG-O- is protonated in water, even at a physiological (neutral) pH.
Table 6.3 shows results of sensitivity testing and determination of MIC for experiments
using NP-drug conjugates on the 60-day old established biofilm colonies. These colonies
were also grown as described in Section 6.1. For this study, succinylated PEG, (PEGCOOH) was used to ensure complete continuous coverage of the NP samples. For this
study, we also investigated the inhibitory properties of zero-valent iron, which is known to
inactivate microbes.
Disk diffusion results for tobramycin were interpreted based on the 2019 CLSI
breakpoints for tobramycin in P. aeruginosa [CLSI 2019], in which the mass of
tobramycin on the disk is 10 µg and a disk diameter ≥15 mm is susceptible (S), 13-14 mm
is intermediate (I) and ≤12 mm is resistant (R). Since there are no established standards for
the investigation of iron oxide nanoparticle susceptibility in any microbes, we used the
same cutoff values as we used with tobramycin in order to maintain consistency. We also
investigated a range of concentrations of both tobramycin, NPs and NP-conjugates in order
to determine susceptibility range. The disk diffusion results (Table 6.3), taken together
with the MIC results, over time, demonstrate that the tobramycin susceptibility decreases,
and resistance increases as the colonies are allowed to grow in biofilm mode for longer
periods of time, despite being tobramycin naïve. Therefore, this is not due to exposurerelated resistance development. It is important to note that the observed increase in
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resistance is not due to a larger initial amount of CFU’s in the 60-day old biofilms, because
cultures were diluted and identical concentrations of CFUs were used for inoculation and
plating for all time periods. These findings suggest that the age of the infection alone (i.e.,
establishment of a chronic infection) contributes to resistance. This is possibly due to
broader genetic diversity in the population. No comparable increase in resistance over time
was observed for the NP samples investigated, suggesting that a genetic resistance
mechanism to counter the action of the compound may not exist. We can speculate that the
mechanism of action of the iron-oxide NPs is not based on inhibition of genes or bacterial
protein synthesis, which implies the toxicity may not be prokaryote-specific.
For the iron-oxide NPs alone, we found that inhibition of established biofilms on agar
plates was observed for low concentrations. When capped with alginate, the inhibition
remained low even though part of the mass of this core-shell type NP consists of nonbioactive alginate. In the case of iron-oxide NPs capped with succinylated PEG, no
inhibition was observed, possibly because the non-biodegradable nature of the capping
agent may keep the iron from interacting directly with the bacteria (see Table 6.3). If the
iron ions contribute to the toxicity, it may be possible that, in this case, they were not
distributed to the colonies, and therefore, could not inhibit bacterial growth.
These findings demonstrate that the crucial role of the capping agent to the impartation
of antimicrobial properties. Therefore, the capping agent also contributes to or negates the
toxicity of this material. We can speculate that a complete succinylated PEG cap may also
reduce the toxicity of NPs known to exhibit cytotoxic effects in vivo since it appears to
limit interaction with the cells, at least in this short exposure time frame.
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Even at high concentrations, we might expect to observe some inhibition due to
incomplete coverage, however, that is not the case. In the case of iron-oxide NPs
conjugated to tobramycin, we find that the bacterial inhibition at these concentrations
mirrors the inhibition trend of iron-oxide NPs alone. It is important to note that these
findings are characteristic of this particular strain, after this period of growth, and its
susceptibility to tobramycin. Recall the previous study which found that after a 1,000
μg/mL concentration of tobramycin was applied to established biofilms, a significant
proportion of the bacterial cells were still viable after 12 hours [Nickel 1985]. This group
also reported that planktonic cells taken from the same strain was completely killed by
only 50 μg/mL. Another relevant study reports the MIC from their clinical isolates to be 8
μg/mL [Shawar 1999]. These published findings suggest a huge theoretical therapeutic
dose ranging from 8 µg/mL to more than 1,000 μg/mL. MIC and susceptibilities appear to
differ dramatically from strain to strain and in planktonic vs biofilm communities.
Therefore, it is probable that these susceptibilities may also differ from strain to strain and
under different growth conditions.
6.2.4 Biofilm and Mucus Model and Static Magnetic Field Application Results
The CF disk diffusion model, grown on solid agar in petri dishes, in which artificial mucin
and alginate barriers were applied over the bacterial colonies cultured from established 60day old biofilms reveal that the application of an external magnetic field, enhances
susceptibility to the iron-oxide NPs and NP-drug conjugates, possibly by promoting
transport across the two barriers. For this study, 50 mg/mL concentrations of NP conjugate
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and NP solution was applied to the disk such that each disk contained 50 µg of test article.
The results with (Table 6.5) and without (Table 6.6) magnetic field application
demonstrate zero susceptibility to tobramycin alone.
Table 6.4
Results of CF biofilm model (magnet applied)
A mucin barrier, an alginate barrier, or both- were applied to 60-day-old biofilm
colonies. For this study, a magnet was placed below the petri dish.
Disk Number/ Compound
Mucin
Alginate
Mucin +
Barrier
Barrier
Alginate
Barriers
1. Iron Oxide NPs †
30/S
0/R
20/S
2. Zero-valent Iron NPs
5/R
20/S
20/S
3. Iron Nitride NPs
30/S
32/S
15/I
4. Iron Oxide NP25/S
19/S
14/I
Tobramycin
5. Tobramycin (200 mg) *
32/R
30/R
20/R
Disk diffusion method was used. Minimum concentrations demonstrating susceptibility in
previous disk diffusion studies were used for NPs and NP-tobramycin conjugates. †Uncapped
NPs *Maximum CLSI cutoff concentration for susceptibility of tobramycin 10 μg absorbed onto
disk. These doses of tobramycin shown are up to seven orders of magnitude higher than the CLSI
standard dose for disk diffusion, therefore, although inhibition was observed, these colonies are
tobramycin resistant by CLSI standard.

Table 6.5
Results of CF biofilm model
A mucin barrier, an alginate barrier, or both were applied to 60-day-old biofilm
colonies. For this study, a magnet was not applied.
Disk Number/ Compound
Mucin
Alginate
Mucin +
Barrier
Barrier
Alginate
Barriers
6. Iron Oxide NPs †
14/I
0/R
22/S
7. Zero-valent Iron NPs
0/R
0/R
14/I
8. Iron Nitride NPs
0/R
0/R
0/R
9. Iron Oxide NP0/R
0/R
0/R
Tobramycin
10. Tobramycin (200 mg) *
30/R
40/R
40/R
Disk diffusion method was used. Minimum concentrations demonstrating susceptibility in previous
disk diffusion studies were used for NPs and NP-tobramycin conjugates. †Uncapped NPs
*Maximum CLSI cutoff concentration for susceptibility of tobramycin 10 μg absorbed onto disk.
These doses of tobramycin shown are up to seven orders of magnitude higher than the CLSI
standard dose for disk diffusion, therefore, although inhibition was observed, these colonies are
tobramycin resistant by CLSI standard.
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No CLSI breakpoints exist for NPs or NP conjugates at present, however, the CLSI
dose for susceptibility determination of P. aeruginosa to tobramycin is 10 μg absorbed
onto disk with cutoff values are ≥15 susceptible, 13-14 intermediate and ≤12 resistant
[CLSI 2019]. The same parameters were used for interpretation of the NP and NP
conjugate results. Tables 6.4 and 6.5 demonstrate the highly statistically significant
contribution of the external magnetic field in enhancing susceptibility to the test articles.
More work is needed to determine the exact role of the magnetic field in addition to
determining the minimum or maximum field strength necessary to achieve maximum
susceptibility. It is possible that the pulling force of the magnet may relate in some way to
the thickness of the biofilm and mucus barriers.
Table 6.6
Summary of biofilm model using alginate barrier, mucin barrier, or both
on 10-day-old biofilms
Comparison between petri dishes in which a magnet was or was not applied.

DI Water
Tobramycin
NP-alginatedrug
NP-citratedrug

Alginate and
Mucin
(No magnet)
R
R
R

Alginate
(magnet)

Mucin
(magnet)

R
S
I

R
R
S

Alginate and
Mucin
(magnet)
R
S
S

R

I

I

I

A summary of the results of a pilot study, presented in Table 6.6, summarizes the
results of a pilot study in which magnetite NPs conjugated to tobramycin was investigated.
The results summarized in Table 6.6 shows that magnetic field application alone enhanced
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susceptibility of biofilms to all the test articles, including tobramycin. Therefore, magnetic
field may be acting as an antimicrobial facilitator by mechanism other than magnetic
gradient-guided transport. It is interesting that this enhancement of the activity of
tobramycin by magnetic field application was not observed in the 60-day-old biofilms.
More work is necessary to determine whether magnetic field application alone, and what
range/ranges of field strength/duration interfere with biofilm growth.
6.2.5 Motility Testing Results
Biofilm bacteria (3-days and older) tested positive for motility, while the liquid cultures
(grown overnight) appeared to have minimal, if any motile individuals. This is a testimony
to the large genetic diversity of the bacteria composing a biofilm.
Figure
motility

6.8
test

Results
for

of
P.

aeruginosa grown in liquid
or biofilm cultures. This
image was taken after a total
of 36 hours of growth.

6.2.6 Comparison of Inhibition in Liquid Cultures
All cultures were inoculated in exactly the same manner with the same volume of bacteria
from the same liquid culture. The OD600 of the negative control samples (containing only
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inoculated broth) was determined to be 0.22 to 0.24. This result is slightly higher than the
lowest treatment concentration (8x10-6 mg/mL). Since there is no CLSI breakpoint or
standard inhibitory concentration, it was necessary to investigate a large range of
concentrations to determine MIC. The range used was 17.35 mg/mL to 8x10-6 mg/mL, in a
consistent volume, determined by serial dilution, as the graph in figure 6.9 illustrates.

Figure 6.9 Shows optical density (OD) at a 600 nm wavelength for liquid
cultures exposed to treatment with iron-oxide NPs, zero-valent iron, or
tobramycin-conjugated iron-oxide NPs. The calculated average error for OD
measurements was ±0.01. Specific errors, not the average error, were used to
calculate statistical significance.
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Complete inhibition was observed for all materials at concentrations at 17.5 mg/mL (or
higher), and various degrees of inhibition fall off somewhat linearly at concentrations
below 17.35 mg/mL (Fig. 6.9). The inhibition by zero-valent iron was, not surprisingly,
higher than iron-oxide NPs and NP-drug conjugates. We attribute this to the high reactivity
of zero-valent iron and its ability to increase reactive oxygen species (ROS) in the local
region [Hsueh 2017]. Although speculative at this stage, it is also possible that high levels
of iron contribute to cellular toxicity. More work is necessary to determine toxic and nontoxic dose ranges.

Figure 6.10 Percent bacterial inhibition vs. treatment concentration in liquid
cultures in cuvette. All NP samples presented here are alginate capped.
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ANOVA results showed that, while there was no statistically significant difference
between the zero-valent iron, iron oxide, or iron-oxide – tobramycin conjugates; when
compared to control, the results for all three NP treatments were found to be extremely
statistically significant (p < 0.0001). The figures show that the inhibition of bacterial cells
was evident even at surprisingly low (8 ng/mL) concentrations, although the minimum
therapeutic dose would probably be much higher. Speculation on a therapeutic dose for
targeted delivery would likely differ from the systemic dose, and both will depend on
observed cytotoxicity in mammalian cell cultures, at these concentrations. Even higher
doses may be required for the treatment of chronic infections involving biofilms that have
been established for several years; however, more research is necessary to determine this.
The MIC for different strains of P. aeruginosa may differ as well. According to
another report, P. aeruginosa (MTTC 1034) was not found to be susceptible to iron-oxide
NPs at 50 mg/mL, whereas our strain exhibited positive susceptibility [Behera 2012]. It has
been shown previously that oxygen limitation and metabolic activity can alter MIC of
tobramycin in P. aeruginosa [Walters 2003]. Differences in zone diameter for
susceptibility testing have also been known to differ with different batches of growth agar
[Reller 1974]. [Niemirowicz 2015] reported positive bacterial inhibition for P. aeruginosa
PAO1, in agreement with our findings. We attribute differences in susceptibilities to
genetic differences among strains in combination with the contribution of environmental
factors, such as growth media and the use of different capping agents.
The mechanism by which iron-oxide NPs exhibit antibacterial activity remains
unknown. However, according to the findings of [Musk 2005], iron may very well be the
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bioactive component. Zero-valent iron, as predicted, had a dramatic antibacterial effect,
verifying the findings of [Diao 2009]. Although zero-valent iron is too reactive for in vivo
use at present, it may be a candidate for incorporation into antibacterial coatings. Similarly,
iron-oxide NPs having high biocompatibility, may be a candidate material for
incorporation into polymer for use as antibacterial coatings on virtually any inert surface
used outside of the body, as well as medical devices such as stents, catheters, and surgical
sutures as a low-cost alternative to silver NPs. We anticipate that the combination of
tobramycin or other drugs with iron-oxide NPs incorporated into biodegradable polymers
may hold promise for the long-term control of biofilms and multidrug resistant microbial
strains. More work is needed to determine antibacterial properties of these materials on
other microbial species.

6.9 Summary of Sensitivity and Dosage Study Findings
We have shown that both drugs; ciprofloxacin and tobramycin, are effective against
biofilms and planktonic cells in a dosage-dependent manner. Magnetic field application
may, in some cases, enhance drug susceptibility. The drug seems to have exerted action
both in the free form, as well as covalently bonded to a crosslinker chain. There appears to
be no need for a drug release mechanism since the bound drug remains bioactive.
Surprisingly, the magnetite NPs alone inhibited bacterial growth and subsequent biofilm
formation. We have examined standard models, in addition to more accurate models using
inert surfaces for biofilm growth, thus allows for purification of the bound colonies from
the planktonic cells. Using this method, we have also shown that the biofilm colonies
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contain motile mutants, previously undocumented evidence of the complex genetics
implied by such a rapid phenotypic switch.
Although it appears that the iron oxide NPs inhibited growth better than drugconjugated iron oxide, we must use caution in the interpretation of these results. Recall that
conjugation was done, which may have increased the mass of the non-active ingredients.
Further characterization such as drug loading efficiency would allow the calculation of the
percentage by mass of iron oxide, tobramycin, and inert material. Once those calculations
are done, these parameters may be further understood as a function of active ingredients. It
is apparent however, that the iron oxide did inhibit bacterial growth via a presently
uncharacterized mechanism.
Zero-valent iron had a dramatic antibacterial effect, verifying the findings of [Diao
2009]. Although zero-valent iron is too reactive for in vivo use at present, it may be a
candidate for incorporation into antibacterial coatings. Iron oxide alone may be a candidate
for antibacterial coatings on medical devices such as stents, catheters, and surgical sutures
as a low-cost alternative to silver NPs. The drug tobramycin, an aminoglycoside
annihilates bacterial cells in a synergistic manner. It electrostatically binds the negatively
charged lipopolysaccharide bacterial membrane, compromising membrane integrity and
thus, resulting in its degradation [Shakil 2008]. Once internalized, acting from the inside of
the bacterial cell, tobramycin inhibits ribosomal translocation thus interfering with protein
synthesis [Saiman 2004]. We anticipate that the combination of tobramycin or other drugs
with iron oxide NPs incorporated into biodegradable polymers may hold promise for the
long-term control of multidrug resistant bacterial strains.
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Chapter 7

CYTOTOXICITY of IRON OXIDE NANOPARTICLEs

Not only is lung toxicity a crucial parameter to investigate due to the nature of our
application, but also, in acute inhalation exposure, the organ system subjected to the
highest initial concentrations is the lungs. Therefore, a thorough investigation of the acute
toxicity of inhaled nanomaterials must begin with a baseline analysis of human lung cell
toxicity. We have investigated the in vitro cytotoxicity of ~16 nm spherical magnetite
nanoparticles capped with succinylated polyethylene glycol on a human lung carcinoma (A
549) cell line at 6, 12, and 24-hour exposure periods and at 0.5 mg/ mL and 1 mg/mL
nanoparticle concentrations. We investigated acute toxicity in a comprehensive study by
comparing overall cytotoxicity, cell viability and apoptosis profiles against positive
controls. We report a dose-dependent decrease in viability at the 12-hour time point,
exhibiting a complete cell recovery by 24-hours, as well as a dose independent, timedependent alteration in cell proliferation rate. No statistically significant deviation from
control in overall cytotoxicity or apoptosis was observed upon exposure to iron oxide
nanoparticles in this cell-line at the time points or concentrations investigated.
Animal models have revealed a link between inhaled particles and murine lung
inflammation [Oberdörster 2000] and lung cancer [Knappen 2004], [Borm 2004].
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Although the dextran-coated iron oxide NP solution, finding application as the IVadministered MRI contrast agent Feridex®, had received FDA approval for human use in
the United States, it was discontinued by the manufacturer [Anselmo 2016, Wei 2016], and
is no longer commercially available. To date, there still exists a significant lack of
knowledge regarding the effects of NPs in general, but more specifically, on the effects of
iron oxide (magnetite) NPs on cell viability and normal functionality [Sonen and De
Cuyper 2010]. In fact, many researchers have reported that the use of these particles can
exert severely detrimental actions on the living cell [Sonen and De Cuyper 2010]. [Wei
2016] reports a SPION dosage-dependent iron overload, linked to cirrhosis of the liver in a
murine systemic toxicity model. Some other negative observations include LDH leakage
and abnormal IL-6 secretion at high (>50 mg/mL) concentrations [Mbeh 2012], significant
reductions in viability in murine and human cell lines [van den Bos 2003, Soto 2007],
[Pisanic 2007], decreased cell proliferation [Berry 2004, van den Bos 2003], and migration
[Berry 2004]. Many of these studies reporting increased toxicity attribute toxic effects to
the failure of the dextran coating to remain bound to the cell. Because of this, we have
engineered the terminal hydroxyl group (OH-) on the FDA approved polymer polyethylene
glycol (PEG) to terminate in a more electronegative carboxyl group (COOH-) by
succinylation, increasing binding efficiency to the metal oxide (M+) NP. Due to the
association of uncapped iron oxide NP and toxicity in some cell types, increased binding
efficiency is expected to reduce cytotoxicity of the iron oxide NPs.
Regarding human inhalation exposure, the occupational health literature abounds
with illustrations of aerosol-associated respiratory hazards and related lung pathologies,
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dating back many decades. However, the context of this prior research pertains specifically
to occupational exposure to nanoscale particulates formed accidentally, as by-products,
from processes such as welding, smelting and combustion [Maynard and Kuempel 2005],
as opposed to engineered nanomaterials. It is crucial that toxicity data on nanomaterials,
having the potential to expose workers via the inhalation aerosol route, be communicated
quickly to researchers so that they may cater future engineering design to reduce toxicity.
At present, there is limited data on the toxicity of these methodically engineered nanoscale
materials in the human respiratory tract. Due to the exponential growth in the manufacture
and utilization of such nanomaterials, which still remains largely unregulated, we
anticipate an exponential increase in their presence in both the natural environment as well
as the workplace. This rapid increased in commercialization of such novel materials,
having unknown toxicity, will merit an accurate determination of a safe exposure range,
not only for a patient receiving nanomedical treatment, but also for the employees
engineering, transporting, administering, and disposing of these materials. Toxicity profiles
are crucial for the determination of proper engineering controls, proper personal protective
equipment (PPE), and emergency procedures for employees administering, transporting,
and manufacturing the material. Dosage-dependent cytotoxicity will also be an important
parameter for determining the feasibility of purposely administering this material to the
lungs and determining and balancing dosages that are both safe and effective.

7.1 Experimental Procedure
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Succinylated PEG-capped iron oxide NPs were prepared as described in Chapters 2 and
capped using the methodology described in Chapter 5.

7.1.1

Materials and Reagents

Iron(III) chloride hexahydrate (97%), m-PEG 5000 (methyl-terminated PEG) powder,
succinic anhydride (>99%), phosphate buffered saline (PBS) powder, TRIS hydrochloride
(PharmaGrade), digitonin, ionomycin, and staurospirine were purchased from SigmaAldrich; n-docosane (99%) was purchased from Alfa Aesar; sodium oleate (>97%) was
purchased from Tokyo Chemical Industry Co.; hexanes (95%), ethanol (99%), and acetone
(99%), chloroform (99.9 %) hexane (99%), pyridine (99%), methanol (99%) were
purchased from EMD Chemicals Inc., the ApoTox-Glo™ triplex assay (Catalog No.
G6320) was purchased from Promega®, A 549, human alveolar epithelial carcinoma cells
(ATCC® No. CLL-185) and 0.25% Trypsin/0.53 mM EDTA (ATCC® No. 30-2101) were
purchased from ATCC®; Ham’s F-12, Kaign’s modification (Catalog No. 21127-022),
10% fetal bovine serum heat-inactivated (Catalog No. 10082-147), and 100 unit/mL penstrep (Catalog No. 15140-122) were purchased from Invitrogen. All chemicals were used
as received without purification.
7.1.2 Dynamic Light Scattering (DLS)
Hydrodynamic size distributions of the nanocrystals have been measured using a DynaPro
Titan DLS module from Wyatt Technology Corporation. In order to reduce aggregation
and maximize the accuracy of the measurement, samples were prepared for analysis by
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diluting the NP stock solution to 50 µg/mL in pure chloroform. The 1 mL sample was
vortexed, then sonicated at 40 Hz for 5 minutes prior to analysis in order to separate
agglomerates and ensure that a more homogeneous solution was analyzed.
7.1.3. UV-vis-NIR Spectroscopy
Light absorbance of iron oxide nanoparticles and succinylated PEG was characterized
using the Cary 5000 UV-vis-NIR Spectrometer. Many published assay results fail to
report, or even consider doing these measurements. Nanomaterials or quantum dot are
known to have highly sought-after interactions with light. It is important that we consider
these interactions when designing experiments using these kinds of assays that were not
developed with such considerations in mind. By determining light absorbance, we are able
to determine any possible interaction or interference of these materials with the assays,
which are dependent on total light detection via the plate reader.
7.1.4 Human Lung Adenocarcinoma Cell Growth
Cells were stored in liquid nitrogen in a cryostat until their use. To initiate growth, the
sample was thawed and centrifuged, and then the culture medium was removed. After that,
the cells were rinsed with 0.25 % Trypsin/0.53 mM EDTA solution to remove any
remaining serum that may contain trypsin inhibitor. Next, 2.5 mL of Trypsin-EDTA
solution was added. After 15 minutes the cells had dispersed into the solution and 7 mL of
complete growth medium (F-12K medium with 10 % FBS) was combined with the cells by
gentile aspiration. Cultures were incubated at 37.0 °C under 5 % carbon dioxide weighted
with HEPA-filtered air.
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7.1.5 Cytotoxicity Assay
Bis-alanylalanyl-phenylalanyl-rhodamine 110 (bis-AAF-R110) is a fluorogenic cellimpermeant peptide substrate marker for dead-cell protease activity. This is used to
measure protease enzyme which has been released from cells that have lost membrane
integrity. No signal from this marker is generated from viable (intact) cells because bisAAF-R110 is not cell-permeant and cannot cross the cell membrane. Dead cells release
protease enzymes that will cleave the rhodamine 110 (R110) from the rest of the molecule
causing it to fluoresce. R110 has an excitation peak at 498 nm and an emission peak at 520
nm.
In growth medium, 0.5 and 1 mg/mL concentrations of NPs were incubated with
the cells for 12 or 24-hours exposure time. Digitonin, ionomycin and staurosporine are
known to elicit cytotoxic, necrotic and apoptotic damage upon cells, respectively, and were
used as positive controls. For the twelve (12) hour exposures, cells in positive control wells
were treated with either 30 µg/mL of digitonin for an incubation period of 15 minutes, 100
µM of ionomycin or 10 µM of staurosporine both applied for 6-hour incubation periods.
For the 24-hour measurements, cells in positive control wells were treated with either 45
µg/mL of digitonin for an incubation period of 30 minutes, 150 µM of ionomycin or 15
µM for staurosporine for 6-hour incubation periods. A 96 well-plate was used, except for
background control wells which contained growth media alone, each individual well was
seeded with 10,000 A 549 cells dispersed in growth media. Each well was filled to a
volume of 100 µL and cells were cultured for the respective time periods. The background
readings from the wells containing no cells were averaged and subtracted from the
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obtained averaged readings. After the 6, 12, or 24-hour period, 20 μL of the
viability/cytotoxicity reagent containing both GF-AFC substrate and bis-AAF-R110
substrate was added to all the wells. Immediately after that, the solutions were mixed by
orbital shaking at 300-500 rpm for ~30 sec. The plate was incubated for 30 minutes at 37
°C. Finally, the samples were exposed to 485 nm light with a 20 nm bandwidth for
excitation, fluorescence measurements were taken at 528 nm with a 20 nm bandwidth.
Measurements were taken with a BioTech Flx800 Microplate Reader, measuring
fluorescence from the bottom of the 96-well plate.
7.1.6 Viability Assay
Glycylphenylalanyl-aminofluorocoumarin (GF-AFC) is a florigenic, cell-permeant peptide
substrate which is used as a marker for live-cells. Since live-cell proteases must be
detected from within the living cell; having an intact membrane, this substrate must cross
the cell-membrane and enter the cell. Once inside the cell, protease enzymes cleave the
AFC from the substrate, triggering the fluorescence signal. The AFC has an excitation
peak at 370 nm and a fluorescence emission peak at 490 nm. Should the membrane rupture
while the substrate is inside the cell, the fluorescence is quenched, and the signal ceases.
Therefore, this substrate is able to give an accurate measure of viable cells.
In growth medium, 0.5 and 1 mg/mL concentrations of NPs were incubated with
the cells for 6, 12, or 24-hours exposure time. Digitonin, ionomycin and staurosporine are
known to elicit cytotoxic, necrotic and apoptotic damage upon cells, respectively, and were
used as positive controls. For the six (6) and twelve (12) hour exposures, cells in positive
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control wells were treated with either 30 µg/mL of digitonin for an incubation period of 15
minutes, 100 µM of ionomycin or 10 µM of staurosporine both applied for 6-hour
incubation periods. For the 24-hour measurements, cells in positive control wells were
treated with either 45 µg/mL of digitonin for an incubation period of 30 minutes, 150 µM
of ionomycin or 15 µM for staurosporine for 6-hour incubation periods. A 96 well-plate
was used, except for background control wells which contained growth media alone, each
individual well was seeded with 10,000 A 549 cells dispersed in growth media. Each well
was filled to a volume of 100 µL and cells were cultured for the respective time periods.
The background readings from the wells containing no cells were averaged and subtracted
from the obtained averaged readings. After the 6, 12, or 24-hour period, 20μL of the
viability/cytotoxicity reagent containing both GF-AFC substrate and bis-AAF-R110
substrate was added to all the wells. Immediately after that, the solutions were mixed by
orbital shaking at 300-500 rpm for ~30 sec. The plate was incubated for 30 minutes at 37
°C. Finally, the samples were exposed to 360 nm light with a 40 nm bandwidth for
excitation, fluorescence measurements were taken at 460 nm with a 40 nm bandwidth.
Measurements were taken with a BioTech Flx800 Microplate Reader, measuring
fluorescence from the bottom of the 96-well plate.
7.1.7 Apoptosis Assay
In this assay, cell apoptosis is measured by detecting the apoptosis biomarkers
caspase 3 and caspase 7. Cell lysis is followed by caspase cleavage of the substrate and
results in generation of a luminescent signal. The fluorophore in this assay is luciferase

145

(aminoluciferin), a natural luminescent molecule borrowed from the firefly [Gould 1988].
Luminescence is proportional to the amount of caspase activity, and thus, apoptosis. The
luminogenic caspase-3/7 substrate, which contains the tetrapeptide sequence DEVD (AspGlu-Val-Asp), in an optimized reagent (Caspase-Glo® 3/7 Reagent, Promega®) optimized
for caspase activity, luciferase activity and cell lysis.
In growth medium, 0.5 and 1 mg/mL concentrations of NPs were incubated with
the cells for 6, 12, or 24-hours exposure time. Ionomycin is known to induce necrosis and
staurosporine is known to induce apoptosis, therefore, these compounds were used as
controls for this assay. For the six (6) and twelve (12) hour exposures, positive control
cells were treated with either 100 µM of ionomycin or 10 µM of staurosporine both
applied for 6-hour incubation periods. For the 24-hour measurements, cells in positive
control wells were treated with either 150 µM of ionomycin or 15 µM for staurosporine for
6-hour incubation periods. A 96 well-plate was used, except for background control wells
which contained growth media alone, each individual well was seeded with 10,000 A 549
cells dispersed in growth media. Each well was filled to a volume of 100 µL and cells were
cultured for the respective time periods. The background readings from the wells
containing no cells were averaged and subtracted from the obtained averaged readings.
After the 6, 12, or 24-hour period, 20μL of the viability/cytotoxicity reagent containing
both GF-AFC substrate and bis-AAF-R110 substrate was added to all the wells.
Immediately after that, the solutions were mixed by orbital shaking at 300-500 rpm for ~30
sec. The plate was incubated for 30 minutes at 37 °C. After fluorescence measurements
were taken, 100μL of Caspase-Glo® 3/7 Reagent was added to all wells and briefly mixed
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by orbital shaking at 300–500 rpm for ~30 sec. Measurements were taken with a BioTech
Flx800 Microplate Reader, measuring luminescence from the bottom of the 96-well plate.
7.1.8 Statistical Analysis, Correction Factor, and Mathematical Methods
This experiment was done in triplicate, the median values presented, and standard
deviations were calculated. For comparison of the mean values for each test, both a twoway analysis of variance (ANOVA) was run for grouped values and to analyze trends over
time and a double-tailed t-test was run to compare single values to control. All statistical
analyses were run in GraphPad Prism®. Values of p<0.5 (95 % confidence interval) were
considered significant, p< 0.01 (99 % confidence interval) were considered very
significant, and values of p< 0.001 (99.9 % confidence interval) were considered extremely
significant.
In order to correct for the signal reduction caused fluorescence absorption by the
colloidal NPs, a general correction was applied as follows. The experimental findings of
[Doak 2009] in which fluorescence quenching by iron oxide NPs was measured at different
concentrations, were plotted as a function of percent signal reduction. The maximum
concentration of fluorescent dye used in the assay, assuming 100 % fluorophore activation,
as calculated from the stock solution concentration and dilution factor, is 5 µM. Although
there is a slight difference in the percent reduction based on the difference between the 2
µM and 4 µM fluorophore concentrations, we analyzed the mean collected values at each
NP concentration compared between the dye concentrations did not find them to be
statistically significant. Although it is unlikely that 100 % of the fluorophores were
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activated in the assay, the maximum concentration, which is not likely to exceed 1 %
variance from the calculated value, and should be encompassed by the correction factor,
and corrected error. The plot (Fig. 7.1) demonstrates a nearly identical trend for both
concentrations of fluorescent dye, which suggest that signal reduction is consistent over a
range of fluorophore concentrations, and the values can be fit to the same trend line.
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Figure 7.1 Reduction of fluorescence signal by magnetite NPs at two fluorescent dye
concentrations. Based on the findings of [Doak 2009].

Extrapolating out one data point encompasses the two concentrations used for this study.
The log transforms and linear curve calculations were run on GraphPad Prism®. The data
was fit to an exponential trend line in Microsoft Excel®. The exponential trend line
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equations for the 4 µM and 2 µM concentrations of fluorescent dye were y=4.3311e 0.3718x
and y=6.9758e0.3062x respectively. According to this model, the next data point,
corresponding to a 1 mg/mL concentration of magnetite NPs is between 58.5-59.5 %. At
this range the variation between the two fluorophore concentrations was found to be only
~1 %. Since the concentration of the fluorophores does contribute minimally to the
measurement, this range was incorporated to the error margin. Based on this model, the
measured fluorescence values were reduced by ~59 % for the 1 mg/mL concentration and
~51% for the 0.5 mg/mL concentration. Since simply taking an increase by the percentage
of the measured value will not return the original value, the measured values must be
adjusted according to:
measured value
(100 % − % reduction)
The collected values were included in the standard deviation for comprehensiveness.
7.2 Results
7.2.1 Dynamic Light Scattering (DLS) Size Distribution
DLS results are shown in Figure 7.2, where the particles were measured for size in
chloroform solution. Because polymer coating increases the NP hydrodynamic size, this
measurement was done prior to polymer capping, in order to verify NP sizes observed in
TEM measurements. The colloidal NPs demonstrate some very minor aggregation
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(responsible for the peaks at 30 and 35 nm). The average hydrodynamic diameter is 15.946
nm with a standard deviation of 4.393 nm, in agreement with the TEM observations.

Figure 7.2 DLS size distribution of colloidal magnetite nanoparticles.
This graph shows an average hydrodynamic diameter of ~16 nm.

7.2.2 UV-vis-NIR Spectroscopy Absorbance Measurements
Absorbance spectrum (Figure 7.3) of iron oxide NPs in colloidal suspension with
chloroform shows a strong absorbance peak at ~375 nm, in the UV portion of the
spectrum. The spectrum shows minimal absorption (0.5 AU) consistently throughout the
rest of the visible and near-infrared range. These findings are in agreement with previously
demonstrated absorbance results for iron oxide NPs [Wang 2005], [Shi 2007], [Awwad
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2012] and [Sathyanarayanan 2013]. The succinylated PEG (capping agent), shows a strong
peak in the UV portion of the spectrum and no absorption throughout the visible range.

Figure 7.3 Absorbance spectrum for magnetite NPs.

Figure 7.4 Absorbance spectrum for succinylated polyethylene glycol (PEG)
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7.2.3 Cytotoxicity Assay Results

Figure 7.5 Cytotoxicity results; dead-cell marker fluorescence at 12- and 24-hours
exposure. *denotes statistical significance where p<0.5

A double-tailed t-test was conducted on the measured values, compared to controls for
each time point. None of the reagents applied to the cells demonstrated any statistically
significant effects at the 12-hour time point, including digitonin, the cytotoxicity positive
control. These findings are important for future use of this assay in this cell type. The
concentrations or periods of exposure for all three positive controls may need to be
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increased in order to elicit a noteworthy response in this cell line. The NPs did not exhibit
a statistically significant cytotoxic effect at this time point for either of the concentrations
investigated. At the 24-hour time point, the cytotoxicity positive control digitonin, as well
as the necrosis positive control, staurosporine, demonstrated statistically significant
cytotoxic effects compared to untreated cells. The magnetite NPs did not exhibit any
statistically significant cytotoxicity at various concentrations or time points.
7.2.4 Viability Assay Results
A two-way ANOVA was run on the treatment results compared to control at all three time
points investigated. The ANOVA showed a statistically significant time factor in all treated
and untreated cells attributed to the normal doubling time, as expected, a linear increase
was observed. The normal doubling time of A549 cells is approximately 22 hours (ATCC);
this rate corresponds to our observed rate. Statistical reductions in viability were found to
be very significant for the staurosporine positive control, the 1 mg/mL concentration of
magnetite NPs and the ionomycin positive control having p-values of 0.0083, 0.0027 and
0.001, respectively. An initial increase in live-cells was observed in the magnetite NP
treated wells, at the six-hour time point. However, a significant concentration-dependent
decrease in viable cells was observed at the 12-hour time point. By the time the 24-hour
measurement was taken, the magnetite NP-treated cells had more than recovered, and the
viable-cell count was in the range of the untreated cells. Taking into consideration the
range of measured values and the slope of the line, it appears that the 0.5 mg/mL NP
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concentration may not have had lethal effects, but simply inhibited cell differentiation over
the 6 to 12-hour time points.
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Figure 7.6 Cell viability over exposure time. Image shows overall increase in live-cell
fluorescence over time for all exposures. The ionomycin positive control and 0.1 mg/mL
concentration of magnetite NPs demonstrate a statistically significant reduction in cell
viability.

The 1 mg/mL NP concentration seems to have had cytotoxic effects, as demonstrated by
the negative slope between the 6- and 12-hour time points. In both cases, the growth rate of
the NP-treated cells seems to have demonstrated an overall increase compared to control,
and the slope of the line corresponding to growth rate, is identical for both NP treatment
concentrations. A double-tailed t-test was performed on the individual treatments
compared to control at the 24-hour time point. The ionomycin positive control was the
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only treatment that exhibited an extremely statistically significant deviation from control at
this time point. No statistically significant reduction in viability was observed in the NP
treated cells at the 24-hour time point.
7.2.5 Apoptosis Assay Results
The apoptosis positive control, staurosporine, showed a statistically significant deviation
from control at all time points. The 0.5 mg/mL NP concentration exhibited nearly identical
results to the untreated cells at the 12 and 24-hour time points. No statistically significant
deviation from control was noted in the NP treated cells at any time point. The higher than
average mean values observed at the 6-hour time point were not only found to be not
statistically significant, due to the range of values, in which low values are very close to
those of control cells, but, are not verified by the results of the viability assay. The
ionomycin (necrosis) marker showed even further reduced apoptosis signal than the other
four treatments. The apoptosis observed in the ionomycin positive control wells were
reduced compared to controls, this reduction was found to be statistically significant and
very statistically significant at the 6 and 12-hour time points, respectively. It is important
to note that cell death is occurring in the ionomycin treated wells, as evidenced by the
reduced viability of cells exposed to this compound. Ionomycin is known to induce cell
death by necrosis, as opposed to apoptosis. Therefore, the low levels of caspase, an enzyme
biomarker for apoptosis specifically, are to be expected.

No statistically significant

increase (or decrease) in apoptosis was observed for NP-treated wells compared to control
at any of the time points investigated.
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Figure 7.7 Apoptosis luminescence. The apoptosis positive control demonstrated
statistically significant results, as expected. The necrosis positive control ionomycin
demonstrates statistically significant results lower than the value for untreated cells. *
denotes significance in which p<0.01 and ** denotes significance in which p<0.001,
***denotes extreme statistical significance (p<0.0001).

The apoptosis time curve shows a linear increase in all treatments and untreated
cells, except the ionomycin-treated cells which show a slight increase from 6 to 12 hours
followed by a plateau from 12 to 24 hours. The apoptosis rate over time is not sufficient to
exhibit a decrease or even steady plateau in cell differentiation, as evidenced by the
viability over time. The apoptosis increase likely demonstrates a percent of the total
number of cells, as opposed to an increased incidence of apoptosis over time.
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Figure 7.8 Apoptosis time curve. Shows relatively linear increase in apoptosis over all
time points for all exposures, to include untreated cells. No statistically significant
differences among iron oxide NPs treatment concentrations or untreated cells were
observed.

This is because we observed the normal doubling rate in the viability studies for all treated
and untreated cells. Therefore, there are more cells at the later time points and apoptosis in
a constant percent of the population would be expected to follow the same linear increase
that the viability graph demonstrated. Although it appears from the graph that the 0.5
mg/mL concentration exhibited increased incidence of apoptosis, the overlap of the error
bars reveals a similar range, and thus, no statistically significant difference between the
two concentrations. Only the apoptosis positive control, staruosporine, was found to
exhibit a statistically significant deviation from the control cells in the apoptosis assay.
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7.3 Discussion
This study investigated the acute in vitro cytotoxicity of two concentrations of colloidal
magnetite NPs in a human lung carcinoma cell line (A549), by comparing cytotoxicity,
viability, and apoptosis profiles over time. Although the reliability of assays used to
investigate nanomaterial toxicity has been called into question due to the potential for
fluorescent NPs to enhance the fluorescent signal, or for other metal and metal oxide NPs
to absorb the fluorescent signal [Doak 2009, 2012], [Monteiro-Riviere 2009], [Han 2011],
[Love 2012], [Darolles 2013], at this time, the fluorescence signal reduction by both
magnetite and maghemite NPs has been well characterized [Doak 2009]. We have
accounted for the fluorescence signal absorption by the magnetite NPs at the
concentrations investigated by producing a mathematical model and correction factor using
experimental data. The absorbance data demonstrates that the absorption of visible light is
consistent throughout all the frequencies detected by the assay, thereby affirming the
reliability of the method. The combination of assays has previously been proposed to
verify findings of a single assay in the investigation of NP toxicity [Han 2011], [Alinovi
2015], therefore, our use of three assays was justified as the comparison of viability and
cytotoxicity data add another dimension of quality control to the interpretation of the data.
This investigation has revealed an overall low-toxicity of magnetite NPs when
capped with PEG. Despite the dose-dependent decreZase in viability at the 12-hour time
point all other parameters did not show a statistically significant deviation from the control
values. The measured viability decrease at the 12-hour time point may need to be
investigated further, as the viability was nearly identical to controls by the 24-hour time
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point. In addition, the cytotoxicity and apoptosis profiles at 12-hours do not demonstrate a
corresponding increase in apoptotoic or necrotic (lysed) cells this time point. Although the
mean apoptosis values for the NP solutions were slightly higher than the control cells, the
overlap of the error bars, demonstrating the range of measured values, makes this not
significant. The slightly elevated apoptosis signal at the 6-hour time point is not
corroborated by the viability and cytotoxicity findings, as the viability was slightly higher
than the control cells at the 6-hour time point, and a low number of dead cells were
measured. Taking into account the increased live cell count at 6-hours and the slope of the
viability over time line in NP-treated wells, it appears that the doubling time (growth rate)
of the cells was altered; initially being increased from 0-6 hours, halted from 6-12 hours,
then increased again from 12-24 hours. If the iron oxide NP solution did, in fact increase
the growth rate of the cells, then the slightly increased apoptosis detection as a percentage
of the total number of viable cells, as demonstrated by the viability results at 6-hours, still
results in a low ratio, comparable to the control wells. The low viability measured at 12hours was not observed as apoptosis by this assay; therefore, either cell death having been
induced by necrosis, cell proliferation was impaired, or both. Typically, we would expect
viability and cytotoxicity to be inversely proportional. However, it has been wellestablished that prototypical anticancer agents can exhibit antiproliferative effects
(specifically, a reduction in cell division) for a prolonged period of time, prior to
membrane rupture. Until membrane rupture occurs, it is difficult to detect cell stress using
this assay. Further investigation, such as detection of pro-inflammatory cytokines,
characteristic of necrosis and present prior to cell death could be used to determine whether
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this pathway has been activated and when. Cell cycle arrest in A549 cells, in response to
potential toxin exposure has been reported, previously in G-1 phase (Chang et al., 2004),
G-2/M cell cycle arrest (Wu et al., 2005; Lee et al., 2011; Wu et al., 2013), S-phase arrest
(Chairuangkitti,et al., 2013), by nanoparticles (Choudhury et al., 2013; Wu et al., 2013;
Kansara et al., 2015), and DNA breaks have been discovered along with cell cycle arrest
(Kansara et al., 2015) in a nanoparticle toxicity study. Since this cell cycle (growth) arrest
is commonly observed in this cell type, we must at least take into consideration the
evidence which seems to suggest that the decrease in viability is due to cell cycle arrest.
The time period of cell cycle arrest is observed as a decline in viability with no
concomitant increase in cytotoxic biomarker, which is exactly what was observed. Caspase
activation, which would have been detectable by the apoptosis marker, may or may not be
measurable during this period. Conversely, a measurable decline in apparent viability may
be paired with a substantially reduced or unmeasurable cytotoxicity biomarker if cells died
early (typically by primary necrosis) in the exposure period (Niles et al., 2008).
Considering the lack of evidence of cytotoxicity of the NPs revealed by the
cytotoxicity assay in combination with the low level of observed apoptosis, in addition to
the numerous evidence suggesting cell cycle arrest as a response to toxicity in A549 cells,
the main contributing factor to the observation of reduced viability (a low measurement of
viable cells) at the 12- hour time point is probably reduced proliferation, both preceded and
followed by increased proliferation, as opposed to cell death. Another study into
nanoparticle toxicity in this cell line showed that Ag NPs reduced cell viability and
modulated cell cycle distribution with an accumulation of cells at G2/M and sub-G1 phases
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(cell death), leading to a decrease in cells at G1 (Lee et al., 2011). Results suggest that Ag
NPs induce strong toxicity and G2/M cell cycle arrest by a mechanism involving PKCζ
downregulation in A549 cells (Lee et al., 2011). It appears that the iron oxide NPs may
also be causing a cell cycle arrest, as evidenced by the decrease in viability at 12-hours.
More work is needed to investigate whether or not this is the case. Superparamagnetic iron
oxide NPs have shown promote cell proliferation by effecting cyclins and cyclindependent kinases in human stem-cells (Huang 2009). The effect on proliferation is
probably dosage-dependent and more dosages and time-points should be investigated in
the future. Therefore, such NPs may very likely have a complex effect on the proliferation
cycle in certain human cell lines. This effect and the mechanism(s) thereof merit
significant further research.
Since PEG is an FDA-approved polymer, and it has been shown to cause no
significant adverse effects [Working 1997], we do not attribute any cytotoxicity or
alterations in cell proliferation to the PEG NP coating. Previous studies on dextran-coated
NPs have shown that detrimental effects of magnetite NPs may be facilitated by the
biochemical modifications to dextran by biological systems as well as the weak interaction
between the dextran coating and the nanoparticle. Dextran undergoes conformational
changes and may completely desorb from the nanoparticle surface [Sonen and De Cuyper
2010]. Cellular uptake of magnetite NPs coated with dextran have been degraded in acidic
lysosomes, leaving a rapidly degraded iron core. This iron can then induce toxic reactive
oxygen species (ROS) intermediates by the Fenton reaction [Arbab 2003], [Idee 2007].
One of the causes for the weak interaction between dextran and the NP stems from the
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functional groups binding to the hydrocarbon polymer to the metal oxide NP. Dextran uses
a hydroxyl (OH-) functional group to bind the NP (M+). As a potential solution to this
problem we succinylated our PEG cap, which changes the terminal functional group from a
hydroxyl to a carbonyl (COOH-) group, increasing the negative character, and thus,
strengthening the bond between the polymer and the NP. This capping method of
incorporation of a stronger bonding, FDA-approved polymer is anticipated to reduce ROSmediated cytotoxicity.
Comprehensive toxicity profiles should include data on toxicity in multiple cell
lines in addition to animal models to include investigations on developmental effects. It is
important to translate cytotoxic effects revealed by exposure to a concentration in cell
culture to a no observed adverse effects level (NOAEL), systemic dose administration,
which is not necessarily straightforward. Even in cases where in vivo studies have
demonstrated a NOAEL, localization in specific organ systems and subsequent toxicity to
those specific cell types may not yet have been identified. In vitro cytotoxicity of NP
systems in specific cell types is also useful for identifying mechanisms of toxicity after
systemic toxicity is observed.

Also, higher concentrations of the investigational

nanomaterial than could be feasibly systemically administered may be investigated in cell
culture. This is important for materials that will be targeted to a specific cell type, or
administered as inhalation aerosols, as in our application.
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CHapter 8

Conclusions and future work
Nanotechnology, being often described as an emerging technology brings with it what we
call, “the promise of nanotechnology.” This promise of nanotechnology hopes to realize
novel batteries, magnetic and semiconductor materials, individualized medicine, faster
computers, in vivo genetic alterations, non-invasive medical procedures and countless
others. A recent article was published in the magazine, “Risk Management,” entitled, “The
big risk of small particles…” I believe this title says it all [Piper 2013]. We must use
caution when embarking on such exciting new scientific ventures. The excitement over our
ability to make these materials must not take precedent over the fact that our knowledge of
the toxicity of both the nanomaterials as well as the procedures for engineering them is, at
present, still limited. Nikola Tesla, the famous electrical engineer, proclaimed that there
was a difference between Progress and Technology. “Progress benefits mankind.
Technology does not necessarily do that. If you have a technology that is polluting the
planet, that's not progress [Tesla 1891].” Therefore, in the interest of progress, let us
examine our methodology.
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8.1 Importance of Green Methodology
In 1857, Michael Faraday discovered and demonstrating that nanostructured colloidal gold
under certain lighting conditions produces different-colored solutions [Thompson 2007]. It
is not until 2005 that the EPA begins reviewing new chemical notices under the Toxic
Substance Control Act (TSCA) for nanoscale materials. This nearly 150-year gap in
regulation of such materials is hardly surprising. During this time, it was the responsibility
of the researchers to ensure safety and environmental soundness. Now, despite the EPA
regulation and some minimal oversight we, as researchers, maintain much of the
responsibility for ensuring immediate safety while tailoring our methods for the long-term
benefit of humanity. Now, more than ever, with the population of the planet well on its
way to reaching 8 billion people, we must maintain consciousness regarding the long-term
effects of our work. Green chemistry standards, along with our adherence to them, will
undoubtedly facilitate true progress. Iron, of course, exists naturally in the environment in
a few phases; the dissolved phase as ferric (Fe3+) or ferrous (Fe2+) salts (as in our
precursor), or in the solid phase iron oxides such as goethite, magnetite or Wüstite (as in
our product), and hematite [Ponnamperuma 1972], [Klaine 2008], [Ševců 2011]. In the
case of this work, I can genuinely affirm that we have done our finest to ensure safety
while minimizing long-term risk to our delicate environment. As described in Chapter 2,
we have replaced harsh metal nitrate precursors with chloride salts in all cases. We have
used as a hydrocarbon carrier for the facilitation of epitaxial (layer-by-layer) crystal
growth, as well as our stabilizing agents with constituents of vegetable oil rather than
petroleum products. We have committed to the use of natural and biodegradable polymers,
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not only due to the positive results realized by their utilization. Additionally, we have
redistilled our waste solvents for multiple uses, reducing waste from 4 L per 200 mg of
product to less than 0.5 L. By using paraffin wax as an alternative to high purity long chain
hydrocarbons, we are able to reuse this wax solvent at least five times, reducing waste, and
cost. It is also important to note that due to the use of these environmentally friendly
solvents and precursors, that the biocompatibility of our engineered materials is
intrinsically amplified.

8.2 Bacterial Sensitivity Discussion
Despite the fact that we have demonstrated the antibacterial properties of NP-drug or NPs
alone, one issue that resists prediction is the cellular permeability of P. aeruginosa by the
tobramycin-loaded Fe3O4 complexes. Future work may overcome the realization that very
little is known regarding uptake NPs by the individual Pseudomonas aeruginosa cells. It is
known that aminoglycoside antibiotics, such as tobramycin, enter the cell through porin
channels, along with water and electrolytes. It is also known that they are not only
somewhat actively transported, but may also cause nonspecific membrane toxicity, even to
the point of bacterial cell lysis [Frasier 1986]. The outer membrane of gram-negative
microbes is composed of lipopolysaccharide which differs from the cell membrane of other
microbes. The outer membranes produce something called periplasmic protrusions under
stress conditions or upon virulence requirements while encountering a host target cell, and
thus such protrusions function as virulence organelles [Yash Roy 1999]. It has been
demonstrated that P. aeruginosa has a comparatively large exclusion limit, the actual
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molecular weight cutoff is 3 kDa allowing the passage low molecular weight organic acids
(amino acids), carbohydrates, alcohols, aliphatic molecules, aromatics, and nitrogenous
compounds used as nutrient sources [Nikaido 2012].
As presented in Chapter 6, it appears that a destructive consequence appears under
of greater concentrations of zero-valent iron and consequently, reactive oxygen species
(ROS) induced by the presence of iron. Experimentation regarding the bactericidal effects
of zero-valent iron and the theoretical mechanisms leading to cell death has been
thoroughly investigated and the established findings may be referenced in any of the
following notable publications. The first of which reports significant disruption of the
Escherichia coli cell membrane by zero-valent iron NPs suggesting inactivation or
enhanced the biocidal effects of dissolved iron as well as oxidative stress as mechanisms of
cell death [Lee 2008]. Another report, [Chen 2011], investigated the use of zero-valent iron
NPs against gram negative Escherichia coli and gram-positive Bacillus subtilis showing
that B. subtilis was more tolerant to zero-valent iron NPs than E. coli, but states that the
bactericidal mechanism has not yet been elucidated. Lastly, another report claims that zerovalent iron had no deleterious effect on total bacterial abundance in the microcosms.
Surprisingly, zero-valent iron with a biodegradable polyaspartate cap actually increased
bacterial populations by an order of magnitude relative to controls [Kirschling 2010].
Perhaps, once naturally oxidized, this material will benefit symbiotic bacterial populations
in the environment by providing beneficial doses of iron.
It is possible that iron NPs may indirectly generate ROS, which subsequently damage
iron–sulfur clusters; located in an assortment of metalloproteins, examples are the well-
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known NADH dehydrogenase, ferredoxins, hydrogenases, nitrogenase, coenzyme Q, and
succinate dehydrogenase [Lippard 1994]. This combination leads to Fenton’s reagent; a
solution of hydrogen peroxide and iron, in which iron is a catalyst that is used to oxidize
contaminants. In industrial applications, Fenton's reagent can be used to destroy organic
compounds by catalyzing the production of additional ROS. ROS generated via this
reaction can easily diffuse into the cell cytoplasm, triggering ROS-induced ROS release in
the mitochondria triggering death. A known mechanism of bacterial cell death induced by
zero-valent iron NPs, as we demonstrated in Chapter 6, and is illustrated in Figure 8.1. In
our case, it also may occur that initial disruption of the outside membrane of bacteria by
tobramycin assists the subsequent penetration of NP-tobramycin complexes and or iron
ions into the bacterial cell via simple diffusion since it is known that one mechanism of
action of aminoglycoside antibiotics is cell wall disruption.
It may also be possible that initial disruption of the outside membrane of bacteria
by tobramycin assists the subsequent penetration of NP-tobramycin complexes and or iron
ions into the bacterial cell via simple diffusion since it is known that one mechanism of
action of aminoglycoside antibiotics is interference with protein synthesis leading to cell
membrane disruption. However, if this is occurring, it is not happening on a large scale
since no statistically significant difference in the MIC or susceptibility was noted in
tobramycin conjugated iron-oxide NPs compared to unconjugated NPs. However, more
work is needed to clarify the antibacterial mechanism(s) of action of iron-oxide NPs alone
and in combination with the aminoglycoside, or other antibiotic drugs, and to clarify the
overall role of the capping agent.
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Figure 8.1 Mechanisms of cell damage and response after exposure to ironcontaining NPs. Iron ions, released from NPs, can cross the membrane via either
active cellular uptake or leakage through sites with reduced membrane integrity.
Highly reactive hydroxyl radicals resulting from Fe2+ reaction with hydrogen
peroxide primarily cause oxidative damage. Fe3+ could be reduced by NADH and,
thus, regenerating Fe2+. OH· radicals could also cause damage to DNA, proteins and
lipids. Fe2+ may also directly damage DNA.

It is apparent that the composition of the capping agent, and possibly the interactions of
the capping agent with the NP surface, the ROS, and the cell surfaces are primarily
responsible for facilitating or negating the antimicrobial effects. Since uncapped iron-oxide
NPs (~16 nm) had similar antibacterial effects as the alginate capped and alginate capped-

168

tobramycin conjugated NPs (~200 nm), whereas the PEG-capped NPs (~40 nm) were
ineffective, we do not attribute these findings to size effects. At least at this size range.

8.3 Conclusions
We have presented an alternative method for the treatment of P. aeruginosa biofilms in
cystic fibrosis, potentially to be administered via the inhalation aerosol route. Positive
inhibition of bacterial growth was observed for uncapped and alginate-capped iron-oxide
NPs, and the corresponding MICs have been presented. We have observed zero
susceptibility to iron-oxide NPs capped with polyethylene glycol (PEG), suggesting that
the capping agent plays a major role in enabling bactericidal ability in of the
nanocomposite. Our findings suggest that the alginate-coated nanocomposites investigated
in this study have the potential to overcome the bacterial biofilm barrier, possibly by
simple diffusion, due to the favorable solubility of the alginate-coated NPs within the
alginate biofilm. Magnetic field application increases the action, likely via enhanced
diffusion of the iron-oxide NPs and NP-drug conjugates through mucin and alginate
barriers, which are characteristic of CF respiratory infections. We have demonstrated that
iron-oxide NPs coated with alginate, as well as alginate-coated magnetite – tobramycin
conjugates inhibit P. aeruginosa growth and biofilm formation in established colonies,
which are often the most difficult to treat. We have also determined that susceptibility to
tobramycin decreases for longer culture times, as the colonies are allowed to differentiate
for longer periods of time. However, susceptibility to the iron-oxide NP compounds did
not demonstrate any comparable decrease with increasing culture time. In addition, these
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findings imply that iron-oxide NPs are promising lower-cost alternatives to silver NPs in
antibacterial coatings, solutions, and drugs, as well as other applications in which
microbial abolition or infestation prevention is sought.
We report on alteration of a basic, repeatable, solvothermal green chemistry
synthesis method that can be used to produce iron oxide nanoparticles in various
monodispersed size ranges from 10-100 nm and in a variety of shapes (spherical,
polymorphous, cube, wire). Taking the iron oxide NPs produced by these methods, we can
convert them into zero-valent iron or iron nitride. We have investigated several capping
agent compositions, and provided proven methods for application of the cap. We have also
demonstrated the importance of the capping agent in functionalization and antibacterial
properties of the nanocomposites.
We have investigated the cytotoxicity of iron oxide NPs on a lung adenocarcinoma
cell line. We have shown that, in general, the NPs did not exhibit a statistically significant
cytotoxic effect at the concentrations investigated. We did observe a slight decrease in
viability at the 12-hour time point, which was not observed at the 24-hour time point.

8.4 Future Work
If future experiments do determine that the NPs do, in fact, enter the cell, further issues
requiring clarification remain. As discussed in Chapter 5, there are five amine groups
present on the tobramycin molecule, representing the functional groups bound to the NP, in
practice one of these functional groups must also bind to the molecule of the ribosomal
RNA, stopping protein synthesis. This property is one responsible for the bactericidal
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effects of the drug. Our drug conjugation does not allow for determination of which of the
amine groups bind to the NP capping agent however may pose an additional problem. It
has been demonstrated that the loss of only one of these sterically unhindered functional
groups reduce binding affinity for RNA 10-fold [Wong 1998]. Although we did not
directly witness a reduction in drug activity, the antibacterial effects of the iron-containing
NP may have balanced out the loss. Tobramycin also binds to a site on the bacterial 30S
and 50S ribosome, preventing formation of the 70S complex, inhibiting protein synthesis
in this manner. Whether or not the entire drug conjugated nanocomposite remains attached
when the drug binds the binding to a site on the bacterial RNA or ribosome, despite
significant steric hindrance, remains to be uncovered.
Despite this, we have shown that iron oxide NPs, zero-valent iron NPs, and
tobramycin-coupled iron oxide NPs exhibit a marked antibacterial result against P.
aeruginosa bacteria in planktonic and biofilm mode. There is no need to, “detach,” the
drug from the NP in order to observe a bactericidal effect. These findings imply that, at
least, a certain percentage of the bound tobramycin molecules, remain active after delivery.
In fact, there does not appear to be a need to conjugate any drug at all, as the iron oxide
NPs with biodegradable alginate coating or no coating, also exhibit a significant
bactericidal effect.
Some minor issues remain to be investigated regarding this work; investigation into
the theory that iron oxide NPs produce ROS, clarification regarding what a therapeutic
dose would be, investigation regarding the feasibility of the use of these materials as
preventative medicine for CF patients, and of course, characterization in vivo. An
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additional, more in-depth investigation into the cytotoxicity of all these materials would be
beneficial. More work is needed to determine the dose-dependent cytotoxicity over a larger
range of concentrations and cell types. A more straightforward method, such as individual
live/dead cell counting might work better due to the potential of iron oxide to absorb light,
and potentially interfere with the fluorescence assay. Largely, our investigations into the
use of SPIONS for the treatment of chronic biofilm infections in cystic fibrosis, shows
promising results for drug-susceptible as well as drug-resistant strains of Pseudomonas
aeruginosa, and may, in the future help to extend the life expectancy of cystic fibrosis in
both developing countries and the developed world.
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APPENDIX I
List of Chemicals and Physical Properties
1. CAS No.
Chemical Name
Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor density
Vapor pressure
Refractive index
EPA substance registry system
Hazard codes

67-64-1
Acetone
2-propanone
C3H6O
58.08
-94 °C
56 °C
-17.22 °C
0.791 g/mL
2
184 Torr
1.359
2-propanone (67-64-1)
F, Xi, T

2. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point
EPA substance registry system
Hazard codes

9005-32-7
Alginic acid
Alginate
(C6H8O6)n
10,000-600,000
300 °C
Alginic acid (9005-32-7)
Xi

3. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor density
Vapor pressure

7664-41-7
Ammonia
Ammonia
NH3
17.03
-78 °C
60 °C
11.11
1.023 g/mL
0.6
8.75 atm
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EPA substance registry system
Hazard codes

Ammonia (7664-41-7)
F, N, T, Xn

4. CAS No.
Chemical name

67-66-3
Chloroform
Trichloromethane, formyl trichloride,
methane trichloride, methyl trichloride
CHCl3
119.38 amu
-63
61
1.492
0.75 g/mL
4.1
160 Torr
1.445
Methane, trichloro-(67-66-3)
Xn, F, T, Xi
Xi

Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor density
Vapor pressure
Refractive index
EPA substance registry system
Hazard codes
Hazard codes
5. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point

Hazard codes

13754-17-1
Citrate
Citrate
C6H5O7
17.03
-78 °C
1,2,3-Propanetricarboxylic acid,
hydroxy-, ion(3-) (13754-17-1)
None

6. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point

64-17-5
Ethanol
Ethyl alcohol, thanol, grain alcohol
C2H6O
46.0684 amu
-114
78
12

EPA substance registry system

220

2-

Density
Refractive index
EPA substance registry system
Hazard codes
Hazard codes
EPA substance registry system
Hazard codes

0.79
1.3614
Ethanol (64-17-5)
Xn, F, T, N
Xi
Ethanol (64-17-5)
F, T, Xn, N

CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor density
Vapor pressure
Refractive index
EPA substance registry system
Hazard codes

112-40-3
n-dodecane
Dodecane
C12H26
170.33 amu
-9.6 °C
215-217 °C
83 °C
0.75 g/mL
5.96
1 Torr
1.421
Dodecane (112-40-3)
Xn

CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor density
Refractive index
Hazard codes

629-97-0
n-docosane
Docosane
C22H46
310.6 amu
42-45 °C
369 °C
95 °C
0.778 g/mL
10.8
1.4455
Xi

CAS No.
Chemical name

112-95-8
n-eicosane
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Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor density
Refractive index
Hazard codes
7. CAS No.

Eicosane, icosane
C20H42
282.55 amu
35-37 °C
343.1 °C
>113 °C
0.7886 g/mL
9.8
1.4425
Xi

Synonyms
Molecular formula
Molecular weight
Melting point

106627-54-7
N-hydroxysulfosuccinimide sodium
salt
Sulfo-NHS sodium salt, NHSS
C4H4NNaO6S
217.13 amu
250 °C

8. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor density
EPA substance registry system
Hazard codes

1333-74-0
Hydrogen gas
Hydrogen
H2
2.02 amu
-259.2 °C
-252.8 °C
<-150 °C
0.0899
0.07
Hydrogen (1333-74-0)
F+

9. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point

73513-42-5
Hexanes
Hexane, cyclohexane
C6H14
86.17536
-95 °C

Chemical name
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Boiling point
Flash point
Density
Vapor density
Refractive index
Hazard codes
EPA substance registry system
Hazard codes

68-70 °C
-22.77 °C
0.672 g/mL
3
1.379
F, Xn, N
Hydrochloric acid (7647-01-0)
T, C, F, Xi, F+, Xn

10. CAS No.
Chemical name

Molecular formula
Molecular weight
Melting point
Density
Hazard codes

1317-61-9
Iron oxide NPs
Black iron oxide, magnetite, iron(III)
oxide
Fe3O4
231.53 amu
1,538 °C
4.8-5.1 g/mL
Xi

11. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
EPA substance registry system
Hazard codes

7439-89-6
Iron
Iron
Fe
55.85 amu
1535 °C
2,750 °C
>110 °C
1.05 g/mL
Iron (7439-89-6)
F, Xi

12. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Hazard codes

None
Phosphate buffered saline
PBS
O4P
94.97 amu
Xi

Synonyms
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13. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor density
Vapor pressure
Refractive index

Hazard codes

25322-68-3
Polyethylene glycol
PEG, poly(oxyethylene)
C2nH4n+2On+1
18.02 + 44.05n g/mol
64-66 °C
>250 °C
270 °C
1.27 g/mL
>1
<0.01 Torr
1.469
Poly(oxy-1,2-ethanediyl), alpha-hydroomega-hydroxy (25322-68-3)
Xi, T

14. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Hazard codes

23335-74-2
Iron oleate
Iron(II,III) oleate
C54H99FeO6
900.21 amu
none

15. CAS No.
Chemical name

Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor pressure
Hazard codes

10025-77-1
Iron chloride hexahydrate
ferric chloride hyxahydrate, iron(III)
chloride
Cl3FeH12O6
270.3 amu
37 °C
280-285 °C
280-285 °C
1.82 g/mL
1 Torr
Xn, C

16. CAS No.
Chemical name

110-86-1
Pyridine

EPA substance registry system

Synonyms
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Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor density
Vapor pressure
Refractive index
EPA substance registry system
Hazard codes

Azabenzine
C5H5N
79.1 amu
-42 °C
96-98 °C
20 °C
0.983 g/mL @ 20 °C
2.72
23.8 Torr
1.509
Pyridine (110-86-1)
T, N, F, Xn

17. CAS No.
Chemical name

1332-37-2
Iron oxide
Red iron oxide, hematite, maghemite,
iron(III) oxide
Fe2O3
159.69 amu
1,539-1,565 °C decomposes
Iron oxide (1332-37-2)
Xi

Synonyms
Molecular formula
Molecular weight
Melting point
EPA substance registry system
Hazard codes
18. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point

Hazard codes

85721-33-1
Ciprofloxacin
Cipro, CPFX
C17H18FN3O3
331.34 amu
255-257 °C
3-quinolinecarboxylic
acid,
1cyclopentyl-6-fluoro-1,4-dihydro-4oxo-7-(piperazinyl) (85721-33-1
Xi

19. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight

77-86-1
Trometamol
TRIS
C4H11NO3
121.14 amu

EPA substance registry system
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Melting point
Boiling point
Flash point
Density
EPA substance registry system
Hazard codes
20. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point

167-172 °C
219-220 °C
219-220 °C
1.353 g/mL
1,3-Propanediol,
2-amino-2(hydroxymethyl)- (77-86-1)
Xi

Hazard codes

143-19-1
Sodium oleate
Sodium oleate
C18H33NaO2
304.44 °C
232-235 °C
1,3-Propanediol,
2-amino-2(hydroxymethyl)- (77-86-1)
None

21. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor density
Vapor pressure
EPA substance registry system
Hazard codes

108-30-5
Succinic anhydride
SAA, SAN, oxolan-2,5-dione
C4H4O3
100.07 amu
118-120 °C
261 °C
157 °C
1.572 g/mL
3.58
1 Torr
2,5-Furandione, dihydro-(108-30-5)
Xi, Xn

22. CAS No.
Chemical name
Synonyms
Molecular formula
Molecular weight
Melting point
Hazard codes

32986-56-4
Tobramycin
tobra, Tobramax
C18H37N5O9
467.51 °C
178
Xi

EPA substance registry system
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23. CAS No.
Chemical Name
Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor density
Vapor pressure
Refractive index
EPA substance registry system
Hazard codes

67-56-1
Methanol
Methyl alcohol
CH4O
32.04 amu
-98 °C
65.4 °C
11.11 °C
0.791 g/mL
1.11
410 Torr
1.329
Methanol (67-56-1)
Xn, T, F

24. CAS No.
Chemical Name
Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point
Density
Vapor density
Vapor pressure
EPA substance registry system
Hazard codes

7647-01-0
Hydrochloric acid
HCl
HCl
36.46 amu
-35 °C
57 °C
-40 °C
1.2 g/mL
1.3
613 psi
hydrochloric acid (7647-01-0)
T, C, F, Xi, F+, Xn

25. CAS No.
Chemical Name
Synonyms
Molecular formula
Molecular weight
Melting point
Boiling point
Flash point

1310-73-2
Sodium hydroxide
NaOH
HNaO
40 amu
681 °C
145 °C
176-178 °C
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Density
Vapor density
Vapor pressure
Refractive index

1.515 g/Ml
<1
1 Torr
1.473-1.475
Sodium hydroxide (Na(OH)) (1310-73EPA substance registry system
2)
Hazard codes
C, Xi
Chemical Hazard Codes and Symbols

References for Appendix I
1. Haynes, William M., ed. CRC handbook of chemistry and physics. CRC press,
2014.
2. "Globally Harmonized System." Hazard symbols. Sigma-Aldrich. Accessed
July

08,

2016.

http://www.sigmaaldrich.com/safety-center/globally-

harmonized.html.
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APPENDIX II
PROCEDURE FOR DRUG CONJUGATION:
TOBRAMYCIN CONJUGATION TO Fe3O4 HYDROPHILLIC NANOPARTICLES VIA
SULFO-NHS

NOTES: Procedure prepared: May 21, 2012
Approved: May 25, 2012
Prepared by Kate Brandt and Leisha Armijo
Source:
1.

Bioconjugate Techniques. G. Hermanson. Second Edition. 2008, p 598.

A. Preparation of coupling (phosphate) buffer (50mM working solution).
i. Using weighing paper and spatula weigh out 9.71 g of Na2HPO4 and add it to the
100 ml graduated cylinder.
ii. Add distilled water to 68.4 ml, cover with parafilm and mix by inverting to dissolve
completely (makes 1M Na2HPO4 stock solution).
iii. Using weighing paper and spatula weigh out 3.79 g of NaH2PO4 and add it to the
100 ml graduated cylinder.
iv. Add distilled water to 31.6 ml, cover with parafilm and mix by inverting to dissolve
completely (makes 1M NaH2PO4 stock solution).
v. Carefully combine the two solutions together in one of the 100 ml graduated
cylinders. Cover the cylinder with parafilm and mix by inverting to mix
completely. Pour the solution into a screw top bottle (makes 1 M phosphate buffer
solution). Label, date and initial.
B. Preparation of 50 mM (working) solution of coupling (phosphate) buffer:
i. Using 500 ml graduated cylinder measure out 190 ml of distilled water.
ii. Using 10 ml graduated cylinder measure out 10 ml of 1 M phosphate buffer and
add it to the water. Pour the solution into a screw top bottle. Label, date and initial.
C. Preparation of 50mM (working) solution of coupling phosphate buffer containing
35 mM Tris-OH:
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i. Using a spatula weigh 21.2 mg of Tris-HCl into a 15 ml conical plastic centrifuge
tube.
ii. Shake the bottle with 50 mM phosphate coupling buffer and add it to 5 ml mark.
Mix solution completely by inverting the tube as needed.
D. Conjugation of NPs to Tobramycin (in fume hood):
i. Transfer nanoparticle (NP) solution (citric acid capped Fe3O4) into glass centrifuge
tube. Spin 5 min at 4,000 rpm to precipitate nanoparticles.
ii. Using glass pipettor carefully remove as much supernatant as you can without
disturbing the pellet. Discard supernatant into the appropriate waste container.
iii. Carefully turn the tube over on paper towel and blot supernatant on it. Position tube
at an angle to allow access of air and leave to dry for 30 - 40 min.
iv. Transfer pellet into the clean centrifuge tube, weigh it and note it down.
v. Add 5 ml of coupling buffer to the tube and gently mix by pipetting it up and down.
vi. Spin 5 min at 4,000 rpm.
vii. Using glass pipettor carefully removes as much supernatant as you can without
disturbing the pellet. Discard into the appropriate waste container.
viii. Repeat previous steps (5-7) one more time.
ix. Finally, add 5 ml of coupling buffer per every100 mg of pellet (adjust all the
following numbers accordingly to the weight of the pellet) to the tube and gently
mix by pipetting it up and down.
x. To make a 10 mg/mL Tobramycin solution weigh out 50 mg of Tobramycin sulfate
for each 100 mg of pellet into a 50 ml beaker. Add small stir bar to the beaker and
then 5 ml of coupling buffer for each 50 mg of Tobramycin.
xi. Dissolve Tobramycin by putting the beaker on the stir plate and stirring until its
complete dissolution.
xii. While stirring, add NP solution to the beaker containing Tobramycin solution. Stir
for 2 min.
xiii. Using weighing paper, weigh 100 mg of EDC for each 100 mg of pellet weight and
add it to the beaker.
xiv. Add the entire 5 mM vial of Sulfo-NHS to the beaker.
xv. Reduce stirring to medium speed and continue stirring to react for 2-4 hours.
xvi. Wash NPs with 5 ml of coupling buffer as described in steps 5-7.
xvii. Resuspend NPs in coupling buffer containing 35 mM Tris.
xviii. Wash NPs twice with coupling buffer as described in steps 5-7.
xix. Resuspend conjugated NPs in 2.5 ml of coupling buffer for every 100 mg of pellet
weight (for a 40 mg/ml concentration) and transfer into a scintillation vial.
xx. Store the remaining 50 mM (working) solution of coupling (phosphate) buffer.
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APPENDIX III
NanoTherics Magnetherm
Derivation of Working Equation to Determine Potential Frequency and
Magnetic Field Capabilities
When resonance occurs in parallel LC
Figure A.III.1. LC Circuit diagram. Image by A.
Noni, 2012, adapted by L. Armijo 2016.

circuits, current circulates between L
so source current is at zero or minimum.
Implies

impedance

of

and C,
This

parallel

combination is at maximum.
Impedance is determined by:

𝑍=

1
𝜔𝐶
1
𝜔𝐿+
𝜔𝐶

𝜔𝐿∗

=

𝜔𝐿
𝜔2 𝐿𝐶+1

=

1
1
𝜔𝐶+
𝜔𝐿

1

= =∞
0

Where impedance is Z, ω is the angular frequency, L is inductance (in Henrys), and C is
capacitance (in Farads).
Differentiating to ω:
𝑑
𝑑𝜔

1

1

[𝜔𝐶 + 𝜔𝐿 = 𝐶 − 𝜔2 𝐿 = 0

and

Figure A.III.2. Impedance in a
parallel resonance circuit. Image by A.
Noni, 2012, adapted by L. Arrmijo
2016.
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Resonance occurs when:
𝑉𝐿 = −𝑉𝐶

,

𝐼𝐿 𝑋𝐿 = −𝐼𝐶 𝑋𝐶

and

where V is voltage, L is inductance, X is reactance, I is current, and C is capacitance.
When
𝑋𝐿 = 𝑋𝐶
The reactances of the inductor and the
capacitor are equal, so:
1

𝜔𝐿 = 𝜔𝐶
And once again, we arrive at:

Figure A.III.3. Current vs frequency diagram at
resonant frequency. Image by A. Noni, 2012, adapted
by L. Armijo2016.

At resonance the parallel circuit produces the same equation as for the series resonance
circuit. Therefore, it makes no difference if the inductor and capacitor are connected in
parallel or series.
To calculate the field inside a Solenoid (from Ampere’s Law):
𝑁

𝐵𝐿 = 𝜇𝑁𝐼 , rearranging to solve for B, we get: 𝐵 = 𝜇0 𝑙 𝐼
Where B is magnetic flux density within the coil, µ0= 4π x7-7 N/A2 is the permeability
constant, l is length. Substituting the relation 𝑛 =

𝑁
𝑙

where n is turn density (in turns/m),

we get: 𝐵 = 𝜇0 𝑛𝐼 The magnetic flux density in the solenoid is equal to the permeability
times turn density times current.
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Total magnetic flux is the product of the average magnetic field times the perpendicular
area that it passes through.

Φ=BA
Where Φ is total magnetic flux, B is magnetic flux density within the coil, and A is the area
of the coil.
Substituting for B, we get:

Φ= 𝜇0

𝑁𝐼𝐴
𝑙

= 𝜇𝑛𝐼𝐴

Inductance is defined by:
𝐿=

𝑁𝛷
𝐼

Where L is inductance, the inductance of a solenoid follows as:
𝐿 = 𝜇0

𝑁2𝐴
𝑙

Rearranging, we get:
𝜇0 𝑁
𝐿
=
𝑙
𝑁𝐴
𝐿𝐼

and 𝐵 = 𝑁𝐴
so, magnetic field is maximum when current is maximum; at resonant frequency.
V across inductor is proportional to reactance, XL=ωL and VL=XLIL

𝐵=(

𝐿
𝑉
𝑉
)∗( )=
𝑁𝐴
𝜔𝐿
𝑁𝐴𝜔
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Thus, our working equation is:
𝑩=

𝑽
𝑵𝑨𝝎

Where N = number of turns in coil = 9 or 17 (2 types of inductors provided by
manufacturer), A = area of coil = 0.004045 m2. Since we have 5 available capacitances and
2 available inductances; there are 10 possible combinations per B value.
Table III.1
Tunability Specifications for Magnetherm Inductive Heater

To Achieve Field Strength of 9 mT at Tunable Frequencies:
Nominal
Frequency
(kHz)

Capacitor
Part No.

Capacitor
Value C
(nF)

Inductor
Coil
Turns (N)

Maximum
(Vp-p)

Nominal
Coil Field
at
Max
Vp-p (mT)

Applied
Vp-p

110
A198
198
17
1200
25
168
A88
88
17
1200
17
176
A198
198
9
800
23
262
A88
88
9
1200
23
335
B22
22
17
2500
17
474
B11
11
17
2500
11
523
B22
22
9
2500
20
633
B6.2
6.2
17
2500
9
739
B11
11
9
2500
16
987
B6.2
6.2
9
2500
12
To Achieve Field Strength of 11 mT at Tunable Frequencies:

427.74
653.28
362.32
539.37
1302.67
1843.18
1076.68
2461.46
1521.35
2031.89

Nominal
Frequency
(kHz)

Capacitor

Capacitor
Value C
(nF)

Inductor
Coil
Turns (N)

Maximum
(Vp-p)

Nominal
Coil Field
at
Max
Vp-p (mT)

Applied
Vp-p

110
168
176
262
335
474
523
633
739
987

A198
A88
A198
A88
B22
B11
B22
B6.2
B11
B6.2

198
88
198
88
22
11
22
6.2
11
6.2

17
17
9
9
17
17
9
17
9
9

1200
1200
800
1200
2500
2500
2500
2500
2500
2500

25
17
23
23
17
11
20
9
16
12

522.8
798.45
422.84
659.23
1592.15
2252.78
1315.94
3008.46
1859.42
2483.42
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To Achieve Field Strength of 12 mT at Tunable Frequencies:
Nominal
Frequency
(kHz)

Capacitor

Capacitor
Value C
(nF)

Inductor
Coil
Turns (N)

Maximum
(Vp-p)

Nominal
Coil Field
at
Max
Vp-p (mT)

Applied
Vp-p

110
A198
198
17
1200
25
168
A88
88
17
1200
17
176
A198
198
9
800
23
262
A88
88
9
1200
23
335
B22
22
17
2500
17
474
B11
11
1as7
2500
11
523
B22
22
9
2500
20
633
B6.2
6.2
17
2500
9
739
B11
11
9
2500
16
987
B6.2
6.2
9
2500
12
To Achieve Field Strength of 16 mT at Tunable Frequencies:

570.32
871.03
483.09
719.15
1736.88
2457.55
1435.55
3281.92
2028.44
2709.16

Nominal
Frequency
(kHz)

Applied
Vp-p

Capacitor

Capacitor
Value C
(nF)

Inductor
Coil
Turns (N)

Maximum
(Vp-p)

Nominal
Coil Field
at
Max
Vp-p (mT)

110
A198
198
17
1200
25
168
A88
88
17
1200
17
176
A198
198
9
800
23
262
A88
88
9
1200
23
335
B22
22
17
2500
17
474
B11
11
17
2500
11
523
B22
22
9
2500
20
633
B6.2
6.2
17
2500
9
739
B11
11
9
2500
16
987
B6.2
6.2
9
2500
12
To Achieve Field Strength of 17 mT at Tunable Frequencies:

760.42
1161.37
644.12
958.87
2315.83
3276.73
1914.07
4375.89
2704.59
3612.21

Nominal
Frequency
(kHz)

Capacitor

Capacitor
Value C
(nF)

Inductor
Coil
Turns (N)

Maximum
(Vp-p)

Nominal
Coil Field
at
Max
Vp-p (mT)

Applied
Vp-p

110
168
176
262
335
474
523
633

A198
A88
A198
A88
B22
B11
B22
B6.2

198
88
198
88
22
11
22
6.2

17
17
9
9
17
17
9
17

1200
1200
800
1200
2500
2500
2500
2500

25
17
23
23
17
11
20
9

807.96
12233.9
684.39
1018.81
2460.6
3481.57
2033.72
4649.43
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739
B11
11
9
2500
16
987
B6.2
6.2
9
2500
12
To Achieve Field Strength of 20 mT at Tunable Frequencies:

2873.65
3838.02

Nominal
Frequency
(kHz)

Applied
Vp-p

Capacitor
Array
Type/Val
ue

Capacitor
Value C
(nF)

Inductor
Coil
Turns (N)

Maximum
(Vp-p)

Nominal
Coil Field
at
Max
Vp-p (mT)

110
A198
198
17
1200
25
168
A88
88
17
1200
17
176
A198
198
9
800
23
262
A88
88
9
1200
23
335
B22
22
17
2500
17
474
B11
11
17
2500
11
523
B22
22
9
2500
20
633
B6.2
6.2
17
2500
9
739
B11
11
9
2500
16
987
B6.2
6.2
9
2500
12
To Achieve Field Strength of 23 mT at Tunable Frequencies:

950.54
1451.73
805.16
1198.59
2894.82
4095.95
2392.61
5469.92
3380.77
4515.31

Nominal
Frequency
(kHz)

Applied
Vp-p

Capacitor

Capacitor
Value C
(nF)

Inductor
Coil
Turns (N)

Maximum
(Vp-p)

Nominal
Coil Field
at
Max
Vp-p (mT)

110
A198
198
17
1200
25
168
A88
88
17
1200
17
176
A198
198
9
800
23
262
A88
88
9
1200
23
335
B22
22
17
2500
17
474
B11
11
17
2500
11
523
B22
22
9
2500
20
633
B6.2
6.2
17
2500
9
739
B11
11
9
2500
16
987
B6.2
6.2
9
2500
12
To Achieve Field Strength of 25 mT at Tunable Frequencies:

1093.12
1669.49
925.94
1378.38
3329.05
4710.35
2751.51
6290.41
3887.88
5192.61

Nominal
Frequency
(kHz)

Capacitor

Capacitor
Value C
(nF)

Inductor
Coil
Turns (N)

Maximum
(Vp-p)

Nominal
Coil Field
at
Max
Vp-p (mT)

Applied
Vp-p

110
168
176
262
335
474

A198
A88
A198
A88
B22
B11

198
88
198
88
22
11

17
17
9
9
17
17

1200
1200
800
1200
2500
2500

25
17
23
23
17
11

1188.17
1814.67
1006.45
1498.24
3618.53
5119.95
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523
633
739
987

B22
B6.2
B11
B6.2

22
6.2
11
6.2

9
17
9
9

2500
2500
2500
2500

20
9
16
16

2990.77
6837.4
4225.96
5644.14

Tables define the parameters for tuning MagneTherm™ to the desired, allowable
frequency and field strengths using different capacitor and inductor combinations. These
tables give the voltage that should be applied as well as the maximum peak to peak voltage
(Vp-p) that may be applied without damage to the equipment.

Note: This information was not provided by the manufacturer and is essential for more indepth future work involving hyperthermia characterization studies using the
MagneTherm™ inductive heater. These tables were produced using the working equation.
Calculations were performed by Leisha Armijo, M.S., Abhyudai Noni, and Gennady
Smolyakov, PhD (Summer, 2012).
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